{"PMC5458453": [["Cell culture ::: Materials and methodsVero (derived from African green monkey kidney cells), HeLa (a human epithelial carcinoma cell line), HepG2 (a human hepatoma cell line), 293T (a transformed embryonic kidney cell line expressing SV40 large T antigen), and L929 (mouse fibroblast cells) were grown in Dulbecco's modified Eagle's medium (DMEM; HyClone, Logan, UT, USA) supplemented with 10% or 2% FBS (Gibco, Carlsbad, CA, USA) at 37 \u00b0C in a humidified 5% CO2 incubator.Synthetic oligonucleotides and transfection ::: Materials and methodsNegative control mimics, miR\u2010127\u20105p mimics, negative control inhibitor, and miR\u2010127\u20105p inhibitor were purchased from RiboBio (Guangzhou, China).", [["Cell", "ANATOMY", 0, 4], ["Vero", "ANATOMY", 38, 42], ["kidney cells", "ANATOMY", 78, 90], ["HeLa", "ANATOMY", 93, 97], ["epithelial carcinoma cell line", "ANATOMY", 107, 137], ["HepG2", "ANATOMY", 140, 145], ["hepatoma cell line", "ANATOMY", 155, 173], ["293T", "ANATOMY", 176, 180], ["embryonic kidney cell line", "ANATOMY", 196, 222], ["L929", "ANATOMY", 261, 265], ["fibroblast cells", "ANATOMY", 273, 289], ["epithelial carcinoma", "DISEASE", 107, 127], ["CO2", "CHEMICAL", 459, 462], ["CO2", "CHEMICAL", 459, 462], ["Cell", "CELL", 0, 4], ["green monkey kidney cells", "CELL", 65, 90], ["HeLa", "CELL", 93, 97], ["human", "ORGANISM", 101, 106], ["epithelial carcinoma cell line", "CELL", 107, 137], ["HepG2", "CELL", 140, 145], ["human", "ORGANISM", 149, 154], ["hepatoma cell line", "CELL", 155, 173], ["293T", "CELL", 176, 180], ["embryonic kidney cell line", "CELL", 196, 222], ["SV40", "ORGANISM", 234, 238], ["large T antigen", "GENE_OR_GENE_PRODUCT", 239, 254], ["L929", "CELL", 261, 265], ["mouse", "ORGANISM", 267, 272], ["fibroblast cells", "CELL", 273, 289], ["FBS", "ORGANISM_SUBSTANCE", 400, 403], ["CO2", "SIMPLE_CHEMICAL", 459, 462], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 567, 577], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 618, 628], ["African green monkey kidney cells", "CELL_LINE", 57, 90], ["HeLa", "CELL_LINE", 93, 97], ["human epithelial carcinoma cell line", "CELL_LINE", 101, 137], ["HepG2", "CELL_LINE", 140, 145], ["human hepatoma cell line", "CELL_LINE", 149, 173], ["293T", "CELL_LINE", 176, 180], ["transformed embryonic kidney cell line", "CELL_LINE", 184, 222], ["SV40 large T antigen", "CELL_LINE", 234, 254], ["L929", "CELL_LINE", 261, 265], ["mouse fibroblast cells", "CELL_LINE", 267, 289], ["green monkey", "SPECIES", 65, 77], ["human", "SPECIES", 101, 106], ["human", "SPECIES", 149, 154], ["mouse", "SPECIES", 267, 272], ["African green monkey", "SPECIES", 57, 77], ["human", "SPECIES", 101, 106], ["human", "SPECIES", 149, 154], ["mouse", "SPECIES", 267, 272], ["Cell culture", "TEST", 0, 12], ["African green monkey kidney cells", "TREATMENT", 57, 90], ["HeLa", "TEST", 93, 97], ["a human epithelial carcinoma cell line", "TREATMENT", 99, 137], ["HepG2", "TEST", 140, 145], ["a human hepatoma cell line", "TREATMENT", 147, 173], ["a transformed embryonic kidney cell line", "TREATMENT", 182, 222], ["SV40 large T antigen", "TEST", 234, 254], ["L929 (mouse fibroblast cells", "PROBLEM", 261, 289], ["a humidified 5% CO2 incubator", "TREATMENT", 443, 472], ["miR\u2010127\u20105p inhibitor", "TREATMENT", 618, 638], ["carcinoma cell line", "OBSERVATION", 118, 137], ["HepG2", "ANATOMY", 140, 145], ["kidney", "ANATOMY", 206, 212], ["cell line", "OBSERVATION", 213, 222], ["fibroblast cells", "OBSERVATION", 273, 289], ["oligonucleotides", "OBSERVATION", 483, 499]]], ["For transfection, the cells were plated in six\u2010well plates, grown to 30% confluence, and were transfected with synthetic oligonucleotides using Lipofectamine 3000 (Life Technologies, Carlsbad, CA, USA), according to the manufacturer's instruction.RNA isolation and quantitative real\u2010time PCR ::: Materials and methodsAccording to the manufacturer's protocol, total RNA was prepared using Trizol reagent (Life Technologies).", [["cells", "ANATOMY", 22, 27], ["cells", "CELL", 22, 27], ["transfection", "TREATMENT", 4, 16], ["synthetic oligonucleotides", "TREATMENT", 111, 137], ["Lipofectamine", "TREATMENT", 144, 157], ["RNA isolation", "TEST", 247, 260], ["quantitative real\u2010time PCR", "TEST", 265, 291], ["the manufacturer's protocol", "TREATMENT", 330, 357], ["total RNA", "TREATMENT", 359, 368], ["Trizol reagent (Life Technologies", "TREATMENT", 388, 421]]], ["Reverse\u2010transcribed cDNA was synthesized using the PrimeScript RT Reagent Kit (TaKaRa, Dalian, China).", [["Reverse\u2010transcribed cDNA", "DNA", 0, 24], ["Reverse\u2010transcribed cDNA", "TREATMENT", 0, 24], ["the PrimeScript RT Reagent Kit", "TREATMENT", 47, 77]]], ["GAPDH mRNA was used as an endogenous control for the expression of SCARB2 and EV71 VP1 genomic RNA.", [["GAPDH", "GENE_OR_GENE_PRODUCT", 0, 5], ["SCARB2", "GENE_OR_GENE_PRODUCT", 67, 73], ["EV71", "ORGANISM", 78, 82], ["VP1", "GENE_OR_GENE_PRODUCT", 83, 86], ["GAPDH mRNA", "RNA", 0, 10], ["SCARB2 and EV71 VP1 genomic RNA", "RNA", 67, 98], ["EV71", "SPECIES", 78, 82], ["GAPDH mRNA", "PROBLEM", 0, 10], ["an endogenous control", "TREATMENT", 23, 44], ["SCARB2", "PROBLEM", 67, 73], ["EV71 VP1 genomic RNA", "PROBLEM", 78, 98], ["VP1 genomic RNA", "OBSERVATION", 83, 98]]], ["The primers used were:RNA isolation and quantitative real\u2010time PCR ::: Materials and methodsSCARB2\u2010F: 5\u2032\u2010CCATAGAAGGCATGCACCCA\u20103\u2032, SCARB2\u2010R: 5\u2032\u2010AGCGCCATGATGATGTAGGG\u20103\u2032, EV71VP1\u2010F: 5\u2032\u2010GCTCTATAGGAGATAGTGTGAGTAGGG\u20103\u2032, EV71 VP1\u2010R: 5\u2032\u2010ATGACTGCTCACCTGCGTGTT\u20103\u2032, GAPDH\u2010F: 5\u2032\u2010TGCACCACCAACTGCTTAGC\u20103\u2032, GAPDH\u2010R: 5\u2032\u2010GGC ATGGACTGTGGTCATGAG\u20103\u2032.RNA isolation and quantitative real\u2010time PCR ::: Materials and methodsTo determine the expression of miRNA in cells, U6 snRNA served as an internal control, and miR\u2010127\u20105p quantitative real\u2010time PCR (qRT\u2010PCR) primers were purchased from RiboBio.", [["cells", "ANATOMY", 440, 445], ["cells", "CELL", 440, 445], ["U6 snRNA", "GENE_OR_GENE_PRODUCT", 447, 455], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 491, 501], ["SCARB2", "PROTEIN", 92, 98], ["GAPDH", "PROTEIN", 255, 260], ["GAPDH", "PROTEIN", 292, 297], ["U6 snRNA", "RNA", 447, 455], ["miR\u2010127\u20105p", "DNA", 491, 501], ["RNA isolation", "TREATMENT", 22, 35], ["quantitative real\u2010time PCR", "TEST", 40, 66], ["SCARB2", "TEST", 92, 98], ["CCATAGAAGGCATGCACCCA", "TEST", 105, 125], ["\u2010", "TEST", 125, 126], ["SCARB2", "TEST", 130, 136], ["AGCGCCATGATGATGTAGGG", "TEST", 143, 163], ["GCTCTATAGGAGATAGTGTGAGTAGGG", "TEST", 182, 209], ["ATGACTGCTCACCTGCGTGTT", "TEST", 229, 250], ["TGCACCACCAACTGCTTAGC", "TEST", 267, 287], ["GAPDH", "TEST", 292, 297], ["RNA isolation", "TEST", 330, 343], ["quantitative real\u2010time PCR", "TEST", 348, 374], ["miRNA in cells", "PROBLEM", 431, 445], ["U6 snRNA", "TREATMENT", 447, 455], ["quantitative real\u2010time PCR", "TEST", 502, 528], ["qRT", "TEST", 530, 533], ["PCR", "TEST", 534, 537]]], ["Real\u2010time PCR was performed using a standard protocol on an Applied Biosystems 7300 system using SYBR green PCR master mix (Life Technologies) according to the manufacturer's instruction.", [["SYBR green", "CHEMICAL", 97, 107], ["Real\u2010time PCR", "TEST", 0, 13], ["a standard protocol", "TREATMENT", 34, 53]]], ["All reactions were performed in triplicate and relative expression was analyzed using the \u0394\u0394Ct method.Western blot and antibody reagent ::: Materials and methodsCells were collected and lysed using RIPA lysis buffer (Santa Cruz, CA, USA) on ice for 20 min and then centrifuged at 12 000 g for 10 min at 4 \u00b0C. Total protein concentrations were determined using the Bicinchoninic Acid (BCA) Protein Assay Kit (Pierce, Rockford, IL, USA).", [["Cells", "ANATOMY", 161, 166], ["Bicinchoninic Acid", "CHEMICAL", 364, 382], ["Bicinchoninic Acid", "CHEMICAL", 364, 382], ["Cells", "CELL", 161, 166], ["Bicinchoninic Acid", "SIMPLE_CHEMICAL", 364, 382], ["All reactions", "PROBLEM", 0, 13], ["the \u0394\u0394Ct method", "TREATMENT", 86, 101], ["Cells", "TEST", 161, 166], ["RIPA lysis buffer", "TREATMENT", 198, 215], ["Total protein concentrations", "TEST", 309, 337], ["the Bicinchoninic Acid (BCA", "TREATMENT", 360, 387]]], ["Proteins were analyzed by SDS/PAGE and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore, Billerica, MA, USA).", [["polyvinylidene difluoride", "CHEMICAL", 54, 79], ["PVDF", "CHEMICAL", 81, 85], ["polyvinylidene difluoride (PVDF) membranes", "TREATMENT", 54, 96]]], ["Nonspecific antibody binding was blocked by Odyssey Blocking buffer (LI\u2010COR Biosciences, Lincoln, NE, USA), and the membranes were incubated with primary antibodies specific for SCARB2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), EV71 VP1 (Abcam, Cambridge, UK), or GAPDH (Santa Cruz Biotechnology) for 4 h at room temperature (RT).", [["membranes", "ANATOMY", 116, 125], ["membranes", "CELLULAR_COMPONENT", 116, 125], ["EV71", "ORGANISM", 234, 238], ["Abcam", "GENE_OR_GENE_PRODUCT", 244, 249], ["GAPDH", "GENE_OR_GENE_PRODUCT", 270, 275], ["primary antibodies", "PROTEIN", 146, 164], ["SCARB2", "PROTEIN", 178, 184], ["Santa Cruz Biotechnology", "PROTEIN", 186, 210], ["EV71 VP1", "PROTEIN", 234, 242], ["GAPDH", "PROTEIN", 270, 275], ["Santa Cruz Biotechnology", "PROTEIN", 277, 301], ["Nonspecific antibody binding", "PROBLEM", 0, 28], ["Odyssey Blocking buffer", "TREATMENT", 44, 67], ["primary antibodies", "TEST", 146, 164], ["EV71 VP1", "TEST", 234, 242], ["antibody binding", "OBSERVATION", 12, 28]]], ["After five washes with PBS\u20100.1% Tween\u201020 (PBS\u2010T buffer), the membranes were incubated with IRDye 800 goat anti\u2010mouse IgG or IRDye 680 donkey anti\u2010rabbit IgG (LI\u2010COR Biosciences) at 1 : 10 000 dilution for 1 h and visualized using Li\u2010COR Odyssey Infrared Imager (LI\u2010COR Biosciences).", [["membranes", "ANATOMY", 61, 70], ["Tween\u201020", "CHEMICAL", 32, 40], ["Tween\u201020", "CHEMICAL", 32, 40], ["IRDye", "CHEMICAL", 91, 96], ["Tween\u201020", "SIMPLE_CHEMICAL", 32, 40], ["membranes", "CELLULAR_COMPONENT", 61, 70], ["IRDye", "SIMPLE_CHEMICAL", 91, 96], ["IRDye", "SIMPLE_CHEMICAL", 124, 129], ["IRDye 800 goat anti\u2010mouse IgG", "PROTEIN", 91, 120], ["IRDye 680 donkey anti\u2010rabbit IgG", "PROTEIN", 124, 156], ["goat", "SPECIES", 101, 105], ["donkey", "SPECIES", 134, 140], ["goat", "SPECIES", 101, 105], ["PBS\u2010", "TREATMENT", 23, 27], ["PBS\u2010T buffer", "TREATMENT", 42, 54], ["IRDye", "TREATMENT", 91, 96], ["IRDye", "TEST", 124, 129]]], ["Bands were quantified by densitometric analysis using odyssey software.Virus titer ::: Materials and methodsEnterovirus 71 Fuyang0805 strain was propagated on Vero cells.", [["Vero cells", "ANATOMY", 159, 169], ["Bands", "GENE_OR_GENE_PRODUCT", 0, 5], ["Virus", "ORGANISM", 71, 76], ["Enterovirus 71", "ORGANISM", 108, 122], ["Vero cells", "CELL", 159, 169], ["Vero cells", "CELL_LINE", 159, 169], ["Bands", "TEST", 0, 5], ["densitometric analysis", "TEST", 25, 47], ["odyssey software", "TEST", 54, 70], ["methodsEnterovirus", "TEST", 101, 119], ["Vero cells", "TREATMENT", 159, 169], ["Vero cells", "OBSERVATION", 159, 169]]], ["Vero cells were grown in 96\u2010well plates, 24 h before virus infection.", [["Vero cells", "ANATOMY", 0, 10], ["infection", "DISEASE", 59, 68], ["Vero cells", "CELL", 0, 10], ["Vero cells", "CELL_LINE", 0, 10], ["Vero cells", "PROBLEM", 0, 10], ["virus infection", "PROBLEM", 53, 68], ["infection", "OBSERVATION", 59, 68]]], ["EV71 was serially diluted with DMEM supplemented with 2% FBS from 103\u2010 to 1010\u2010fold, and a dilution of EV71 was added to triplicate wells.", [["EV71", "ORGANISM", 0, 4], ["FBS", "ORGANISM_SUBSTANCE", 57, 60], ["EV71", "ORGANISM", 103, 107], ["EV71", "SPECIES", 0, 4], ["EV71", "SPECIES", 103, 107], ["EV71", "PROBLEM", 0, 4], ["2% FBS", "TREATMENT", 54, 60], ["a dilution of EV71", "TREATMENT", 89, 107]]], ["The plates were then incubated at 37 \u00b0C with 5% CO2.", [["CO2", "CHEMICAL", 48, 51], ["CO2", "CHEMICAL", 48, 51], ["CO2", "SIMPLE_CHEMICAL", 48, 51], ["5% CO2", "TREATMENT", 45, 51], ["plates", "OBSERVATION_MODIFIER", 4, 10]]], ["The cytopathic effect (CPE) was recorded under the microscope after 3 days.", [["The cytopathic effect (CPE", "PROBLEM", 0, 26], ["cytopathic", "OBSERVATION_MODIFIER", 4, 14], ["effect", "OBSERVATION_MODIFIER", 15, 21]]], ["Virus titers were calculated as the 50% tissue culture infectious dose (TCID50) using the Reed\u2013M\u00fcnch method.Plasmid constructs ::: Materials and methodsThe wild\u2010type pmirGLO\u2010SCARB2 3\u2032 UTR reporter plasmid was constructed by inserting the 3\u2032 UTR (nucleotides 270\u20131240) of SCARB2 into the pmirGLO luciferase vector between the XhoI and XbaI sites.", [["tissue", "ANATOMY", 40, 46], ["nucleotides 270\u20131240", "CHEMICAL", 246, 266], ["nucleotides", "CHEMICAL", 246, 257], ["Virus", "ORGANISM", 0, 5], ["tissue", "TISSUE", 40, 46], ["SCARB2", "GENE_OR_GENE_PRODUCT", 271, 277], ["pmirGLO", "GENE_OR_GENE_PRODUCT", 287, 294], ["luciferase", "GENE_OR_GENE_PRODUCT", 295, 305], ["XhoI", "GENE_OR_GENE_PRODUCT", 325, 329], ["XbaI", "GENE_OR_GENE_PRODUCT", 334, 338], ["Plasmid constructs", "DNA", 108, 126], ["wild\u2010type pmirGLO", "PROTEIN", 156, 173], ["SCARB2 3", "PROTEIN", 174, 182], ["UTR reporter plasmid", "DNA", 184, 204], ["UTR", "DNA", 241, 244], ["nucleotides 270\u20131240", "DNA", 246, 266], ["SCARB2", "DNA", 271, 277], ["pmirGLO luciferase vector", "DNA", 287, 312], ["XhoI and XbaI sites", "DNA", 325, 344], ["Virus titers", "TEST", 0, 12], ["the Reed\u2013M\u00fcnch method", "TREATMENT", 86, 107], ["UTR reporter plasmid", "TREATMENT", 184, 204], ["nucleotides", "TEST", 246, 257], ["SCARB2", "TREATMENT", 271, 277], ["XbaI sites", "TREATMENT", 334, 344], ["XhoI", "ANATOMY", 325, 329]]], ["The SCARB2 3\u2032 UTR was amplified from cDNA using forward primer F (5\u2032 \u2010CCGCTCGAGTTGTTGGGTGCTGGTAGCTC\u20103\u2032) and the reverse primer R (5\u2032\u2010GCTCTAGAGGTGTCTCTGCTTCTGGTCC\u20103\u2032).", [["SCARB2 3", "DNA", 4, 12], ["UTR", "DNA", 14, 17], ["cDNA", "DNA", 37, 41], ["reverse primer R", "DNA", 112, 128], ["UTR", "PROBLEM", 14, 17], ["forward primer F", "TREATMENT", 48, 64], ["CCGCTCGAGTTGTTGGGTGCTGGTAGCTC", "TEST", 70, 99]]], ["The mutant pmirGLO\u2010SCARB2 3\u2032 UTR construct was generated by inducing a point mutation using the overlap extension PCR method.Luciferase assay ::: Materials and methodsFor the luciferase assay, 293T cells were plated at a density of 1 \u00d7 105 cells per well in 24\u2010well plates and luciferase reporter plasmids and pLR\u2010Tk (Promega, Madison, WI, USA) were cotransfected into 293T cells using Lipofectamine 3000 (Life Technologies).", [["293T cells", "ANATOMY", 193, 203], ["cells", "ANATOMY", 240, 245], ["plasmids", "ANATOMY", 297, 305], ["293T cells", "ANATOMY", 369, 379], ["luciferase", "GENE_OR_GENE_PRODUCT", 175, 185], ["293T cells", "CELL", 193, 203], ["cells", "CELL", 240, 245], ["luciferase", "GENE_OR_GENE_PRODUCT", 277, 287], ["293T cells", "CELL", 369, 379], ["mutant pmirGLO", "PROTEIN", 4, 18], ["SCARB2 3", "PROTEIN", 19, 27], ["UTR construct", "DNA", 29, 42], ["luciferase", "PROTEIN", 175, 185], ["293T cells", "CELL_LINE", 193, 203], ["luciferase reporter plasmids", "DNA", 277, 305], ["pLR", "DNA", 310, 313], ["293T cells", "CELL_LINE", 369, 379], ["UTR construct", "PROBLEM", 29, 42], ["a point mutation", "PROBLEM", 69, 85], ["the overlap extension PCR method", "TREATMENT", 92, 124], ["the luciferase assay", "TEST", 171, 191], ["luciferase reporter plasmids", "TREATMENT", 277, 305], ["pLR", "TEST", 310, 313], ["Tk", "TEST", 314, 316], ["Lipofectamine", "TREATMENT", 386, 399]]], ["After 48 h of incubation, the cells were harvested, washed once with PBS, and lysed with Passive lysis buffer (Promega).", [["cells", "ANATOMY", 30, 35], ["cells", "CELL", 30, 35], ["incubation", "TREATMENT", 14, 24], ["the cells", "TREATMENT", 26, 35], ["PBS", "TREATMENT", 69, 72], ["Passive lysis buffer (Promega)", "TREATMENT", 89, 119]]], ["Supernatants were collected after 15 min, and centrifuged at 12 000 g for 30 s.", [["Supernatants", "ANATOMY", 0, 12], ["Supernatants", "CELL", 0, 12]]], ["The luciferase activities were measured using a dual\u2010luciferase reporter system (Promega).Immunofluorescence assay ::: Materials and methodsCells were seeded on glass coverslips, and were infected with EV71 at the indicated time, followed by fixation with 4% paraformaldehyde for 15 min at room temperature.", [["Cells", "ANATOMY", 140, 145], ["paraformaldehyde", "CHEMICAL", 259, 275], ["luciferase", "GENE_OR_GENE_PRODUCT", 4, 14], ["Cells", "CELL", 140, 145], ["EV71", "ORGANISM", 202, 206], ["paraformaldehyde", "SIMPLE_CHEMICAL", 259, 275], ["luciferase", "PROTEIN", 4, 14], ["EV71", "SPECIES", 202, 206], ["The luciferase activities", "TEST", 0, 25], ["a dual\u2010luciferase reporter system", "TREATMENT", 46, 79], ["Immunofluorescence assay", "TEST", 90, 114], ["glass coverslips", "TREATMENT", 161, 177], ["EV71", "TREATMENT", 202, 206], ["fixation", "TREATMENT", 242, 250], ["4% paraformaldehyde", "TREATMENT", 256, 275]]], ["After being washed twice with PBS, the cells were treated with specific primary antibodies against the proteins.", [["cells", "ANATOMY", 39, 44], ["cells", "CELL", 39, 44], ["primary antibodies", "PROTEIN", 72, 90], ["PBS", "TREATMENT", 30, 33], ["specific primary antibodies", "TREATMENT", 63, 90]]], ["The respective secondary antibody was Alexa Fluor 594\u2010labeled donkey anti\u2010mouse IgG (Molecular Probes, Life technologies) diluted at 1 : 1000.", [["Alexa Fluor 594", "CHEMICAL", 38, 53], ["Alexa Fluor 594\u2010", "SIMPLE_CHEMICAL", 38, 54], ["Alexa Fluor 594\u2010labeled donkey anti\u2010mouse IgG", "PROTEIN", 38, 83], ["donkey", "SPECIES", 62, 68], ["Alexa Fluor 594", "SPECIES", 38, 53], ["Alexa Fluor", "TEST", 38, 49], ["donkey anti\u2010mouse IgG (Molecular Probes, Life technologies", "TREATMENT", 62, 120]]], ["Images were acquired with an Olympus Fluoview FV10i laser scanning confocal microscope (Tokyo, Japan).Flow cytometry ::: Materials and methodsThe cells were dispersed with PBS containing 0.02% EDTA, harvested, and fixed in 4% paraformaldehyde.", [["cells", "ANATOMY", 146, 151], ["EDTA", "CHEMICAL", 193, 197], ["EDTA", "CHEMICAL", 193, 197], ["paraformaldehyde", "CHEMICAL", 226, 242], ["cells", "CELL", 146, 151], ["EDTA", "SIMPLE_CHEMICAL", 193, 197], ["paraformaldehyde", "SIMPLE_CHEMICAL", 226, 242], ["Images", "TEST", 0, 6], ["PBS", "TREATMENT", 172, 175], ["0.02% EDTA", "TREATMENT", 187, 197], ["4% paraformaldehyde", "TREATMENT", 223, 242]]], ["After three washes with PBS, cells were incubated with the SCARB2\u2010specific antibody (diluted 1 : 100, Santa Cruz, CA, USA) in PBS containing 1% BSA at room temperature for 1 h, followed by incubation with the Alexa Fluor 488\u2010labeled goat anti\u2010mouse IgG (Molecular Probes, Life technologies) at 1 : 1000 for 30 min.", [["cells", "ANATOMY", 29, 34], ["BSA", "CHEMICAL", 144, 147], ["Alexa Fluor 488", "CHEMICAL", 209, 224], ["cells", "CELL", 29, 34], ["SCARB2", "GENE_OR_GENE_PRODUCT", 59, 65], ["BSA", "SIMPLE_CHEMICAL", 144, 147], ["Alexa Fluor 488\u2010", "SIMPLE_CHEMICAL", 209, 225], ["goat", "ORGANISM", 233, 237], ["SCARB2\u2010specific antibody", "PROTEIN", 59, 83], ["Alexa Fluor 488\u2010labeled goat anti\u2010mouse IgG", "PROTEIN", 209, 252], ["goat", "SPECIES", 233, 237], ["goat", "SPECIES", 233, 237], ["PBS", "TREATMENT", 24, 27], ["the SCARB2\u2010specific antibody", "TEST", 55, 83], ["the Alexa Fluor", "TREATMENT", 205, 220]]], ["SCARB2 protein on the cell surface was analyzed by flow cytometry (FACSCalibur, BD Biosciences, San Jose, CA, USA) using a flowjo software (TreeStar Software, San Carlos, CA, USA).Statistical analysis ::: Materials and methodsThe statistical analyses were performed using prism 5.0 software (GraphPad Software, La Jolla, CA, USA).", [["cell surface", "ANATOMY", 22, 34], ["SCARB2", "GENE_OR_GENE_PRODUCT", 0, 6], ["cell surface", "CELLULAR_COMPONENT", 22, 34], ["SCARB2 protein", "PROTEIN", 0, 14], ["the cell surface", "TEST", 18, 34], ["flow cytometry", "TEST", 51, 65], ["The statistical analyses", "TEST", 226, 250], ["prism", "TEST", 272, 277], ["Software", "TEST", 301, 309], ["flow cytometry", "OBSERVATION", 51, 65]]], ["Differences between experimental groups were statistically evaluated using Student's t\u2010test.", [["Student's t\u2010test", "TEST", 75, 91]]], ["P\u2010value of <0.05 was considered statistically significant (P < 0.001).", [["P\u2010value", "TEST", 0, 7]]], ["All the results are presented as means \u00b1 SD of at least three independent experiments.miR\u2010127\u20105p inhibits SCARB2 expression by targeting its 3\u2032 UTR ::: ResultsRecently, Siebert, et al. 29 reported that miR\u2010127\u20105p targeted SCARB2 3\u2032 UTR and reduced the protein expression of SCARB2.", [["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 86, 96], ["SCARB2", "GENE_OR_GENE_PRODUCT", 106, 112], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 202, 212], ["SCARB2 3", "GENE_OR_GENE_PRODUCT", 222, 230], ["SCARB2", "GENE_OR_GENE_PRODUCT", 274, 280], ["miR\u2010127\u20105p", "DNA", 86, 96], ["SCARB2", "PROTEIN", 106, 112], ["UTR", "DNA", 144, 147], ["miR\u2010127\u20105p", "DNA", 202, 212], ["SCARB2 3", "DNA", 222, 230], ["UTR", "DNA", 232, 235], ["SCARB2", "PROTEIN", 274, 280], ["UTR", "PROBLEM", 232, 235], ["reduced the protein expression of SCARB2", "PROBLEM", 240, 280], ["reduced", "OBSERVATION_MODIFIER", 240, 247], ["protein expression", "OBSERVATION", 252, 270]]], ["As a cellular receptor, SCARB2 can facilitate efficient EV71 infection 35.", [["cellular", "ANATOMY", 5, 13], ["EV71 infection", "DISEASE", 56, 70], ["cellular", "CELL", 5, 13], ["SCARB2", "GENE_OR_GENE_PRODUCT", 24, 30], ["EV71", "ORGANISM", 56, 60], ["cellular receptor", "PROTEIN", 5, 22], ["SCARB2", "PROTEIN", 24, 30], ["EV71", "SPECIES", 56, 60], ["efficient EV71 infection", "PROBLEM", 46, 70]]], ["Firstly, we observed the differential surface expression of SCARB2 on HeLa and HepG2 cells (Fig. 1A), and showed that this differential expression of SCARB2 appears to impact on the susceptibility of HeLa and HepG2 cells to EV71 infection (Fig. 1B).", [["surface", "ANATOMY", 38, 45], ["HeLa", "ANATOMY", 70, 74], ["HepG2 cells", "ANATOMY", 79, 90], ["HeLa", "ANATOMY", 200, 204], ["HepG2 cells", "ANATOMY", 209, 220], ["EV71 infection", "DISEASE", 224, 238], ["SCARB2", "GENE_OR_GENE_PRODUCT", 60, 66], ["HeLa", "CELL", 70, 74], ["HepG2 cells", "CELL", 79, 90], ["Fig. 1A", "CELL", 92, 99], ["SCARB2", "GENE_OR_GENE_PRODUCT", 150, 156], ["HeLa", "CELL", 200, 204], ["HepG2 cells", "CELL", 209, 220], ["EV71", "ORGANISM", 224, 228], ["SCARB2", "PROTEIN", 60, 66], ["HeLa", "CELL_LINE", 70, 74], ["HepG2 cells", "CELL_LINE", 79, 90], ["SCARB2", "PROTEIN", 150, 156], ["HeLa", "CELL_LINE", 200, 204], ["HepG2 cells", "CELL_LINE", 209, 220], ["EV71", "SPECIES", 224, 228], ["SCARB2 on HeLa", "PROBLEM", 60, 74], ["HepG2 cells", "TEST", 79, 90], ["SCARB2", "PROBLEM", 150, 156], ["the susceptibility of HeLa", "PROBLEM", 178, 204], ["HepG2 cells", "PROBLEM", 209, 220], ["EV71 infection", "PROBLEM", 224, 238]]], ["We found that the progression of cytopathic effects in HepG2 cells was slower than that in HeLa cells, suggesting that the efficiency of EV71 infection was correlated with the level of cell surface SCARB2 expression (Fig. 1A,B).", [["HepG2 cells", "ANATOMY", 55, 66], ["HeLa cells", "ANATOMY", 91, 101], ["cell surface", "ANATOMY", 185, 197], ["EV71 infection", "DISEASE", 137, 151], ["HepG2 cells", "CELL", 55, 66], ["HeLa cells", "CELL", 91, 101], ["EV71", "ORGANISM", 137, 141], ["cell", "CELL", 185, 189], ["SCARB2", "GENE_OR_GENE_PRODUCT", 198, 204], ["B", "GENE_OR_GENE_PRODUCT", 225, 226], ["HepG2 cells", "CELL_LINE", 55, 66], ["HeLa cells", "CELL_LINE", 91, 101], ["SCARB2", "PROTEIN", 198, 204], ["EV71", "SPECIES", 137, 141], ["cytopathic effects in HepG2 cells", "PROBLEM", 33, 66], ["HeLa cells", "PROBLEM", 91, 101], ["EV71 infection", "PROBLEM", 137, 151], ["progression", "OBSERVATION_MODIFIER", 18, 29], ["cytopathic", "OBSERVATION_MODIFIER", 33, 43], ["HepG2 cells", "OBSERVATION", 55, 66], ["HeLa cells", "OBSERVATION", 91, 101], ["EV71", "OBSERVATION_MODIFIER", 137, 141], ["infection", "OBSERVATION", 142, 151]]], ["Additionally, we also found that HeLa cells expressed a relative lower level of miR\u2010127\u20105p (Fig. 1C).", [["HeLa cells", "ANATOMY", 33, 43], ["HeLa cells", "CELL", 33, 43], ["miR\u2010127\u20105", "GENE_OR_GENE_PRODUCT", 80, 89], ["HeLa cells", "CELL_LINE", 33, 43], ["HeLa cells", "PROBLEM", 33, 43], ["HeLa cells", "OBSERVATION", 33, 43]]], ["We then investigated if miR\u2010127\u20105p directly suppresses SCARB2 expression by transfecting miR\u2010127\u20105p mimics into both HeLa and HepG2 cells, and then measuring the expression of both SCARB2 mRNA and the protein.", [["HeLa", "ANATOMY", 117, 121], ["HepG2 cells", "ANATOMY", 126, 137], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 24, 34], ["SCARB2", "GENE_OR_GENE_PRODUCT", 55, 61], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 89, 99], ["HeLa", "CELL", 117, 121], ["HepG2 cells", "CELL", 126, 137], ["SCARB2", "GENE_OR_GENE_PRODUCT", 181, 187], ["miR\u2010127\u20105p", "DNA", 24, 34], ["SCARB2", "PROTEIN", 55, 61], ["miR\u2010127\u20105p", "DNA", 89, 99], ["HeLa", "CELL_LINE", 117, 121], ["HepG2 cells", "CELL_LINE", 126, 137], ["SCARB2 mRNA", "RNA", 181, 192], ["HepG2 cells", "TEST", 126, 137]]], ["We found that miR\u2010127\u20105p mimics significantly reduced both the mRNA level (Fig. 1D) and protein expression of SCARB2 (Fig. 1E), consistent with the previous observations obtained from different cell lines 29.", [["cell lines", "ANATOMY", 194, 204], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 14, 24], ["SCARB2", "GENE_OR_GENE_PRODUCT", 110, 116], ["Fig. 1E", "GENE_OR_GENE_PRODUCT", 118, 125], ["cell lines 29", "CELL", 194, 207], ["SCARB2", "PROTEIN", 110, 116], ["Fig. 1E", "PROTEIN", 118, 125], ["cell lines 29", "CELL_LINE", 194, 207], ["protein expression", "TEST", 88, 106], ["SCARB2", "TEST", 110, 116], ["different cell lines", "TREATMENT", 184, 204], ["consistent with", "UNCERTAINTY", 128, 143], ["cell lines", "OBSERVATION", 194, 204]]], ["Consistent with above observation, a miR\u2010127\u20105p inhibitor significantly increased mRNA level (Fig. 1F) and protein expression of SCARB2 (Fig. 1G), as compared to the negative control.", [["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 37, 47], ["SCARB2", "GENE_OR_GENE_PRODUCT", 129, 135], ["Fig. 1G", "GENE_OR_GENE_PRODUCT", 137, 144], ["SCARB2", "PROTEIN", 129, 135], ["a miR\u2010127\u20105p inhibitor", "TREATMENT", 35, 57], ["mRNA level", "TEST", 82, 92], ["SCARB2", "TEST", 129, 135]]], ["To further verify that the downregulation of SCARB2 expression is due to targeting by miR\u2010127\u20105p, we performed a bioinformatic search using microRNA (http://www.microrna.org/ to identify putative binding site and identified two seed regions at the 3\u2032 UTR of SCARB2 (nucleotides 369\u2013374 and 484\u2013490) that may bind miR\u2010127\u20105p.", [["nucleotides", "CHEMICAL", 266, 277], ["SCARB2", "GENE_OR_GENE_PRODUCT", 45, 51], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 86, 96], ["SCARB2", "GENE_OR_GENE_PRODUCT", 258, 264], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 313, 323], ["SCARB2", "PROTEIN", 45, 51], ["miR\u2010127\u20105p", "DNA", 86, 96], ["microRNA", "DNA", 140, 148], ["http://www.microrna.org", "DNA", 150, 173], ["putative binding site", "DNA", 187, 208], ["UTR", "DNA", 251, 254], ["SCARB2", "DNA", 258, 264], ["nucleotides 369\u2013374 and 484\u2013490", "DNA", 266, 297], ["miR\u2010127\u20105p", "DNA", 313, 323], ["putative binding site", "PROBLEM", 187, 208], ["nucleotides", "TEST", 266, 277]]], ["In order to demonstrate that the binding sites are specific, we constructed expression plasmids of SCARB2 wild\u2010type/mutant 3\u2032 UTR containing the putative miR\u2010127\u20105p\u2010binding sites by cloning into the pmirGLO reporter vector.", [["plasmids", "ANATOMY", 87, 95], ["SCARB2", "GENE_OR_GENE_PRODUCT", 99, 105], ["miR\u2010127\u20105", "GENE_OR_GENE_PRODUCT", 154, 163], ["pmirGLO", "GENE_OR_GENE_PRODUCT", 199, 206], ["binding sites", "DNA", 33, 46], ["expression plasmids", "DNA", 76, 95], ["SCARB2", "PROTEIN", 99, 105], ["UTR", "DNA", 126, 129], ["miR\u2010127\u20105p\u2010binding sites", "DNA", 154, 178], ["pmirGLO reporter vector", "DNA", 199, 222], ["the binding sites", "PROBLEM", 29, 46]]], ["Mutant reporter constructs were generated with underlined nucleotides indicating the mutated sequences as shown in Fig. 1H.", [["nucleotides", "CHEMICAL", 58, 69], ["Mutant reporter constructs", "DNA", 0, 26], ["mutated sequences", "DNA", 85, 102], ["Mutant reporter constructs", "PROBLEM", 0, 26], ["the mutated sequences", "PROBLEM", 81, 102]]], ["We cotransfected pmirGLO plasmid into 293T cells, along with miR\u2010127\u20105p mimics or negative control mimics.", [["plasmid", "ANATOMY", 25, 32], ["293T cells", "ANATOMY", 38, 48], ["pmirGLO", "GENE_OR_GENE_PRODUCT", 17, 24], ["293T cells", "CELL", 38, 48], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 61, 71], ["pmirGLO plasmid", "DNA", 17, 32], ["293T cells", "CELL_LINE", 38, 48], ["miR\u2010127\u20105p", "DNA", 61, 71], ["cotransfected pmirGLO plasmid", "TREATMENT", 3, 32], ["293T cells", "OBSERVATION", 38, 48]]], ["The luciferase activity of SCARB2 3\u2032 UTR wt was significantly reduced in 293T cells treated with miR\u2010127\u20105p mimics, whereas the SCARB2 3\u2032 UTR mut1 or SCARB2 3\u2032 UTR mut2 partly reversed the inhibition of luciferase activity by miR\u2010127\u20105p mimics.", [["293T cells", "ANATOMY", 73, 83], ["luciferase", "GENE_OR_GENE_PRODUCT", 4, 14], ["SCARB2 3", "GENE_OR_GENE_PRODUCT", 27, 35], ["293T cells", "CELL", 73, 83], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 97, 107], ["mut2", "GENE_OR_GENE_PRODUCT", 164, 168], ["luciferase", "GENE_OR_GENE_PRODUCT", 203, 213], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 226, 236], ["luciferase", "PROTEIN", 4, 14], ["SCARB2 3", "PROTEIN", 27, 35], ["UTR", "DNA", 37, 40], ["293T cells", "CELL_LINE", 73, 83], ["miR\u2010127\u20105p", "DNA", 97, 107], ["SCARB2 3\u2032 UTR", "DNA", 128, 141], ["mut1", "DNA", 142, 146], ["SCARB2 3", "DNA", 150, 158], ["UTR mut2", "DNA", 160, 168], ["luciferase", "PROTEIN", 203, 213], ["miR\u2010127\u20105p", "DNA", 226, 236], ["UTR wt", "TEST", 37, 43], ["SCARB2", "TEST", 150, 156], ["luciferase activity", "OBSERVATION", 4, 23], ["293T cells", "OBSERVATION", 73, 83]]], ["Additionally, the luciferase activity in the cells transfected with the SCARB2 3\u2032 UTR mut1/2 vector was unaffected by the miR\u2010127\u20105p mimics (Fig. 1I).", [["cells", "ANATOMY", 45, 50], ["luciferase", "GENE_OR_GENE_PRODUCT", 18, 28], ["cells", "CELL", 45, 50], ["SCARB2 3", "GENE_OR_GENE_PRODUCT", 72, 80], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 122, 132], ["luciferase", "PROTEIN", 18, 28], ["SCARB2 3\u2032 UTR mut1/2 vector", "DNA", 72, 99], ["miR\u2010127\u20105p", "DNA", 122, 132], ["the SCARB2", "TREATMENT", 68, 78], ["UTR mut1/2 vector", "TREATMENT", 82, 99], ["luciferase activity", "OBSERVATION", 18, 37]]], ["This result was in agreement with a previous study showing that miR\u2010127\u20105p had effect on the luciferase activity of pMir\u2010SCARB2 3\u2032 UTR plasmid 29.", [["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 64, 74], ["luciferase", "GENE_OR_GENE_PRODUCT", 93, 103], ["pMir", "GENE_OR_GENE_PRODUCT", 116, 120], ["miR\u2010127\u20105p", "DNA", 64, 74], ["luciferase", "PROTEIN", 93, 103], ["pMir", "PROTEIN", 116, 120], ["SCARB2 3", "PROTEIN", 121, 129], ["UTR plasmid 29", "DNA", 131, 145], ["a previous study", "TEST", 34, 50], ["UTR plasmid", "TREATMENT", 131, 142]]], ["In summary, these data suggested that SCARB2 is a direct target of miR\u2010127\u20105p and that its expression is modulated by miR\u2010127\u20105p.EV71 infection upregulates miR\u2010127\u20105p expression ::: ResultsWe investigated the expression of miR\u2010127\u20105p in EV71\u2010infected HeLa cells and found that cellular miR\u2010127\u20105p expression at 12 h and 24 h postinfection was 2.8\u2010 and 3\u2010fold higher, respectively, than that of the mock\u2010infected HeLa cells (Fig. 2A).", [["HeLa cells", "ANATOMY", 251, 261], ["cellular", "ANATOMY", 277, 285], ["HeLa cells", "ANATOMY", 412, 422], ["EV71 infection", "DISEASE", 129, 143], ["SCARB2", "GENE_OR_GENE_PRODUCT", 38, 44], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 67, 77], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 118, 128], ["EV71", "ORGANISM", 129, 133], ["miR\u2010127\u20105", "GENE_OR_GENE_PRODUCT", 156, 165], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 223, 233], ["EV71", "ORGANISM", 237, 241], ["HeLa cells", "CELL", 251, 261], ["cellular", "CELL", 277, 285], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 286, 296], ["HeLa cells", "CELL", 412, 422], ["Fig. 2A", "CELL", 424, 431], ["SCARB2", "PROTEIN", 38, 44], ["miR\u2010127\u20105p", "DNA", 67, 77], ["miR\u2010127\u20105p", "DNA", 118, 128], ["miR", "DNA", 156, 159], ["miR\u2010127\u20105p", "DNA", 223, 233], ["EV71\u2010infected HeLa cells", "CELL_LINE", 237, 261], ["mock\u2010infected HeLa cells", "CELL_LINE", 398, 422], ["EV71", "SPECIES", 129, 133], ["EV71", "SPECIES", 237, 241], ["HeLa cells", "TEST", 251, 261], ["cellular miR", "TEST", 277, 289], ["expression", "TEST", 297, 307], ["postinfection", "TEST", 325, 338], ["HeLa cells", "OBSERVATION", 412, 422]]], ["In EV71\u2010infected HepG2 cells, the miR\u2010127\u20105p expression at 12 h and 24 h was 2.4\u2010 and 2.5\u2010fold higher than those of the mock\u2010infected cells, respectively (Fig. 2B).", [["HepG2 cells", "ANATOMY", 17, 28], ["cells", "ANATOMY", 134, 139], ["EV71", "ORGANISM", 3, 7], ["HepG2 cells", "CELL", 17, 28], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 34, 44], ["cells", "CELL", 134, 139], ["EV71\u2010infected HepG2 cells", "CELL_LINE", 3, 28], ["miR\u2010127\u20105p", "DNA", 34, 44], ["mock\u2010infected cells", "CELL_LINE", 120, 139], ["EV71", "SPECIES", 3, 7], ["HepG2 cells", "TEST", 17, 28], ["the miR", "TEST", 30, 37], ["expression", "TEST", 45, 55], ["HepG2 cells", "OBSERVATION", 17, 28]]], ["Thus, these results demonstrated that EV71 infection upregulated miR\u2010127\u20105p expression.", [["EV71 infection", "DISEASE", 38, 52], ["EV71", "ORGANISM", 38, 42], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 65, 75], ["miR\u2010127\u20105p", "DNA", 65, 75], ["EV71", "SPECIES", 38, 42], ["EV71 infection", "PROBLEM", 38, 52]]], ["To investigate whether upregulation of the miR\u2010127\u20105p following EV71 infection could affect SCARB2 expression, quantitative real\u2010time PCR and western blot were performed simultaneously to measure the SCARB2 expression in HeLa (Fig. 2C) and HepG2 cells (Fig. 2D) and, as expected, SCARB2 was slightly, but significantly, downregulated after EV71 infection.EV71 gene expression and replication are attenuated by miR\u2010127\u20105p overexpression ::: ResultsEarlier studies showed that SCARB2 siRNA treatment inhibited EV71 infection 34, 36.", [["HeLa", "ANATOMY", 221, 225], ["HepG2 cells", "ANATOMY", 240, 251], ["EV71 infection", "DISEASE", 64, 78], ["EV71 infection", "DISEASE", 340, 354], ["SCARB2", "CHEMICAL", 475, 481], ["EV71 infection", "DISEASE", 508, 522], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 43, 53], ["EV71", "ORGANISM", 64, 68], ["SCARB2", "GENE_OR_GENE_PRODUCT", 92, 98], ["SCARB2", "GENE_OR_GENE_PRODUCT", 200, 206], ["HeLa", "CELL", 221, 225], ["Fig. 2C)", "CELL", 227, 235], ["HepG2 cells", "CELL", 240, 251], ["Fig. 2D", "CELL", 253, 260], ["SCARB2", "GENE_OR_GENE_PRODUCT", 280, 286], ["EV71", "ORGANISM", 340, 344], ["EV71", "ORGANISM", 355, 359], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 410, 420], ["SCARB2", "GENE_OR_GENE_PRODUCT", 475, 481], ["EV71", "ORGANISM", 508, 512], ["miR\u2010127\u20105p", "DNA", 43, 53], ["SCARB2", "PROTEIN", 92, 98], ["SCARB2", "PROTEIN", 200, 206], ["HeLa", "CELL_LINE", 221, 225], ["HepG2 cells", "CELL_LINE", 240, 251], ["SCARB2", "PROTEIN", 280, 286], ["EV71 gene", "DNA", 355, 364], ["miR\u2010127\u20105p", "DNA", 410, 420], ["EV71", "SPECIES", 64, 68], ["EV71", "SPECIES", 340, 344], ["EV71", "SPECIES", 355, 359], ["EV71 infection", "PROBLEM", 64, 78], ["quantitative real\u2010time PCR", "TEST", 111, 137], ["western blot", "TEST", 142, 154], ["HepG2 cells", "TEST", 240, 251], ["EV71 infection", "PROBLEM", 340, 354], ["ResultsEarlier studies", "TEST", 440, 462], ["SCARB2 siRNA treatment", "TREATMENT", 475, 497], ["EV71 infection", "PROBLEM", 508, 522], ["infection", "OBSERVATION", 69, 78], ["infection", "OBSERVATION", 345, 354]]], ["Similarly, our results have confirmed that miR\u2010127\u20105p could suppress the SCARB2 expression (Fig. 1A,B).", [["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 43, 53], ["SCARB2", "GENE_OR_GENE_PRODUCT", 73, 79], ["B", "GENE_OR_GENE_PRODUCT", 100, 101], ["miR\u2010127\u20105p", "DNA", 43, 53], ["SCARB2", "PROTEIN", 73, 79]]], ["To further substantiate whether modulation of miR\u2010127\u20105p expression would affect the surface expression of SCARB2, we transfected miR\u2010127\u20105p mimics into both HeLa and HepG2 cells, and then analyzed by flow cytometry.", [["surface", "ANATOMY", 85, 92], ["HeLa", "ANATOMY", 158, 162], ["HepG2 cells", "ANATOMY", 167, 178], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 46, 56], ["surface", "CELLULAR_COMPONENT", 85, 92], ["SCARB2", "GENE_OR_GENE_PRODUCT", 107, 113], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 130, 140], ["HeLa", "CELL", 158, 162], ["HepG2 cells", "CELL", 167, 178], ["miR\u2010127\u20105p", "PROTEIN", 46, 56], ["SCARB2", "PROTEIN", 107, 113], ["miR\u2010127\u20105p", "DNA", 130, 140], ["HeLa", "CELL_LINE", 158, 162], ["HepG2 cells", "CELL_LINE", 167, 178], ["HepG2 cells", "TEST", 167, 178], ["flow cytometry", "TEST", 201, 215], ["HeLa", "ANATOMY", 158, 162], ["HepG2", "ANATOMY", 167, 172]]], ["The result suggested that upregulation of the miR\u2010127\u20105p level led to a decrease in the surface expression of SCARB2 (Fig. 3A).", [["surface", "ANATOMY", 88, 95], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 46, 56], ["SCARB2", "GENE_OR_GENE_PRODUCT", 110, 116], ["Fig. 3A", "GENE_OR_GENE_PRODUCT", 118, 125], ["miR\u2010127\u20105p", "PROTEIN", 46, 56], ["SCARB2", "PROTEIN", 110, 116], ["Fig. 3A", "PROTEIN", 118, 125], ["the miR", "TEST", 42, 49], ["a decrease", "PROBLEM", 70, 80], ["decrease", "OBSERVATION_MODIFIER", 72, 80]]], ["Therefore, it is of interest to evaluate the effect of miR\u2010127\u20105p on EV71 replication.", [["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 55, 65], ["EV71", "ORGANISM", 69, 73], ["miR\u2010127\u20105p", "DNA", 55, 65], ["EV71", "SPECIES", 69, 73], ["EV71 replication", "TREATMENT", 69, 85]]], ["For this purpose, miR\u2010127\u20105p was overexpressed by miRNA mimics transfection and its effect on EV71 replication was assessed by measuring EV71 VP1 expression, the viral RNA level, viral titer, and percentage of infected cells.", [["cells", "ANATOMY", 219, 224], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 18, 28], ["EV71", "ORGANISM", 94, 98], ["EV71", "ORGANISM", 137, 141], ["VP1", "GENE_OR_GENE_PRODUCT", 142, 145], ["cells", "CELL", 219, 224], ["miR\u2010127\u20105p", "DNA", 18, 28], ["EV71 VP1", "PROTEIN", 137, 145], ["viral RNA", "RNA", 162, 171], ["infected cells", "CELL_TYPE", 210, 224], ["EV71", "SPECIES", 94, 98], ["EV71", "SPECIES", 137, 141], ["miRNA mimics transfection", "TREATMENT", 50, 75], ["EV71 replication", "TREATMENT", 94, 110], ["EV71 VP1 expression", "TEST", 137, 156], ["the viral RNA level", "TEST", 158, 177], ["viral titer", "TEST", 179, 190], ["infected cells", "PROBLEM", 210, 224], ["viral RNA", "OBSERVATION", 162, 171], ["viral titer", "OBSERVATION", 179, 190], ["infected cells", "OBSERVATION", 210, 224]]], ["EV71 VP1 protein decreased in both HeLa and HepG2 cells overexpressing miR\u2010127\u20105p, as compared to the negative control cells (Fig. 3B).", [["HeLa", "ANATOMY", 35, 39], ["HepG2 cells", "ANATOMY", 44, 55], ["cells", "ANATOMY", 119, 124], ["EV71", "ORGANISM", 0, 4], ["VP1", "GENE_OR_GENE_PRODUCT", 5, 8], ["HeLa", "CELL", 35, 39], ["HepG2 cells", "CELL", 44, 55], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 71, 81], ["cells", "CELL", 119, 124], ["EV71 VP1 protein", "PROTEIN", 0, 16], ["HeLa", "CELL_LINE", 35, 39], ["HepG2 cells", "CELL_LINE", 44, 55], ["miR\u2010127\u20105p", "DNA", 71, 81], ["negative control cells", "CELL_TYPE", 102, 124], ["EV71", "SPECIES", 0, 4], ["EV71 VP1 protein", "TEST", 0, 16], ["HepG2 cells", "TEST", 44, 55], ["miR", "TEST", 71, 74], ["decreased", "OBSERVATION_MODIFIER", 17, 26], ["both", "ANATOMY_MODIFIER", 30, 34], ["HeLa", "ANATOMY", 35, 39]]], ["The levels of SCARB2 mRNA (Fig. 3C) and EV71 RNA (Fig. 3D) in cells transfected with miR\u2010127\u20105p mimics were significantly reduced.", [["cells", "ANATOMY", 62, 67], ["SCARB2", "GENE_OR_GENE_PRODUCT", 14, 20], ["Fig. 3C", "GENE_OR_GENE_PRODUCT", 27, 34], ["cells", "CELL", 62, 67], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 85, 95], ["SCARB2 mRNA", "RNA", 14, 25], ["Fig. 3C", "RNA", 27, 34], ["EV71 RNA", "RNA", 40, 48], ["miR\u2010127\u20105p", "DNA", 85, 95], ["EV71", "SPECIES", 40, 44], ["The levels", "TEST", 0, 10], ["SCARB2 mRNA", "TEST", 14, 25], ["EV71 RNA", "TEST", 40, 48], ["reduced", "OBSERVATION_MODIFIER", 122, 129]]], ["The EV71 titers at various times postinfection were also significantly suppressed by miR\u2010127\u20105p overexpression, as compared to the control (Fig. 3E).", [["EV71", "ORGANISM", 4, 8], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 85, 95], ["EV71", "SPECIES", 4, 8], ["The EV71 titers", "TEST", 0, 15]]], ["Immunofluorescence staining of viral VP1 showed that the percentage of infected cells in cells overexpressing miR\u2010127\u20105p was reduced by nearly 50%, as compared to the control, at 24 h postinfection (Fig. 3F).", [["cells", "ANATOMY", 80, 85], ["cells", "ANATOMY", 89, 94], ["cells", "CELL", 80, 85], ["cells", "CELL", 89, 94], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 110, 120], ["viral VP1", "PROTEIN", 31, 40], ["infected cells", "CELL_TYPE", 71, 85], ["miR\u2010127\u20105p", "DNA", 110, 120], ["Immunofluorescence staining", "TEST", 0, 27], ["viral VP1", "TEST", 31, 40], ["infected cells", "PROBLEM", 71, 85], ["viral VP1", "OBSERVATION", 31, 40], ["infected cells", "OBSERVATION", 71, 85]]], ["When HeLa cells were transfected with increasing concentrations of miR\u2010127\u20105p mimics (10, 20, 40, and 50 nm), followed by EV71 infection, both SCARB2 mRNA and protein levels, as well as EV71 VP1 protein, were inhibited as a function of the dose of miR\u2010127\u20105p mimics (Fig. 3G).", [["HeLa cells", "ANATOMY", 5, 15], ["EV71 infection", "DISEASE", 122, 136], ["HeLa cells", "CELL", 5, 15], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 67, 77], ["EV71", "ORGANISM", 122, 126], ["SCARB2", "GENE_OR_GENE_PRODUCT", 143, 149], ["EV71 VP1", "GENE_OR_GENE_PRODUCT", 186, 194], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 248, 258], ["HeLa cells", "CELL_LINE", 5, 15], ["miR\u2010127\u20105p", "DNA", 67, 77], ["SCARB2 mRNA", "RNA", 143, 154], ["EV71 VP1 protein", "PROTEIN", 186, 202], ["miR\u2010127\u20105p", "DNA", 248, 258], ["EV71", "SPECIES", 122, 126], ["EV71", "SPECIES", 186, 190], ["HeLa cells", "PROBLEM", 5, 15], ["EV71 infection", "PROBLEM", 122, 136], ["protein levels", "TEST", 159, 173], ["EV71 VP1 protein", "TEST", 186, 202], ["infection", "OBSERVATION", 127, 136]]], ["These results showed that miR\u2010127\u20105p overexpression downregulated SCARB2 expression and thus significantly reduced EV71 infection.Suppression of endogenous miR\u2010127\u20105p enhances EV71 replication ::: ResultsNext, we performed experiments to determine whether inhibition of endogenous miR\u2010127\u20105p expression affects EV71 replication.", [["EV71 infection", "DISEASE", 115, 129], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 26, 36], ["SCARB2", "GENE_OR_GENE_PRODUCT", 66, 72], ["EV71", "ORGANISM", 115, 119], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 156, 166], ["EV71", "ORGANISM", 176, 180], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 281, 291], ["EV71", "ORGANISM", 311, 315], ["SCARB2", "PROTEIN", 66, 72], ["endogenous miR\u2010127\u20105p", "DNA", 145, 166], ["EV71", "SPECIES", 115, 119], ["EV71", "SPECIES", 311, 315], ["overexpression downregulated SCARB2 expression", "PROBLEM", 37, 83], ["significantly reduced EV71 infection", "PROBLEM", 93, 129], ["EV71 replication", "TREATMENT", 311, 327], ["reduced", "OBSERVATION_MODIFIER", 107, 114], ["EV71", "OBSERVATION_MODIFIER", 115, 119], ["infection", "OBSERVATION", 120, 129], ["endogenous miR", "OBSERVATION", 145, 159]]], ["A chemically synthesized oligonucleotide with sequence complementary to endogenous miR\u2010127\u20105p was used to inhibit endogenous miR\u2010127\u20105p expression.", [["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 83, 93], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 125, 135], ["endogenous miR\u2010127\u20105p", "DNA", 72, 93], ["miR\u2010127\u20105p", "DNA", 125, 135], ["A chemically synthesized oligonucleotide", "TREATMENT", 0, 40]]], ["Such inhibitor oligonucleotides have been shown to sequester intracellular miRNAs and to inhibit their activity in the RNA interference pathway 37, 38.", [["intracellular", "ANATOMY", 61, 74], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 61, 74], ["Such inhibitor oligonucleotides", "TREATMENT", 0, 31]]], ["Interestingly, transfection of miR\u2010127\u20105p inhibitor increased the surface SCARB2 expression (Fig. 4A).", [["surface", "ANATOMY", 66, 73], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 31, 41], ["SCARB2", "GENE_OR_GENE_PRODUCT", 74, 80], ["SCARB2", "PROTEIN", 74, 80], ["miR\u2010127\u20105p inhibitor", "TREATMENT", 31, 51]]], ["Moreover, HeLa and HepG2 cells transfected with the miR\u2010127\u20105p inhibitor or NC inhibitor were subsequently infected with EV71, and EV71 VP1 expression, SCARB2 mRNA level, the viral RNA level, and viral titers were determined, respectively.", [["HeLa", "ANATOMY", 10, 14], ["HepG2 cells", "ANATOMY", 19, 30], ["HeLa", "CELL", 10, 14], ["HepG2 cells", "CELL", 19, 30], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 52, 62], ["NC", "GENE_OR_GENE_PRODUCT", 76, 78], ["EV71", "ORGANISM", 121, 125], ["EV71", "ORGANISM", 131, 135], ["VP1", "GENE_OR_GENE_PRODUCT", 136, 139], ["SCARB2", "GENE_OR_GENE_PRODUCT", 152, 158], ["HeLa", "CELL_LINE", 10, 14], ["HepG2 cells", "CELL_LINE", 19, 30], ["SCARB2 mRNA", "RNA", 152, 163], ["viral RNA", "RNA", 175, 184], ["EV71", "SPECIES", 121, 125], ["EV71", "SPECIES", 131, 135], ["HeLa and HepG2 cells", "TREATMENT", 10, 30], ["the miR\u2010127\u20105p inhibitor", "TREATMENT", 48, 72], ["NC inhibitor", "TREATMENT", 76, 88], ["EV71", "TEST", 121, 125], ["EV71 VP1 expression", "TEST", 131, 150], ["SCARB2 mRNA level", "TEST", 152, 169], ["the viral RNA level", "TEST", 171, 190], ["viral titers", "TEST", 196, 208], ["viral RNA", "OBSERVATION", 175, 184], ["viral titers", "OBSERVATION", 196, 208]]], ["The expression of EV71 VP1 protein (Fig. 4B) in HeLa and HepG2 cells was upregulated by the inhibition of endogenous miR\u2010127\u20105p, as shown by western blot analysis.", [["HeLa", "ANATOMY", 48, 52], ["HepG2 cells", "ANATOMY", 57, 68], ["EV71", "ORGANISM", 18, 22], ["VP1", "GENE_OR_GENE_PRODUCT", 23, 26], ["Fig. 4B", "GENE_OR_GENE_PRODUCT", 36, 43], ["HeLa", "CELL", 48, 52], ["HepG2 cells", "CELL", 57, 68], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 117, 127], ["EV71 VP1 protein", "PROTEIN", 18, 34], ["Fig. 4B", "PROTEIN", 36, 43], ["HeLa", "CELL_LINE", 48, 52], ["HepG2 cells", "CELL_LINE", 57, 68], ["EV71", "SPECIES", 18, 22], ["EV71 VP1 protein", "TEST", 18, 34], ["HeLa and HepG2 cells", "TREATMENT", 48, 68], ["blot analysis", "TEST", 149, 162]]], ["Consistently, the levels of SCARB2 mRNA (Fig. 4C) and EV71 RNA (Fig. 4D) were also higher in cells transfected with miR\u2010127\u20105p inhibitor than in the negative control cells.", [["cells", "ANATOMY", 93, 98], ["cells", "ANATOMY", 166, 171], ["SCARB2", "GENE_OR_GENE_PRODUCT", 28, 34], ["Fig. 4C", "GENE_OR_GENE_PRODUCT", 41, 48], ["cells", "CELL", 93, 98], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 116, 126], ["cells", "CELL", 166, 171], ["SCARB2 mRNA", "RNA", 28, 39], ["Fig. 4C", "RNA", 41, 48], ["EV71 RNA", "RNA", 54, 62], ["negative control cells", "CELL_LINE", 149, 171], ["EV71", "SPECIES", 54, 58], ["the levels", "TEST", 14, 24], ["SCARB2 mRNA", "TEST", 28, 39], ["EV71 RNA", "TEST", 54, 62], ["miR\u2010127\u20105p inhibitor", "TREATMENT", 116, 136]]], ["We also found that the EV71 titer was significantly higher in cells treated with miR\u2010127\u20105p inhibitor than that in untreated cells (Fig. 4E).", [["cells", "ANATOMY", 62, 67], ["cells", "ANATOMY", 125, 130], ["EV71", "ORGANISM", 23, 27], ["cells", "CELL", 62, 67], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 81, 91], ["cells", "CELL", 125, 130], ["untreated cells", "CELL_TYPE", 115, 130], ["EV71", "SPECIES", 23, 27], ["the EV71 titer", "TEST", 19, 33], ["miR\u2010127\u20105p inhibitor", "TREATMENT", 81, 101]]], ["In conclusion, these results demonstrated that inhibition of endogenous miR\u2010127\u20105p led to enhancement of EV71 replication.miR\u2010127\u20105p does not influence intracellular replication of EV71 ::: ResultsWe postulate that mechanistically miR\u2010127\u20105p downregulates cellular receptor SCARB2 and thus prevents the EV71 attachment to and entry into the cells.", [["intracellular", "ANATOMY", 152, 165], ["cellular", "ANATOMY", 256, 264], ["cells", "ANATOMY", 341, 346], ["miR\u2010127\u20105p", "CHEMICAL", 72, 82], ["EV71", "DISEASE", 181, 185], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 72, 82], ["EV71", "ORGANISM", 105, 109], ["miR\u2010127\u20105", "GENE_OR_GENE_PRODUCT", 122, 131], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 152, 165], ["EV71", "ORGANISM", 181, 185], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 231, 241], ["cellular", "CELL", 256, 264], ["SCARB2", "GENE_OR_GENE_PRODUCT", 274, 280], ["EV71", "ORGANISM", 303, 307], ["cells", "CELL", 341, 346], ["miR\u2010127\u20105p", "DNA", 72, 82], ["miR", "DNA", 122, 125], ["miR\u2010127\u20105p", "PROTEIN", 231, 241], ["SCARB2", "PROTEIN", 274, 280], ["EV71", "SPECIES", 105, 109], ["EV71", "SPECIES", 181, 185], ["EV71 replication", "TREATMENT", 105, 121], ["cellular receptor SCARB2", "TREATMENT", 256, 280], ["the EV71 attachment", "PROBLEM", 299, 318], ["EV71 replication", "OBSERVATION", 105, 121], ["cells", "ANATOMY", 341, 346]]], ["To further investigate the mechanism of miR\u2010127\u20105p inhibition, we conducted a virus attachment analysis to determine if viral attachment is affected by the miR\u2010127\u20105p\u2010mediated down\u2010modulation of SCARB2.", [["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 40, 50], ["miR\u2010127\u20105", "GENE_OR_GENE_PRODUCT", 156, 165], ["SCARB2", "GENE_OR_GENE_PRODUCT", 195, 201], ["miR\u2010127\u20105p", "DNA", 40, 50], ["SCARB2", "PROTEIN", 195, 201], ["a virus attachment analysis", "TEST", 76, 103], ["viral attachment", "PROBLEM", 120, 136]]], ["The result showed that miR\u2010127\u20105p significantly reduced the amount of VP1, as compared to the control cells (Fig. 5A).", [["cells", "ANATOMY", 102, 107], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 23, 33], ["VP1", "GENE_OR_GENE_PRODUCT", 70, 73], ["cells", "CELL", 102, 107], ["miR\u2010127\u20105p", "DNA", 23, 33], ["VP1", "PROTEIN", 70, 73], ["control cells", "CELL_TYPE", 94, 107], ["VP1", "TEST", 70, 73], ["amount", "OBSERVATION_MODIFIER", 60, 66]]], ["The above results suggested that miR\u2010127\u20105p blocked entry of EV71 by inhibiting expression of the viral receptor SCARB2, resulting in the reduction of viral attachment.miR\u2010127\u20105p does not influence intracellular replication of EV71 ::: ResultsPrevious studies reported that viral genomic RNA is directly targeted by host miRNAs 39, 40.", [["intracellular", "ANATOMY", 198, 211], ["EV71", "DISEASE", 61, 65], ["EV71", "DISEASE", 227, 231], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 33, 43], ["EV71", "ORGANISM", 61, 65], ["SCARB2", "GENE_OR_GENE_PRODUCT", 113, 119], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 168, 178], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 198, 211], ["EV71", "ORGANISM", 227, 231], ["miR\u2010127\u20105p", "PROTEIN", 33, 43], ["viral receptor", "PROTEIN", 98, 112], ["SCARB2", "PROTEIN", 113, 119], ["miR\u2010127\u20105p", "DNA", 168, 178], ["viral genomic RNA", "RNA", 274, 291], ["EV71", "SPECIES", 61, 65], ["EV71", "SPECIES", 227, 231], ["EV71", "PROBLEM", 61, 65], ["the viral receptor SCARB2", "PROBLEM", 94, 119], ["viral attachment", "PROBLEM", 151, 167], ["ResultsPrevious studies", "TEST", 236, 259], ["viral genomic RNA", "PROBLEM", 274, 291], ["viral receptor SCARB2", "OBSERVATION", 98, 119], ["reduction", "OBSERVATION_MODIFIER", 138, 147], ["viral attachment", "OBSERVATION", 151, 167], ["viral genomic RNA", "OBSERVATION", 274, 291]]], ["In order to rule out the possibility that EV71 genomic RNA is targeted by miR\u2010127\u20105p in our research, studies were carried out to determine if EV71 genomic RNA contains potential target sequences for miR\u2010127\u20105p.", [["EV71", "ORGANISM", 42, 46], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 74, 84], ["EV71", "ORGANISM", 143, 147], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 200, 210], ["EV71 genomic RNA", "RNA", 42, 58], ["miR\u2010127\u20105p", "DNA", 74, 84], ["EV71 genomic RNA", "RNA", 143, 159], ["target sequences", "DNA", 179, 195], ["miR\u2010127\u20105p", "DNA", 200, 210], ["EV71", "SPECIES", 42, 46], ["EV71", "SPECIES", 143, 147], ["EV71 genomic RNA", "PROBLEM", 42, 58], ["EV71 genomic RNA", "PROBLEM", 143, 159]]], ["It had been demonstrated that hSCARB2, but not mScarb2, bound efficiently to EV71 41.", [["hSCARB2", "GENE_OR_GENE_PRODUCT", 30, 37], ["mScarb2", "GENE_OR_GENE_PRODUCT", 47, 54], ["EV71", "ORGANISM", 77, 81], ["hSCARB2", "PROTEIN", 30, 37], ["mScarb2", "PROTEIN", 47, 54], ["EV71", "TEST", 77, 81]]], ["Mouse L929 cells are not susceptible to EV71 infection and allow only inefficient EV71 infection, because they lack the cellular receptor 21, 24, 35.", [["L929 cells", "ANATOMY", 6, 16], ["cellular", "ANATOMY", 120, 128], ["EV71 infection", "DISEASE", 40, 54], ["EV71 infection", "DISEASE", 82, 96], ["Mouse", "ORGANISM", 0, 5], ["L929 cells", "CELL", 6, 16], ["EV71", "ORGANISM", 40, 44], ["EV71", "ORGANISM", 82, 86], ["cellular", "CELL", 120, 128], ["Mouse L929 cells", "CELL_LINE", 0, 16], ["cellular receptor 21, 24, 35", "PROTEIN", 120, 148], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["EV71", "SPECIES", 40, 44], ["EV71", "SPECIES", 82, 86], ["Mouse L929 cells", "PROBLEM", 0, 16], ["EV71 infection", "PROBLEM", 40, 54], ["inefficient EV71 infection", "PROBLEM", 70, 96], ["the cellular receptor", "TEST", 116, 137], ["L929 cells", "OBSERVATION", 6, 16], ["infection", "OBSERVATION", 45, 54], ["infection", "OBSERVATION", 87, 96]]], ["In this study, we used L929 cells to investigate whether EV71 replication initiated by transfection of infectious viral genomic RNA is affected by miR\u2010127\u20105p.", [["L929 cells", "ANATOMY", 23, 33], ["L929 cells", "CELL", 23, 33], ["EV71", "ORGANISM", 57, 61], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 147, 157], ["L929 cells", "CELL_LINE", 23, 33], ["infectious viral genomic RNA", "RNA", 103, 131], ["miR\u2010127\u20105p", "DNA", 147, 157], ["EV71", "SPECIES", 57, 61], ["this study", "TEST", 3, 13], ["L929 cells", "TREATMENT", 23, 33], ["EV71 replication", "TREATMENT", 57, 73], ["infectious viral genomic RNA", "PROBLEM", 103, 131], ["infectious", "OBSERVATION_MODIFIER", 103, 113]]], ["High level of miR\u2010127\u20105p was detected in miR\u2010127\u20105p\u2010transfected L929 cells, suggesting that the miR\u2010127\u20105p was efficiently incorporated intracellularly (Fig. 5B).", [["L929 cells", "ANATOMY", 64, 74], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 14, 24], ["miR\u2010127\u20105", "GENE_OR_GENE_PRODUCT", 41, 50], ["L929 cells", "CELL", 64, 74], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 96, 106], ["miR\u2010127\u20105p", "DNA", 14, 24], ["miR\u2010127\u20105", "CELL_LINE", 41, 50], ["L929 cells", "CELL_LINE", 64, 74], ["miR\u2010127\u20105p", "DNA", 96, 106], ["the miR\u2010", "TEST", 92, 100]]], ["In the L929 cells transfected with EV71 genomic RNA, although increasing amounts of viral RNA were detected, no inhibitory effect of miR\u2010127\u20105p was observed (Fig. 5C).", [["L929 cells", "ANATOMY", 7, 17], ["L929 cells", "CELL", 7, 17], ["EV71", "ORGANISM", 35, 39], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 133, 143], ["L929 cells", "CELL_LINE", 7, 17], ["EV71 genomic RNA", "RNA", 35, 51], ["viral RNA", "RNA", 84, 93], ["miR\u2010127\u20105p", "DNA", 133, 143], ["EV71", "SPECIES", 35, 39], ["EV71 genomic RNA", "PROBLEM", 35, 51], ["increasing amounts of viral RNA", "PROBLEM", 62, 93], ["EV71 genomic RNA", "OBSERVATION", 35, 51], ["increasing", "OBSERVATION_MODIFIER", 62, 72], ["amounts", "OBSERVATION_MODIFIER", 73, 80], ["viral RNA", "OBSERVATION", 84, 93]]], ["In addition, EV71 VP1 expression showed no difference between the cells overexpressing miR\u2010127\u20105p and the control cells (Fig. 5D).", [["cells", "ANATOMY", 66, 71], ["cells", "ANATOMY", 114, 119], ["EV71", "ORGANISM", 13, 17], ["VP1", "GENE_OR_GENE_PRODUCT", 18, 21], ["cells", "CELL", 66, 71], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 87, 97], ["cells", "CELL", 114, 119], ["EV71 VP1", "PROTEIN", 13, 21], ["miR\u2010127\u20105p", "DNA", 87, 97], ["control cells", "CELL_TYPE", 106, 119], ["EV71", "SPECIES", 13, 17], ["EV71 VP1 expression", "TEST", 13, 32], ["no", "UNCERTAINTY", 40, 42]]], ["These results demonstrated that miR\u2010127\u20105p suppressed infection of EV71 by downregulating the expression of its major cellular receptor, SCARB2, rather than impairing the intracellular viral replication.DiscussionIn recent years, morbidity and mortality due to EV71 infection have increased, whereas the underlying pathogenic mechanisms remain elusive, and intervention and therapeutic approaches are still limited.", [["cellular", "ANATOMY", 118, 126], ["intracellular", "ANATOMY", 171, 184], ["miR\u2010127\u20105p", "CHEMICAL", 32, 42], ["infection", "DISEASE", 54, 63], ["EV71", "DISEASE", 67, 71], ["EV71 infection", "DISEASE", 261, 275], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 32, 42], ["EV71", "ORGANISM", 67, 71], ["cellular", "CELL", 118, 126], ["SCARB2", "GENE_OR_GENE_PRODUCT", 137, 143], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 171, 184], ["EV71", "ORGANISM", 261, 265], ["miR\u2010127\u20105p", "PROTEIN", 32, 42], ["major cellular receptor", "PROTEIN", 112, 135], ["SCARB2", "PROTEIN", 137, 143], ["EV71", "SPECIES", 67, 71], ["EV71", "SPECIES", 261, 265], ["suppressed infection of EV71", "PROBLEM", 43, 71], ["the intracellular viral replication", "TREATMENT", 167, 202], ["morbidity", "PROBLEM", 230, 239], ["EV71 infection", "PROBLEM", 261, 275], ["the underlying pathogenic mechanisms", "PROBLEM", 300, 336], ["intervention", "TREATMENT", 357, 369], ["therapeutic approaches", "TREATMENT", 374, 396], ["major", "OBSERVATION_MODIFIER", 112, 117], ["cellular receptor", "OBSERVATION", 118, 135], ["intracellular", "OBSERVATION", 171, 184], ["viral replication", "OBSERVATION", 185, 202], ["infection", "OBSERVATION", 266, 275], ["increased", "OBSERVATION_MODIFIER", 281, 290]]], ["MicroRNAs serve as multifunctional regulators, and the significance of miRNAs in virus\u2013host interactions is becoming evident.", [["miRNAs in virus\u2013host interactions", "PROBLEM", 71, 104]]], ["A growing number of studies show that host miRNAs can regulate viral replication by altering the expression of host genes required for viral response 30, 42, 43 or by directly targeting viral genomic RNAs 39, 40, 44.", [["host genes", "DNA", 111, 121], ["studies", "TEST", 20, 27], ["host miRNAs", "PROBLEM", 38, 49], ["viral replication", "TREATMENT", 63, 80], ["viral response", "TEST", 135, 149], ["viral genomic RNAs", "TEST", 186, 204], ["viral replication", "OBSERVATION", 63, 80]]], ["To date, few studies have already explored the effects of miRNAs in EV71 infection; for example, miR\u2010296\u20105p targets the EV71 genome to suppress viral replication 39; miR\u201023b inhibits EV71 replication through downregulation of VP1 protein 45; and our study showed that miR\u201030a inhibited EV71 replication by modulating EV71\u2010induced autophagy 46.", [["EV71 infection", "DISEASE", 68, 82], ["miR\u201030a", "CHEMICAL", 268, 275], ["EV71", "ORGANISM", 68, 72], ["miR\u2010296\u20105p", "GENE_OR_GENE_PRODUCT", 97, 107], ["EV71", "ORGANISM", 120, 124], ["miR\u201023b", "GENE_OR_GENE_PRODUCT", 166, 173], ["EV71", "ORGANISM", 183, 187], ["VP1 protein 45", "GENE_OR_GENE_PRODUCT", 226, 240], ["miR\u201030a", "GENE_OR_GENE_PRODUCT", 268, 275], ["EV71", "ORGANISM", 286, 290], ["EV71", "ORGANISM", 317, 321], ["miR\u2010296\u20105p", "DNA", 97, 107], ["EV71 genome", "DNA", 120, 131], ["miR\u201023b", "DNA", 166, 173], ["VP1 protein 45", "PROTEIN", 226, 240], ["miR\u201030a", "PROTEIN", 268, 275], ["EV71", "SPECIES", 68, 72], ["EV71", "SPECIES", 183, 187], ["EV71", "SPECIES", 286, 290], ["EV71", "SPECIES", 317, 321], ["few studies", "TEST", 9, 20], ["miRNAs in EV71 infection", "PROBLEM", 58, 82], ["the EV71 genome", "TREATMENT", 116, 131], ["viral replication", "TEST", 144, 161], ["miR\u2010", "TEST", 166, 170], ["EV71 replication", "TREATMENT", 183, 199], ["VP1 protein", "TEST", 226, 237], ["our study", "TEST", 246, 255], ["EV71 replication", "TREATMENT", 286, 302], ["infection", "OBSERVATION", 73, 82]]], ["In this report, we provided evidence on the effect of cellular miR\u2010127\u20105p on SCARB2 expression and its inhibitory activity on EV71 infection.", [["cellular", "ANATOMY", 54, 62], ["EV71 infection", "DISEASE", 126, 140], ["cellular", "CELL", 54, 62], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 63, 73], ["SCARB2", "GENE_OR_GENE_PRODUCT", 77, 83], ["EV71", "ORGANISM", 126, 130], ["cellular miR\u2010127\u20105p", "PROTEIN", 54, 73], ["SCARB2", "PROTEIN", 77, 83], ["EV71", "SPECIES", 126, 130], ["cellular miR", "TEST", 54, 66], ["SCARB2 expression", "TREATMENT", 77, 94], ["EV71 infection", "PROBLEM", 126, 140], ["infection", "OBSERVATION", 131, 140]]], ["SCARB2 is considered to be a crucial EV71 receptor 23.DiscussionSCARB2 plays critical roles in viral attachment, entry, and uncoating, and it can promote EV71 infection 24.", [["EV71 infection", "DISEASE", 154, 168], ["SCARB2", "GENE_OR_GENE_PRODUCT", 0, 6], ["DiscussionSCARB2", "GENE_OR_GENE_PRODUCT", 54, 70], ["EV71", "ORGANISM", 154, 158], ["SCARB2", "PROTEIN", 0, 6], ["EV71 receptor 23", "PROTEIN", 37, 53], ["DiscussionSCARB2", "PROTEIN", 54, 70], ["EV71", "SPECIES", 154, 158], ["a crucial EV71 receptor", "TEST", 27, 50], ["EV71 infection", "PROBLEM", 154, 168], ["considered to be", "UNCERTAINTY", 10, 26], ["viral attachment", "OBSERVATION", 95, 111]]], ["Recently, a study demonstrated that human miR\u2010127\u20105p significantly downregulated SCARB2 protein level by directly targeting SCARB2 mRNA 29.", [["human", "ORGANISM", 36, 41], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 42, 52], ["SCARB2", "GENE_OR_GENE_PRODUCT", 81, 87], ["SCARB2", "GENE_OR_GENE_PRODUCT", 124, 130], ["human miR\u2010127\u20105p", "PROTEIN", 36, 52], ["SCARB2", "PROTEIN", 81, 87], ["SCARB2 mRNA 29", "RNA", 124, 138], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 36, 41], ["a study", "TEST", 10, 17], ["human miR", "TEST", 36, 45], ["protein level", "TEST", 88, 101], ["mRNA", "TEST", 131, 135]]], ["As an important receptor for EV71, reduction in SCARB2 may prevent viral entry during primary infection.", [["primary infection", "DISEASE", 86, 103], ["EV71", "ORGANISM", 29, 33], ["SCARB2", "GENE_OR_GENE_PRODUCT", 48, 54], ["SCARB2", "PROTEIN", 48, 54], ["EV71", "PROBLEM", 29, 33], ["reduction", "TREATMENT", 35, 44], ["SCARB2", "TREATMENT", 48, 54], ["viral entry", "PROBLEM", 67, 78], ["primary infection", "PROBLEM", 86, 103], ["infection", "OBSERVATION", 94, 103]]], ["Thus, it is plausible to assume that miR\u2010127\u20105p may impact EV71 infection by regulating SCARB2 expression.", [["EV71 infection", "DISEASE", 59, 73], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 37, 47], ["EV71", "ORGANISM", 59, 63], ["SCARB2", "GENE_OR_GENE_PRODUCT", 88, 94], ["miR\u2010127\u20105p", "DNA", 37, 47], ["SCARB2", "PROTEIN", 88, 94], ["EV71", "SPECIES", 59, 63], ["EV71 infection", "PROBLEM", 59, 73], ["EV71", "OBSERVATION_MODIFIER", 59, 63], ["infection", "OBSERVATION", 64, 73]]], ["In the current study, we first analyzed the influence of miR\u2010127\u20105p mimics (Fig. 1E) or inhibitor (Fig. 1F) on the total cellular SCARB2 level by western blotting.", [["cellular", "ANATOMY", 121, 129], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 57, 67], ["Fig. 1E", "GENE_OR_GENE_PRODUCT", 76, 83], ["cellular", "CELL", 121, 129], ["SCARB2", "GENE_OR_GENE_PRODUCT", 130, 136], ["miR\u2010127\u20105p", "PROTEIN", 57, 67], ["SCARB2", "PROTEIN", 130, 136], ["the current study", "TEST", 3, 20], ["miR\u2010", "TREATMENT", 57, 61], ["mimics (Fig. 1E)", "TREATMENT", 68, 84], ["inhibitor (Fig. 1F", "TREATMENT", 88, 106]]], ["Because SCARB2 is a lysosomal protein, and the majority of the protein is located in the lysosome and endosomes, these results will be difficult to accurately reflect the change of surface SCARB2.", [["lysosomal", "ANATOMY", 20, 29], ["lysosome", "ANATOMY", 89, 97], ["endosomes", "ANATOMY", 102, 111], ["surface", "ANATOMY", 181, 188], ["SCARB2", "GENE_OR_GENE_PRODUCT", 8, 14], ["lysosomal", "CELLULAR_COMPONENT", 20, 29], ["lysosome", "CELLULAR_COMPONENT", 89, 97], ["endosomes", "CELLULAR_COMPONENT", 102, 111], ["surface", "CELLULAR_COMPONENT", 181, 188], ["SCARB2", "GENE_OR_GENE_PRODUCT", 189, 195], ["SCARB2", "PROTEIN", 8, 14], ["lysosomal protein", "PROTEIN", 20, 37], ["surface SCARB2", "PROTEIN", 181, 195], ["a lysosomal protein", "PROBLEM", 18, 37], ["lysosomal protein", "OBSERVATION", 20, 37], ["surface", "OBSERVATION_MODIFIER", 181, 188]]], ["Therefore, we performed the flow cytometric analysis of the cell surface SCARB2 expression, and the data indicated that overexpression of miR\u2010127\u20105p significantly inhibited the surface SCARB2 expression (Fig. 3A), while inhibition of endogenous miR\u2010127\u20105p significantly elevated the surface SCARB2 (Fig. 4A).", [["cell surface", "ANATOMY", 60, 72], ["surface", "ANATOMY", 177, 184], ["surface", "ANATOMY", 283, 290], ["cell", "CELL", 60, 64], ["SCARB2", "GENE_OR_GENE_PRODUCT", 73, 79], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 138, 148], ["SCARB2", "GENE_OR_GENE_PRODUCT", 185, 191], ["Fig. 3A", "GENE_OR_GENE_PRODUCT", 204, 211], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 245, 255], ["Fig. 4A", "GENE_OR_GENE_PRODUCT", 299, 306], ["SCARB2", "PROTEIN", 73, 79], ["miR\u2010127\u20105p", "DNA", 138, 148], ["SCARB2", "PROTEIN", 185, 191], ["miR\u2010127\u20105p", "DNA", 245, 255], ["surface SCARB2", "PROTEIN", 283, 297], ["Fig. 4A", "PROTEIN", 299, 306], ["the flow cytometric analysis", "TEST", 24, 52], ["the data", "TEST", 96, 104], ["endogenous miR", "TEST", 234, 248]]], ["Consistently, overexpression of miR\u2010127\u20105p or inhibition of endogenous miRNA\u2010127\u20105p resulted in repressed (Fig. 3B) or enhanced (Fig. 4B) production of EV71, respectively.", [["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 32, 42], ["miRNA\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 71, 83], ["EV71", "ORGANISM", 152, 156], ["miR\u2010127\u20105p", "DNA", 32, 42], ["endogenous miRNA\u2010127\u20105p", "DNA", 60, 83], ["endogenous miRNA", "TEST", 60, 76], ["EV71", "PROBLEM", 152, 156]]], ["Results from dual\u2010luciferase assay validated that miR\u2010127\u20105p targeted SCARB2 and thus inhibited protein translation of SCARB2.", [["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 50, 60], ["SCARB2", "GENE_OR_GENE_PRODUCT", 70, 76], ["SCARB2", "GENE_OR_GENE_PRODUCT", 119, 125], ["miR\u2010127\u20105p", "DNA", 50, 60], ["SCARB2", "PROTEIN", 70, 76], ["SCARB2", "PROTEIN", 119, 125], ["dual\u2010luciferase assay", "TEST", 13, 34], ["SCARB2", "PROBLEM", 119, 125]]], ["Studies with SCARB2 mutants and the inability of miR\u2010127\u20105p in inhibition of EV71 replication in L929 cells (Fig. 5B\u2013D) suggested that this miR\u2010127\u20105p\u2010mediated downregulation of SCARB2 was specific and miR\u2010127\u20105p did not target at intracellular or viral sequences.DiscussionAs miR\u2010127\u20105p\u2010mediated downregulation of SCARB2 likely impact only on the uninfected cells for their susceptibility to EV71 infection, it is likely that reduced infection is mainly resulted from decreased viral attachment to the cells with miR\u2010127\u20105p\u2010mediated SCARB2 downregulation.", [["L929 cells", "ANATOMY", 97, 107], ["intracellular", "ANATOMY", 231, 244], ["cells", "ANATOMY", 359, 364], ["cells", "ANATOMY", 503, 508], ["EV71 infection", "DISEASE", 393, 407], ["infection", "DISEASE", 435, 444], ["SCARB2", "GENE_OR_GENE_PRODUCT", 13, 19], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 49, 59], ["EV71", "ORGANISM", 77, 81], ["L929 cells", "CELL", 97, 107], ["Fig. 5B\u2013D", "CELL", 109, 118], ["miR", "GENE_OR_GENE_PRODUCT", 140, 143], ["127\u20105", "GENE_OR_GENE_PRODUCT", 144, 149], ["SCARB2", "GENE_OR_GENE_PRODUCT", 178, 184], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 202, 212], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 231, 244], ["miR\u2010127\u20105", "GENE_OR_GENE_PRODUCT", 277, 286], ["SCARB2", "GENE_OR_GENE_PRODUCT", 315, 321], ["cells", "CELL", 359, 364], ["EV71", "ORGANISM", 393, 397], ["cells", "CELL", 503, 508], ["miR\u2010127\u20105", "GENE_OR_GENE_PRODUCT", 514, 523], ["SCARB2", "GENE_OR_GENE_PRODUCT", 534, 540], ["SCARB2 mutants", "PROTEIN", 13, 27], ["miR\u2010127\u20105p", "DNA", 49, 59], ["L929 cells", "CELL_LINE", 97, 107], ["Fig. 5B\u2013D", "CELL_LINE", 109, 118], ["SCARB2", "PROTEIN", 178, 184], ["miR\u2010127\u20105p", "DNA", 202, 212], ["intracellular or viral sequences", "DNA", 231, 263], ["miR\u2010127\u20105", "DNA", 277, 286], ["SCARB2", "PROTEIN", 315, 321], ["uninfected cells", "CELL_TYPE", 348, 364], ["SCARB2", "PROTEIN", 534, 540], ["EV71", "SPECIES", 77, 81], ["EV71", "SPECIES", 393, 397], ["Studies", "TEST", 0, 7], ["SCARB2 mutants", "PROBLEM", 13, 27], ["EV71 replication", "TREATMENT", 77, 93], ["SCARB2", "TREATMENT", 315, 321], ["the uninfected cells", "TREATMENT", 344, 364], ["EV71 infection", "PROBLEM", 393, 407], ["reduced infection", "PROBLEM", 427, 444], ["decreased viral attachment", "PROBLEM", 469, 495], ["L929 cells", "OBSERVATION", 97, 107], ["infection", "OBSERVATION", 398, 407], ["likely that", "UNCERTAINTY", 415, 426], ["reduced", "OBSERVATION_MODIFIER", 427, 434], ["infection", "OBSERVATION", 435, 444], ["decreased", "OBSERVATION_MODIFIER", 469, 478], ["viral attachment", "OBSERVATION", 479, 495]]], ["Our evidence that VP1 was reduced by more than 50% in cells overexpressing miR\u2010127\u20105p and infected with EV71 for 1 h at 4 \u00b0C illustrated that the downregulated SCARB2 led to the reduced viral attachment.", [["cells", "ANATOMY", 54, 59], ["VP1", "GENE_OR_GENE_PRODUCT", 18, 21], ["cells", "CELL", 54, 59], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 75, 85], ["EV71", "ORGANISM", 104, 108], ["SCARB2", "GENE_OR_GENE_PRODUCT", 160, 166], ["VP1", "DNA", 18, 21], ["miR\u2010127\u20105p", "PROTEIN", 75, 85], ["SCARB2", "PROTEIN", 160, 166], ["EV71", "SPECIES", 104, 108], ["VP1", "PROBLEM", 18, 21], ["EV71", "TEST", 104, 108], ["the downregulated SCARB2", "PROBLEM", 142, 166], ["the reduced viral attachment", "PROBLEM", 174, 202], ["VP1", "OBSERVATION", 18, 21], ["reduced", "OBSERVATION_MODIFIER", 26, 33], ["reduced", "OBSERVATION_MODIFIER", 178, 185], ["viral attachment", "OBSERVATION", 186, 202]]], ["Downregulation of SCARB2 by miR\u2010127\u20105p may be of significance for host defense to the EV71 as the binding of virus to the host cell is the initial step for viral entry; therefore, transient downregulation of cell surface molecules may be an effective strategy to block and reduce viral transmission.", [["cell", "ANATOMY", 127, 131], ["cell surface", "ANATOMY", 208, 220], ["EV71", "DISEASE", 86, 90], ["SCARB2", "GENE_OR_GENE_PRODUCT", 18, 24], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 28, 38], ["EV71", "ORGANISM", 86, 90], ["host cell", "CELL", 122, 131], ["cell", "CELL", 208, 212], ["SCARB2", "PROTEIN", 18, 24], ["miR\u2010127\u20105p", "DNA", 28, 38], ["cell surface molecules", "PROTEIN", 208, 230], ["EV71", "SPECIES", 86, 90], ["host defense to the EV71", "PROBLEM", 66, 90], ["viral entry", "PROBLEM", 156, 167], ["transient downregulation of cell surface molecules", "PROBLEM", 180, 230], ["block", "PROBLEM", 263, 268], ["viral transmission", "PROBLEM", 280, 298], ["host cell", "OBSERVATION", 122, 131], ["cell surface", "OBSERVATION", 208, 220], ["viral", "OBSERVATION", 280, 285]]], ["As several reports have shown 47, 48, 49, siRNAs can inhibit viral infection through various different mechanisms and can be used to control virus diseases in vivo.DiscussionOverall, we identified miR\u2010127\u20105p as a novel EV71 entry inhibitor through targeting SCARB2 expression.", [["viral infection", "DISEASE", 61, 76], ["miR\u2010127\u20105p", "GENE_OR_GENE_PRODUCT", 197, 207], ["EV71", "ORGANISM", 219, 223], ["SCARB2", "GENE_OR_GENE_PRODUCT", 258, 264], ["SCARB2", "PROTEIN", 258, 264], ["siRNAs", "TREATMENT", 42, 48], ["viral infection", "PROBLEM", 61, 76], ["virus diseases", "PROBLEM", 141, 155], ["a novel EV71 entry inhibitor", "TREATMENT", 211, 239], ["viral", "OBSERVATION_MODIFIER", 61, 66], ["infection", "OBSERVATION", 67, 76]]], ["To our knowledge this is the first study describing the role of microRNAs in regulating SCARB2 expression during EV71 infection.", [["EV71 infection", "DISEASE", 113, 127], ["SCARB2", "GENE_OR_GENE_PRODUCT", 88, 94], ["EV71", "ORGANISM", 113, 117], ["SCARB2", "PROTEIN", 88, 94], ["EV71", "SPECIES", 113, 117], ["the first study", "TEST", 25, 40], ["EV71 infection", "PROBLEM", 113, 127], ["infection", "OBSERVATION", 118, 127]]], ["Endogenous miRNAs may possess advantages over siRNAs on safety and fewer side effects.", [["Endogenous miRNAs", "PROBLEM", 0, 17], ["fewer side effects", "PROBLEM", 67, 85], ["miRNAs", "OBSERVATION", 11, 17]]], ["The current study provides a new perspective for miRNA\u2010mediated antiviral effects and contributes to the better understanding of host\u2013virus interaction mechanisms.Author contributionsZW conceived and supervised the study.", [["host\u2013virus", "GENE_OR_GENE_PRODUCT", 129, 139], ["The current study", "TEST", 0, 17], ["miRNA\u2010mediated antiviral effects", "TREATMENT", 49, 81], ["host\u2013virus interaction mechanisms", "PROBLEM", 129, 162], ["the study", "TEST", 211, 220]]], ["YF and DC provided new reagents and analyzed data.", [["DC", "ANATOMY", 7, 9], ["YF", "DISEASE", 0, 2], ["YF", "ORGANISM", 0, 2], ["DC", "CELL_TYPE", 7, 9], ["new reagents", "TREATMENT", 19, 31], ["analyzed data", "TEST", 36, 49]]], ["LZ and LC provided new reagents.", [["new reagents", "TREATMENT", 19, 31], ["LC", "ANATOMY", 7, 9]]], ["ZW made manuscript revisions.", [["manuscript revisions", "TREATMENT", 8, 28], ["revisions", "OBSERVATION", 19, 28]]]], "PMC7521710": [["IntroductionOne of the most important procedure in routine ocular examination is the measurement of the intraocular pressure (IOP).", [["ocular", "ANATOMY", 59, 65], ["intraocular", "ANATOMY", 104, 115], ["ocular", "ORGAN", 59, 65], ["intraocular", "MULTI-TISSUE_STRUCTURE", 104, 115], ["routine ocular examination", "TEST", 51, 77], ["the intraocular pressure", "TEST", 100, 124], ["intraocular pressure", "OBSERVATION", 104, 124]]], ["Indirect IOP measurement using different techniques, such as applanation and indentation, are generally used in clinics.", [["Indirect IOP measurement", "TEST", 0, 24], ["different techniques", "TREATMENT", 31, 51], ["applanation", "TEST", 61, 72]]], ["Tono-Pen\u24c7 (TP; Reichert, New York, USA) is a handheld, digital tonometer that involves both indentation and applanation mechanisms.", [["Tono", "TEST", 0, 4], ["digital tonometer", "TREATMENT", 55, 72], ["both indentation", "OBSERVATION", 87, 103]]], ["It demonstrates comparable measurement of IOP compared to the Goldmann applanation tonometry (GAT) which is the gold standard method [1, 2].", [["IOP", "TEST", 42, 45], ["the Goldmann applanation tonometry", "TEST", 58, 92], ["IOP", "OBSERVATION", 42, 45]]], ["It can measure the IOP in a small area on the cornea and can be used on patient in any position.", [["cornea", "ANATOMY", 46, 52], ["cornea", "ORGAN", 46, 52], ["patient", "ORGANISM", 72, 79], ["patient", "SPECIES", 72, 79], ["the IOP in a small area on the cornea", "PROBLEM", 15, 52], ["IOP", "OBSERVATION_MODIFIER", 19, 22], ["small", "OBSERVATION_MODIFIER", 28, 33], ["area", "OBSERVATION_MODIFIER", 34, 38], ["cornea", "ANATOMY", 46, 52]]], ["This easy-to-use device can be used by novice medical personnel without compromising the result [3].", [["device", "TREATMENT", 17, 23]]], ["There is a good intra-session repeatability in both glaucoma and healthy patients [4].", [["glaucoma", "ANATOMY", 52, 60], ["glaucoma", "DISEASE", 52, 60], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["both glaucoma", "PROBLEM", 47, 60], ["good", "OBSERVATION_MODIFIER", 11, 15], ["both", "OBSERVATION_MODIFIER", 47, 51], ["glaucoma", "OBSERVATION", 52, 60]]], ["The use of TP requires a tip cover to prevent damage to the transducer tip and cross contamination.", [["TP", "CHEMICAL", 11, 13], ["TP", "GENE_OR_GENE_PRODUCT", 11, 13], ["TP", "TREATMENT", 11, 13], ["a tip cover", "TREATMENT", 23, 34], ["damage", "PROBLEM", 46, 52], ["the transducer tip", "TREATMENT", 56, 74], ["cross contamination", "PROBLEM", 79, 98]]], ["Ocufilm\u24c7 (OF, Reichert, New York, USA) is a commercially available disposable tip cover made from latex that can cause allergy.", [["Ocufilm\u24c7", "CHEMICAL", 0, 8], ["allergy", "DISEASE", 119, 126], ["disposable tip cover", "TREATMENT", 67, 87], ["latex", "TREATMENT", 98, 103], ["allergy", "PROBLEM", 119, 126]]], ["The prevalence of latex allergy in the general population worldwide is approximately 4.3% [5].", [["latex allergy", "DISEASE", 18, 31], ["latex allergy", "PROBLEM", 18, 31], ["latex allergy", "OBSERVATION", 18, 31]]], ["Patients with severe latex allergy were reported to develop conjunctival injection, eyelid erythema, and eyelid edema after IOP measurement with latex tip cover [6].IntroductionOF tip cover is sanitized but not sterilized.", [["conjunctival", "ANATOMY", 60, 72], ["eyelid", "ANATOMY", 84, 90], ["eyelid edema", "ANATOMY", 105, 117], ["latex allergy", "DISEASE", 21, 34], ["eyelid erythema", "DISEASE", 84, 99], ["eyelid edema", "DISEASE", 105, 117], ["Patients", "ORGANISM", 0, 8], ["conjunctival", "PATHOLOGICAL_FORMATION", 60, 72], ["eyelid edema", "PATHOLOGICAL_FORMATION", 105, 117], ["Patients", "SPECIES", 0, 8], ["severe latex allergy", "PROBLEM", 14, 34], ["conjunctival injection", "PROBLEM", 60, 82], ["eyelid erythema", "PROBLEM", 84, 99], ["eyelid edema", "PROBLEM", 105, 117], ["IOP measurement", "TEST", 124, 139], ["latex tip cover", "TREATMENT", 145, 160], ["IntroductionOF tip cover", "TREATMENT", 165, 189], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["latex allergy", "OBSERVATION", 21, 34], ["conjunctival", "ANATOMY", 60, 72], ["eyelid", "ANATOMY", 84, 90], ["erythema", "OBSERVATION", 91, 99], ["eyelid", "ANATOMY", 105, 111], ["edema", "OBSERVATION", 112, 117], ["tip", "OBSERVATION_MODIFIER", 180, 183]]], ["This prevents its use in post-operative eyes that need sterile instrument for IOP measurement.", [["eyes", "ANATOMY", 40, 44], ["eyes", "ORGAN", 40, 44], ["sterile instrument", "TREATMENT", 55, 73], ["IOP measurement", "TEST", 78, 93]]], ["The cost of this single use tip cover may cause financial burden, especially in developing countries.", [["this single use tip", "TREATMENT", 12, 31], ["financial burden", "PROBLEM", 48, 64], ["may cause", "UNCERTAINTY", 38, 47], ["financial burden", "OBSERVATION", 48, 64]]], ["In addition, sometimes there are shortages of OF tip cover.", [["tip cover", "TREATMENT", 49, 58], ["shortages", "OBSERVATION_MODIFIER", 33, 42], ["tip", "OBSERVATION_MODIFIER", 49, 52]]], ["In order to overcome these barriers, a previous study demonstrated that a fingertip of the surgical glove could be used as a tip cover and showed satisfactory repeatability and agreement with OF [7].", [["a previous study", "TEST", 37, 53], ["the surgical glove", "TREATMENT", 87, 105], ["a tip cover", "TREATMENT", 123, 134], ["surgical glove", "OBSERVATION", 91, 105]]], ["However, the cost of latex surgical glove is significant and latex allergy is still possible.IntroductionAlternative material should be considered such as plastic wrap for packaging the food which has a smooth surface and barrier properties against moisture, gas, and organisms.", [["surface", "ANATOMY", 210, 217], ["allergy", "DISEASE", 67, 74], ["latex surgical glove", "TREATMENT", 21, 41], ["latex allergy", "PROBLEM", 61, 74], ["IntroductionAlternative material", "TREATMENT", 93, 125], ["plastic wrap", "TREATMENT", 155, 167], ["packaging the food", "TREATMENT", 172, 190], ["a smooth surface", "TREATMENT", 201, 217], ["barrier properties", "TREATMENT", 222, 240], ["moisture, gas", "TEST", 249, 262], ["surgical glove", "OBSERVATION", 27, 41], ["significant", "OBSERVATION_MODIFIER", 45, 56], ["latex allergy", "OBSERVATION", 61, 74]]], ["This economical and readily available material can be attached to any surface without adhesive.", [["surface", "ANATOMY", 70, 77], ["surface", "CELLULAR_COMPONENT", 70, 77]]], ["The majority of food grade plastic wrap is made from either polyethylene or polyvinyl chloride.", [["polyethylene or polyvinyl chloride", "CHEMICAL", 60, 94], ["polyethylene", "CHEMICAL", 60, 72], ["polyvinyl chloride", "CHEMICAL", 76, 94], ["polyethylene", "SIMPLE_CHEMICAL", 60, 72], ["polyvinyl chloride", "SIMPLE_CHEMICAL", 76, 94], ["food grade plastic wrap", "TREATMENT", 16, 39], ["polyethylene or polyvinyl chloride", "TREATMENT", 60, 94], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["plastic wrap", "OBSERVATION", 27, 39]]], ["Both types of the plastics are widely used in medical applications, such as catheters and synthetic materials.", [["the plastics", "TREATMENT", 14, 26], ["medical applications", "TREATMENT", 46, 66], ["catheters and synthetic materials", "TREATMENT", 76, 109], ["plastics", "OBSERVATION", 18, 26], ["widely", "OBSERVATION_MODIFIER", 31, 37], ["catheters", "OBSERVATION", 76, 85]]], ["In ophthalmology, polyethylene has long been used in ocular surgery [8].", [["ocular", "ANATOMY", 53, 59], ["polyethylene", "CHEMICAL", 18, 30], ["polyethylene", "CHEMICAL", 18, 30], ["polyethylene", "SIMPLE_CHEMICAL", 18, 30], ["ocular", "ORGAN", 53, 59], ["polyethylene", "TREATMENT", 18, 30], ["ocular surgery", "TREATMENT", 53, 67]]], ["Its use can cause some postoperative reaction after being inserted into rabbit eyes [9].", [["eyes", "ANATOMY", 79, 83], ["rabbit", "ORGANISM", 72, 78], ["rabbit", "SPECIES", 72, 78], ["rabbit", "SPECIES", 72, 78], ["some postoperative reaction", "PROBLEM", 18, 45]]], ["Plastic wrap has been reported to be used as a barrier in GAT and contact A-scan ultrasonography [10\u201312].", [["GAT", "SIMPLE_CHEMICAL", 58, 61], ["Plastic wrap", "TREATMENT", 0, 12], ["contact A-scan ultrasonography", "TEST", 66, 96], ["wrap", "OBSERVATION", 8, 12]]], ["For IOP measurement with TP, our previous eye model and study conducted in canine eyes showed good repeatability and agreement between the custom-made polyethylene wrap (PW) tip cover and OF without causing any ocular surface complications [13, 14].IntroductionThe purpose of this study was to evaluate the repeatability, reproducibility, and agreement of IOP measurement with TP using OF and PW in human eyes.", [["eye", "ANATOMY", 42, 45], ["eyes", "ANATOMY", 82, 86], ["ocular surface", "ANATOMY", 211, 225], ["eyes", "ANATOMY", 405, 409], ["polyethylene", "CHEMICAL", 151, 163], ["TP", "GENE_OR_GENE_PRODUCT", 25, 27], ["eye", "ORGAN", 42, 45], ["canine", "ORGANISM", 75, 81], ["eyes", "ORGAN", 82, 86], ["TP", "GENE_OR_GENE_PRODUCT", 377, 379], ["human", "ORGANISM", 399, 404], ["eyes", "ORGAN", 405, 409], ["human", "SPECIES", 399, 404], ["canine", "SPECIES", 75, 81], ["human", "SPECIES", 399, 404], ["IOP measurement", "TEST", 4, 19], ["TP", "TREATMENT", 25, 27], ["our previous eye model", "TEST", 29, 51], ["study", "TEST", 56, 61], ["polyethylene wrap (PW) tip cover", "TREATMENT", 151, 183], ["any ocular surface complications", "PROBLEM", 207, 239], ["this study", "TEST", 276, 286], ["IOP measurement", "TEST", 356, 371], ["TP using OF and PW in human eyes", "TREATMENT", 377, 409], ["without causing", "UNCERTAINTY", 191, 206], ["ocular", "ANATOMY", 211, 217], ["human eyes", "ANATOMY", 399, 409]]], ["The safety and cost comparison between both tip covers were also evaluated.Participants ::: Materials and methodsOphthalmic patients and healthy volunteers, at least 18 years old, were invited to enroll in this study.", [["patients", "ORGANISM", 124, 132], ["volunteers", "ORGANISM", 145, 155], ["Participants", "SPECIES", 75, 87], ["patients", "SPECIES", 124, 132], ["this study", "TEST", 206, 216], ["tip", "OBSERVATION_MODIFIER", 44, 47]]], ["All participants underwent a thorough ocular examination, including visual acuity testing, and slit lamp examination of the anterior and posterior segments.", [["ocular", "ANATOMY", 38, 44], ["anterior", "ANATOMY", 124, 132], ["anterior", "MULTI-TISSUE_STRUCTURE", 124, 132], ["posterior segments", "MULTI-TISSUE_STRUCTURE", 137, 155], ["participants", "SPECIES", 4, 16], ["a thorough ocular examination", "TEST", 27, 56], ["visual acuity testing", "TEST", 68, 89], ["slit lamp examination", "TEST", 95, 116], ["anterior", "ANATOMY_MODIFIER", 124, 132], ["posterior", "ANATOMY_MODIFIER", 137, 146], ["segments", "ANATOMY_MODIFIER", 147, 155]]], ["Those with a history of plastic or latex allergy, history of intraocular surgery rather than an uncomplicated small incision cataract surgery with phacoemulsification technique, or have corneal surface pathologies in either eye such as abrasion, infiltration, and scar, were excluded from the study.", [["intraocular", "ANATOMY", 61, 72], ["corneal surface", "ANATOMY", 186, 201], ["eye", "ANATOMY", 224, 227], ["scar", "ANATOMY", 264, 268], ["latex allergy", "DISEASE", 35, 48], ["cataract", "DISEASE", 125, 133], ["abrasion", "DISEASE", 236, 244], ["eye", "ORGAN", 224, 227], ["scar", "PATHOLOGICAL_FORMATION", 264, 268], ["plastic or latex allergy", "PROBLEM", 24, 48], ["intraocular surgery", "TREATMENT", 61, 80], ["an uncomplicated small incision cataract surgery", "TREATMENT", 93, 141], ["phacoemulsification technique", "TREATMENT", 147, 176], ["corneal surface pathologies in either eye", "PROBLEM", 186, 227], ["abrasion", "PROBLEM", 236, 244], ["infiltration", "PROBLEM", 246, 258], ["scar", "PROBLEM", 264, 268], ["the study", "TEST", 289, 298], ["intraocular surgery", "OBSERVATION", 61, 80], ["uncomplicated", "OBSERVATION_MODIFIER", 96, 109], ["small", "OBSERVATION_MODIFIER", 110, 115], ["incision cataract", "OBSERVATION", 116, 133], ["phacoemulsification", "OBSERVATION", 147, 166], ["corneal", "ANATOMY", 186, 193], ["surface", "OBSERVATION_MODIFIER", 194, 201], ["pathologies", "OBSERVATION", 202, 213], ["eye", "ANATOMY", 224, 227], ["abrasion", "OBSERVATION", 236, 244], ["infiltration", "OBSERVATION", 246, 258], ["scar", "OBSERVATION", 264, 268]]], ["IOP measurement was done by two examiners; examiner A was an ophthalmologist and examiner B was a general practitioner.IOP measurement ::: Materials and methodsTono-Pen AVIA\u24c7 was used in this study.", [["Tono-Pen AVIA\u24c7", "SIMPLE_CHEMICAL", 160, 174], ["IOP measurement", "TEST", 0, 15], ["IOP measurement", "TEST", 119, 134], ["methodsTono-Pen AVIA\u24c7", "TREATMENT", 153, 174], ["this study", "TEST", 187, 197]]], ["A drop of 0.5% tetracaine was instilled to both eyes to achieve adequate anaesthesia.", [["eyes", "ANATOMY", 48, 52], ["tetracaine", "CHEMICAL", 15, 25], ["tetracaine", "CHEMICAL", 15, 25], ["tetracaine", "SIMPLE_CHEMICAL", 15, 25], ["eyes", "ORGAN", 48, 52], ["A drop of 0.5% tetracaine", "TREATMENT", 0, 25], ["adequate anaesthesia", "TREATMENT", 64, 84], ["drop", "OBSERVATION_MODIFIER", 2, 6], ["anaesthesia", "OBSERVATION", 73, 84]]], ["Ten gentle applanations at the central cornea were performed for each measurement to obtain an average IOP.", [["central cornea", "ANATOMY", 31, 45], ["cornea", "ORGAN", 39, 45], ["central cornea", "ANATOMY", 31, 45]]], ["Only IOP reading with a statistical confidence indicator of 95 was considered reliable and was used in the analysis.PW tip cover ::: Materials and methodsPW used in this study (Cleanwrap\u24c7, Seoul, Korea) which was identical to that used in our previous studies [13, 14].", [["IOP", "TEST", 5, 8], ["the analysis", "TEST", 103, 115], ["methodsPW", "TREATMENT", 147, 156], ["this study", "TEST", 165, 175], ["tip", "OBSERVATION_MODIFIER", 119, 122]]], ["The thickness of the film was 10 micrometres.", [["The thickness of the film", "TEST", 0, 25], ["thickness", "OBSERVATION_MODIFIER", 4, 13]]], ["It was sent for cytotoxic testing at the National Metal and Materials Technology Center (MTEC) using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay which tested the viability of mouse fibroblast after 24-hour exposure to the material.", [["fibroblast", "ANATOMY", 210, 220], ["3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide", "CHEMICAL", 101, 161], ["3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide", "CHEMICAL", 101, 161], ["MTT", "CHEMICAL", 163, 166], ["3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide", "SIMPLE_CHEMICAL", 101, 161], ["mouse", "ORGANISM", 204, 209], ["fibroblast", "CELL", 210, 220], ["mouse fibroblast", "CELL_TYPE", 204, 220], ["mouse", "SPECIES", 204, 209], ["mouse", "SPECIES", 204, 209], ["cytotoxic testing", "TEST", 16, 33], ["dimethylthiazol", "TREATMENT", 108, 123], ["diphenyltetrazolium bromide", "TREATMENT", 134, 161], ["mouse fibroblast", "PROBLEM", 204, 220]]], ["The test demonstrated no cytotoxic potential with 100% viability of the cells (report no. MTEC1200/62).PW tip cover ::: Materials and methodsPW tip cover was prepared by cutting the commercial PW to a size of 5 by 5 centimetres.", [["cells", "ANATOMY", 72, 77], ["cells", "CELL", 72, 77], ["MTEC1200/62", "PROTEIN", 90, 101], ["The test", "TEST", 0, 8], ["methodsPW tip", "TREATMENT", 134, 147], ["no", "UNCERTAINTY", 22, 24], ["cytotoxic", "OBSERVATION_MODIFIER", 25, 34], ["tip", "OBSERVATION_MODIFIER", 106, 109], ["tip", "OBSERVATION_MODIFIER", 144, 147], ["size", "OBSERVATION_MODIFIER", 201, 205]]], ["A cover holder was created by cutting the paper ring from the OF tip cover package in half widthwise (Fig 1A).", [["A cover holder", "TREATMENT", 0, 14], ["tip cover package", "TREATMENT", 65, 82], ["tip", "OBSERVATION_MODIFIER", 65, 68]]], ["Both materials were put in a sterilization pouch.", [["pouch", "PATHOLOGICAL_FORMATION", 43, 48], ["a sterilization pouch", "TREATMENT", 27, 48], ["sterilization pouch", "OBSERVATION", 29, 48]]], ["This package was sent for ethylene oxide sterilization (Fig 1B).", [["ethylene oxide", "CHEMICAL", 26, 40], ["ethylene oxide", "CHEMICAL", 26, 40], ["ethylene oxide", "SIMPLE_CHEMICAL", 26, 40], ["This package", "TREATMENT", 0, 12], ["ethylene oxide sterilization", "TREATMENT", 26, 54]]], ["When in use, the sterilized pouch was peeled off and the PW was carefully lifted out of the pouch by touching only its edge without touching the central part of the PW.", [["pouch", "ANATOMY", 28, 33], ["pouch", "ANATOMY", 92, 97], ["pouch", "ORGAN", 28, 33], ["pouch", "ORGAN", 92, 97], ["the sterilized pouch", "TREATMENT", 13, 33], ["the PW", "TREATMENT", 53, 59], ["pouch", "ANATOMY", 28, 33], ["pouch", "ANATOMY", 92, 97]]], ["Then, the PW was placed over the TP tip and the cover holder was put on top of the PW and advanced to the neck of the TP head until the PW was secured in place and attached smoothly over the TP tip (Fig 2B).Measurement protocol ::: Materials and methodsThe overall study flow diagram is shown in Fig 3.", [["neck", "ANATOMY", 106, 110], ["head", "ANATOMY", 121, 125], ["neck", "ORGANISM_SUBDIVISION", 106, 110], ["TP head", "MULTI-TISSUE_STRUCTURE", 118, 125], ["the PW", "TREATMENT", 6, 12], ["the TP tip", "TREATMENT", 29, 39], ["the cover holder", "TREATMENT", 44, 60], ["the PW", "TREATMENT", 79, 85], ["the PW", "TREATMENT", 132, 138], ["the TP tip", "TREATMENT", 187, 197], ["Measurement protocol", "TEST", 207, 227], ["The overall study flow diagram", "TEST", 253, 283], ["TP", "OBSERVATION_MODIFIER", 33, 35], ["tip", "OBSERVATION_MODIFIER", 36, 39], ["neck", "ANATOMY", 106, 110], ["TP head", "ANATOMY", 118, 125], ["secured", "OBSERVATION", 143, 150], ["TP", "OBSERVATION_MODIFIER", 191, 193], ["tip", "OBSERVATION_MODIFIER", 194, 197], ["flow diagram", "OBSERVATION", 271, 283]]], ["The right eye of each participant was used to assess the intra-observer repeatability and inter-observer reproducibility of PW.", [["right eye", "ANATOMY", 4, 13], ["eye", "ORGAN", 10, 13], ["participant", "SPECIES", 22, 33], ["the intra-observer repeatability", "TEST", 53, 85], ["PW", "PROBLEM", 124, 126], ["right", "ANATOMY_MODIFIER", 4, 9], ["eye", "ANATOMY", 10, 13]]], ["Four IOP measurements, performed twice by examiners A and B, were done on the right eye.Measurement protocol ::: Materials and methodsThe left eye of each participant was used to study the agreement between OF and PW tip covers and intra-observer repeatability of both types.", [["right eye", "ANATOMY", 78, 87], ["left eye", "ANATOMY", 138, 146], ["eye", "ORGAN", 84, 87], ["eye", "ORGAN", 143, 146], ["participant", "SPECIES", 155, 166], ["Four IOP measurements", "TEST", 0, 21], ["PW tip covers", "TREATMENT", 214, 227], ["intra-observer repeatability", "TEST", 232, 260], ["right", "ANATOMY_MODIFIER", 78, 83], ["eye", "ANATOMY", 84, 87], ["left", "ANATOMY_MODIFIER", 138, 142], ["eye", "ANATOMY", 143, 146]]], ["Four IOP measurements, twice for PW and OF, were done by examiner A. To balance the effect of decreasing IOP after repeated measurements, the order of measurement by the tip covers and the examiners were done in random sequence.Measurement protocol ::: Materials and methodsFor safety evaluation, ocular surface examination with fluorescein staining under cobalt blue light was performed after each measurement to detect any damages that might have occurred during the procedure.", [["ocular surface", "ANATOMY", 297, 311], ["fluorescein", "CHEMICAL", 329, 340], ["cobalt blue", "CHEMICAL", 356, 367], ["fluorescein", "CHEMICAL", 329, 340], ["cobalt blue", "CHEMICAL", 356, 367], ["fluorescein", "SIMPLE_CHEMICAL", 329, 340], ["Four IOP measurements", "TEST", 0, 21], ["decreasing IOP", "TREATMENT", 94, 108], ["repeated measurements", "TEST", 115, 136], ["the examiners", "TEST", 185, 198], ["Measurement protocol", "TEST", 228, 248], ["safety evaluation", "TEST", 278, 295], ["ocular surface examination", "TEST", 297, 323], ["fluorescein staining", "TEST", 329, 349], ["each measurement", "TEST", 394, 410], ["any damages", "PROBLEM", 421, 432], ["the procedure", "TREATMENT", 465, 478]]], ["Any new pathologies compared to the baseline examination, including punctate epithelial erosion, corneal epithelial defect, conjunctival injection, conjunctival papillary reaction, and chemosis, were noted.Statistical analyses ::: Materials and methodsAll statistical analyses and graphs were generated using MedCalc for Windows, version 19.2 (MedCalc Software, Ostend, Belgium).", [["punctate epithelial", "ANATOMY", 68, 87], ["corneal epithelial", "ANATOMY", 97, 115], ["conjunctival", "ANATOMY", 124, 136], ["conjunctival papillary", "ANATOMY", 148, 170], ["conjunctival papillary reaction", "DISEASE", 148, 179], ["chemosis", "DISEASE", 185, 193], ["epithelial", "TISSUE", 77, 87], ["corneal epithelial", "TISSUE", 97, 115], ["conjunctival", "MULTI-TISSUE_STRUCTURE", 124, 136], ["Any new pathologies", "PROBLEM", 0, 19], ["the baseline examination", "TEST", 32, 56], ["punctate epithelial erosion", "PROBLEM", 68, 95], ["corneal epithelial defect", "PROBLEM", 97, 122], ["conjunctival injection", "PROBLEM", 124, 146], ["conjunctival papillary reaction", "PROBLEM", 148, 179], ["chemosis", "PROBLEM", 185, 193], ["All statistical analyses", "TEST", 252, 276], ["graphs", "TEST", 281, 287], ["version", "TEST", 330, 337], ["new", "OBSERVATION_MODIFIER", 4, 7], ["pathologies", "OBSERVATION", 8, 19], ["punctate", "OBSERVATION_MODIFIER", 68, 76], ["epithelial", "ANATOMY_MODIFIER", 77, 87], ["erosion", "OBSERVATION", 88, 95], ["corneal epithelial defect", "OBSERVATION", 97, 122], ["conjunctival injection", "OBSERVATION", 124, 146], ["conjunctival papillary", "ANATOMY", 148, 170], ["chemosis", "OBSERVATION", 185, 193]]], ["The unit of analysis was the eye.", [["eye", "ANATOMY", 29, 32], ["eye", "ORGAN", 29, 32], ["analysis", "TEST", 12, 20], ["eye", "ANATOMY", 29, 32]]], ["Baseline characteristics and complications were reported using descriptive statistics as appropriate.", [["complications", "PROBLEM", 29, 42]]], ["For intra-observer repeatability of OF and PW, Bland-Altman plot (BA plot) was used to demonstrate mean differences (MD), limits of agreement (LOA) and their 95% confidence intervals (95% CI) [15].", [["intra-observer repeatability", "TEST", 4, 32], ["PW", "TEST", 43, 45]]], ["For inter-observer reproducibility and agreement between OF and PW, BA plot with multiple measurements per participant was used [16].", [["participant", "SPECIES", 107, 118], ["inter-observer reproducibility", "TEST", 4, 34], ["BA plot", "TEST", 68, 75]]], ["Intraclass correlation coefficient (ICC) estimates and their 95% CI were calculated based on the following parameters: mean rating (k = 2), absolute agreement, two-way model, single measures and same raters for all participants.", [["participants", "SPECIES", 215, 227], ["CI", "TEST", 65, 67], ["mean rating", "TEST", 119, 130], ["k", "TEST", 132, 133]]], ["ICC estimates were interpreted using Koo and Li classification [17].", [["ICC estimates", "TEST", 0, 13]]], ["Cost minimization analysis was performed by comparing the cost of materials and production of each tip cover.ResultsA total of 128 participants (256 eyes) were recruited into the study.", [["eyes", "ANATOMY", 149, 153], ["participants", "ORGANISM", 131, 143], ["eyes", "ORGAN", 149, 153], ["participants", "SPECIES", 131, 143], ["Cost minimization analysis", "TEST", 0, 26], ["each tip cover", "TREATMENT", 94, 108], ["the study", "TEST", 175, 184], ["tip", "OBSERVATION_MODIFIER", 99, 102]]], ["Majority of the participants were female (78.1%).", [["participants", "ORGANISM", 16, 28], ["participants", "SPECIES", 16, 28]]], ["Nine of the right eyes and 4 of the left eyes had pseudophakia.ResultsFor intra-observer repeatability of PW by examiner A (right eyes), the MD (95% CI) was -0.34 (-0.58 to -0.10).", [["right eyes", "ANATOMY", 12, 22], ["left eyes", "ANATOMY", 36, 45], ["right eyes", "ANATOMY", 124, 134], ["pseudophakia", "DISEASE", 50, 62], ["eyes", "ORGAN", 18, 22], ["eyes", "ORGAN", 41, 45], ["eyes", "ORGAN", 130, 134], ["pseudophakia", "PROBLEM", 50, 62], ["CI", "TEST", 149, 151], ["right", "ANATOMY_MODIFIER", 12, 17], ["eyes", "ANATOMY", 18, 22], ["left eyes", "ANATOMY", 36, 45], ["pseudophakia", "OBSERVATION", 50, 62], ["right eyes", "ANATOMY", 124, 134]]], ["The 95% LOA (95% CI) were -3.04 (-3.46 to -2.63) to 2.36 (1.94 to 2.77) (Fig 4).", [["CI", "TEST", 17, 19], ["Fig", "TEST", 73, 76]]], ["The ICC (95% CI) was 0.93 (0.90 to 0.95).", [["CI", "TEST", 13, 15]]], ["For intra-observer repeatability of PW by examiner B (right eyes), the MD (95% CI) was -0.02 (-0.28 to 0.23).", [["right eyes", "ANATOMY", 54, 64], ["eyes", "ORGAN", 60, 64], ["CI", "TEST", 79, 81], ["right eyes", "ANATOMY", 54, 64]]], ["The 95% LOA (95% CI) were -2.88 (-3.31 to -2.44) to 2.83 (2.39 to 3.26) (Fig 5).", [["CI", "TEST", 17, 19], ["Fig", "TEST", 73, 76]]], ["ICC (95% CI) was 0.92 (0.89 to 0.94).", [["ICC", "TEST", 0, 3], ["CI", "TEST", 9, 11]]], ["The 95% LOA (95% CI) were -3.34 (-3.84 to -2.93) to 4.07 (3.66 to 4.56) (Fig 6).", [["CI", "TEST", 17, 19], ["Fig", "TEST", 73, 76]]], ["The ICC (95% CI) was 0.90 (0.85 to 0.93).ResultsFor intra-observer repeatability of OF by examiner A (left eyes), the MD (95% CI) was -0.42 (-0.63 to -0.21).", [["left eyes", "ANATOMY", 102, 111], ["eyes", "ORGAN", 107, 111], ["CI", "TEST", 13, 15], ["intra-observer repeatability", "TEST", 52, 80], ["CI", "TEST", 126, 128], ["left eyes", "ANATOMY", 102, 111]]], ["The 95% LOA (95% CI) were -2.75 (-3.11 to -2.39) to 1.91 (1.55 to 2.26) (Fig 7).", [["CI", "TEST", 17, 19], ["Fig", "TEST", 73, 76]]], ["ICC (95% CI) was 0.95 (0.92 to 0.97).", [["ICC", "TEST", 0, 3], ["CI", "TEST", 9, 11]]], ["For intra-observer repeatability of PW by examiner A (left eyes), the MD (95% CI) was -0.33 (-0.57 to -0.09).", [["left eyes", "ANATOMY", 54, 63], ["eyes", "ORGAN", 59, 63], ["CI", "TEST", 78, 80], ["left eyes", "ANATOMY", 54, 63]]], ["The 95% LOA (95% CI) were -3.01 (-3.42 to -2.60) to 2.36 (1.95 to 2.77) (Fig 8).", [["CI", "TEST", 17, 19], ["Fig", "TEST", 73, 76]]], ["ICC (95% CI) was 0.93 (0.90 to 0.95).", [["ICC", "TEST", 0, 3], ["CI", "TEST", 9, 11]]], ["For agreement between OF and PW by examiner A (left eyes), the MD (95% CI) was -0.71 (-1.07, -0.35).", [["left eyes", "ANATOMY", 47, 56], ["eyes", "ORGAN", 52, 56], ["CI", "TEST", 71, 73], ["left eyes", "ANATOMY", 47, 56]]], ["The 95% LOA (95% CI) were -5.18 (-5.83 to -4.63) to 3.76 (3.21 to 4.40) (Fig 9).", [["CI", "TEST", 17, 19], ["Fig", "TEST", 73, 76]]], ["ICC (95% CI) was 0.83 (0.75 to 0.89).", [["ICC", "TEST", 0, 3], ["CI", "TEST", 9, 11]]], ["All analyses are summarized in Table 1.ResultsAll of the eyes had no serious complications post-measurement by both OF and PW.", [["eyes", "ANATOMY", 57, 61], ["eyes", "ORGAN", 57, 61], ["serious complications", "PROBLEM", 69, 90], ["no", "UNCERTAINTY", 66, 68], ["serious", "OBSERVATION_MODIFIER", 69, 76], ["complications", "OBSERVATION", 77, 90]]], ["The only complication found in the study was punctate epithelial erosion (PEE).", [["punctate epithelial", "ANATOMY", 45, 64], ["PEE", "DISEASE", 74, 77], ["epithelial", "TISSUE", 54, 64], ["complication", "PROBLEM", 9, 21], ["the study", "TEST", 31, 40], ["punctate epithelial erosion", "PROBLEM", 45, 72], ["complication", "OBSERVATION", 9, 21], ["punctate", "OBSERVATION_MODIFIER", 45, 53], ["epithelial", "OBSERVATION_MODIFIER", 54, 64], ["erosion", "OBSERVATION", 65, 72]]], ["For PW, 7 (5.5%) of the right eyes and 1 (0.8%) of the left eye had PEE after all measurements were done.", [["right eyes", "ANATOMY", 24, 34], ["left eye", "ANATOMY", 55, 63], ["eyes", "ORGAN", 30, 34], ["eye", "ORGAN", 60, 63], ["PW", "TEST", 4, 6], ["all measurements", "TEST", 78, 94], ["right", "ANATOMY_MODIFIER", 24, 29], ["eyes", "ANATOMY", 30, 34], ["left", "ANATOMY_MODIFIER", 55, 59], ["eye", "ANATOMY", 60, 63]]], ["For OF, 3 (2.3%) of the left eyes were found to have PEE.", [["left eyes", "ANATOMY", 24, 33], ["PEE", "DISEASE", 53, 56], ["eyes", "ORGAN", 29, 33], ["left eyes", "ANATOMY", 24, 33], ["PEE", "OBSERVATION", 53, 56]]], ["None of the participants reported any post-measurement complications within the first 24 hours.", [["participants", "SPECIES", 12, 24], ["any post-measurement complications", "PROBLEM", 34, 68]]], ["There were no vision-threatening complications such as corneal epithelial defect and keratitis, or any allergic reactions.ResultsTable 2 shows the detail of the cost to produce PW.", [["corneal epithelial", "ANATOMY", 55, 73], ["corneal epithelial defect", "DISEASE", 55, 80], ["keratitis", "DISEASE", 85, 94], ["allergic reactions", "DISEASE", 103, 121], ["corneal epithelial", "TISSUE", 55, 73], ["vision-threatening complications", "PROBLEM", 14, 46], ["corneal epithelial defect", "PROBLEM", 55, 80], ["keratitis", "PROBLEM", 85, 94], ["any allergic reactions", "PROBLEM", 99, 121], ["no", "UNCERTAINTY", 11, 13], ["corneal", "ANATOMY", 55, 62], ["epithelial defect", "OBSERVATION", 63, 80], ["keratitis", "OBSERVATION", 85, 94]]], ["From the cost minimization analysis, the average cost of OF was around 0.8 USD.", [["the cost minimization analysis", "TEST", 5, 35]]], ["The average cost of one PW was 0.1 USD.", [["average", "OBSERVATION_MODIFIER", 4, 11]]], ["The cost difference between OF and PW tip cover was 0.7 USD.", [["PW tip cover", "TREATMENT", 35, 47], ["cost", "OBSERVATION_MODIFIER", 4, 8], ["difference", "OBSERVATION_MODIFIER", 9, 19], ["tip", "OBSERVATION_MODIFIER", 38, 41]]], ["The exchange rate at the time of this study was around 32 Baht per 1 USD.DiscussionIn the present study, we have demonstrated that PW could be used as an alternative to Ocufilm for TP tip cover.", [["PW", "SIMPLE_CHEMICAL", 131, 133], ["TP", "GENE_OR_GENE_PRODUCT", 181, 183], ["The exchange rate", "TEST", 0, 17], ["this study", "TEST", 33, 43], ["the present study", "TEST", 86, 103], ["TP tip cover", "TREATMENT", 181, 193]]], ["According to published literature, test-retest variability of OF was 0.1 mmHg, 95% LOA were -3.3 to 3.5 mmHg, and the ICC range was 0.82 to 0.85 [2, 18, 19].", [["test", "TEST", 35, 39], ["retest variability", "TEST", 40, 58], ["LOA", "TEST", 83, 86]]], ["In our study, the intra-observer repeatability of OF was -0.42 mmHg but the LOA were narrower (-2.75 to 1.91 mmHg) with excellent ICC (0.95) (Table 1).", [["our study", "TEST", 3, 12], ["the intra-observer repeatability", "TEST", 14, 46], ["the LOA", "TEST", 72, 79], ["LOA", "OBSERVATION", 76, 79], ["narrower", "OBSERVATION_MODIFIER", 85, 93]]], ["The intra-observer repeatability of PW by both examiner A (right eye = -0.34 mmHg, left eye = -0.33 mmHg) and examiner B (right eye = -0.02 mmHg) were acceptable.", [["right eye", "ANATOMY", 59, 68], ["left eye", "ANATOMY", 83, 91], ["right eye", "ANATOMY", 122, 131], ["eye", "ORGAN", 65, 68], ["eye", "ORGAN", 88, 91], ["eye", "ORGAN", 128, 131], ["PW", "TEST", 36, 38], ["mmHg", "TEST", 77, 81], ["left eye", "TEST", 83, 91], ["examiner B (right eye", "TEST", 110, 131], ["right", "ANATOMY_MODIFIER", 59, 64], ["left", "ANATOMY_MODIFIER", 83, 87], ["eye", "ANATOMY", 88, 91], ["right", "ANATOMY_MODIFIER", 122, 127]]], ["The LOA of examiner A (right eye = -3.04 to 2.36 mmHg, left eye = -3.01 to 2.36 mmHg) and examiner B (right eye = -2.88 to 2.83 mmHg) were acceptable.", [["right eye", "ANATOMY", 23, 32], ["left eye", "ANATOMY", 55, 63], ["right eye", "ANATOMY", 102, 111], ["eye", "ORGAN", 29, 32], ["eye", "ORGAN", 60, 63], ["eye", "ORGAN", 108, 111], ["The LOA of examiner A (right eye", "TEST", 0, 32], ["left eye", "TEST", 55, 63], ["examiner B (right eye", "TEST", 90, 111], ["LOA", "OBSERVATION", 4, 7], ["right", "ANATOMY_MODIFIER", 23, 28], ["left", "ANATOMY_MODIFIER", 55, 59], ["eye", "ANATOMY", 60, 63], ["right", "ANATOMY_MODIFIER", 102, 107]]], ["Both examiners produced very similar LOA which indicated that the IOP measurement with PW was independent of the examiner\u2019s experience.", [["the IOP measurement", "TEST", 62, 81], ["LOA", "OBSERVATION", 37, 40]]], ["These results were similar to our previous studies that used PW in an eye model (intra-observer repeatability = -0.25 mmHg, 95% LOA = -4.55 to 4.05 mmHg) [13] and in canine eyes (intra-observer repeatability = 0.27 mmHg, 95% LOA = -2.74 to 3.27 mmHg) [14].DiscussionThe inter-observer reproducibility of PW (0.36 mmHg) and LOA (-3.34 to 4.07 mmHg) were acceptable (Table 1) and comparable to our previous study done in canine eyes (inter-observer reproducibility = -0.39 mmHg, 95% LOA = -4.79 to 4.01 mmHg) [14].DiscussionPW and OF are different in many aspects, including materials and thickness.", [["eye", "ANATOMY", 70, 73], ["eyes", "ANATOMY", 173, 177], ["eyes", "ANATOMY", 426, 430], ["eye", "ORGAN", 70, 73], ["canine", "ORGANISM", 166, 172], ["eyes", "ORGAN", 173, 177], ["canine", "ORGANISM", 419, 425], ["eyes", "ORGAN", 426, 430], ["canine", "SPECIES", 166, 172], ["canine", "SPECIES", 419, 425], ["our previous studies", "TEST", 30, 50], ["intra-observer repeatability", "TEST", 81, 109], ["LOA", "TEST", 128, 131], ["repeatability", "TEST", 194, 207], ["mmHg", "TEST", 215, 219], ["LOA", "TEST", 225, 228], ["PW", "TEST", 304, 306], ["LOA", "TEST", 323, 326], ["our previous study", "TEST", 392, 410], ["reproducibility", "TEST", 447, 462], ["mmHg", "TEST", 471, 475], ["LOA", "TEST", 481, 484], ["eye", "ANATOMY", 70, 73], ["canine eyes", "ANATOMY", 166, 177], ["different", "OBSERVATION_MODIFIER", 536, 545]]], ["The thickness of PW is 10 microns.", [["thickness", "OBSERVATION_MODIFIER", 4, 13], ["10 microns", "OBSERVATION_MODIFIER", 23, 33]]], ["OF is grossly thicker, but its actual thickness is not available from the manufacturer.", [["grossly thicker", "PROBLEM", 6, 21], ["grossly", "OBSERVATION_MODIFIER", 6, 13], ["thicker", "OBSERVATION", 14, 21], ["actual thickness", "OBSERVATION_MODIFIER", 31, 47]]], ["However, our study found an acceptable agreement between both tip covers, although PW produced slightly higher readings.", [["our study", "TEST", 9, 18], ["PW", "TEST", 83, 85], ["tip", "OBSERVATION_MODIFIER", 62, 65], ["slightly", "OBSERVATION_MODIFIER", 95, 103], ["higher", "OBSERVATION_MODIFIER", 104, 110]]], ["In addition, the ICC showed moderate to good agreement.", [["moderate", "OBSERVATION_MODIFIER", 28, 36]]], ["Similar results were found in our previous eye model (MD = 0.29, 95% LOA = -5.68 to 6.26) [13] and study conducted in canine eyes (MD = 0.13, 95% LOA = -3.92 to 4.18) [14].", [["eye", "ANATOMY", 43, 46], ["eyes", "ANATOMY", 125, 129], ["eye", "ORGAN", 43, 46], ["canine", "ORGANISM", 118, 124], ["eyes", "ORGAN", 125, 129], ["MD", "TEST", 54, 56], ["LOA", "TEST", 69, 72], ["study", "TEST", 99, 104], ["MD", "TEST", 131, 133], ["LOA", "TEST", 146, 149], ["eye", "ANATOMY", 43, 46], ["canine eyes", "ANATOMY", 118, 129]]], ["Thus, PW and OF could be used as TP tip cover interchangeably.DiscussionIt is interesting that TP itself has a relatively wide range of 95% LOA as previously mentioned, and the range is even larger when it is compared to other tonometers.", [["TP", "GENE_OR_GENE_PRODUCT", 33, 35], ["TP", "GENE_OR_GENE_PRODUCT", 95, 97], ["PW", "TREATMENT", 6, 8], ["TP tip", "TREATMENT", 33, 39], ["relatively", "OBSERVATION_MODIFIER", 111, 121], ["wide", "OBSERVATION_MODIFIER", 122, 126], ["larger", "OBSERVATION_MODIFIER", 191, 197]]], ["Compared to GAT, the current gold standard, TP demonstrated varying results in different populations, with MD varying from -0.27 to 1.63 mmHg and the range of 95% LOA were 4.88 to 16.34 mmHg in normal individuals [1, 18, 20\u201323].", [["GAT", "SIMPLE_CHEMICAL", 12, 15], ["TP", "GENE_OR_GENE_PRODUCT", 44, 46], ["GAT", "DNA", 12, 15], ["GAT", "TEST", 12, 15], ["LOA", "TEST", 163, 166], ["varying", "OBSERVATION_MODIFIER", 60, 67], ["different", "OBSERVATION_MODIFIER", 79, 88], ["populations", "OBSERVATION_MODIFIER", 89, 100]]], ["For glaucoma patients, especially those who have uncontrolled and elevated IOP, MD could be as high as 6.8 (range of 95% LOA = 25.9 mmHg) [24].", [["glaucoma", "ANATOMY", 4, 12], ["glaucoma", "DISEASE", 4, 12], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["glaucoma", "PROBLEM", 4, 12], ["elevated IOP", "PROBLEM", 66, 78], ["LOA", "TEST", 121, 124], ["glaucoma", "OBSERVATION", 4, 12]]], ["A systematic review denoted that only 48% of the results from TP were within 2 mmHg from GAT value [25].", [["TP", "GENE_OR_GENE_PRODUCT", 62, 64], ["A systematic review", "TEST", 0, 19], ["TP", "TEST", 62, 64], ["GAT value", "TEST", 89, 98]]], ["This high variation could partly be explained by the dynamic change of IOP under several factors such as time of measurement, repeated measurements, area of cornea contact, patient\u2019s stress and unintentional Valsalva maneuver, and the examiner\u2019s experience.", [["cornea", "ANATOMY", 157, 163], ["cornea", "TISSUE", 157, 163], ["patient", "ORGANISM", 173, 180], ["patient", "SPECIES", 173, 180], ["repeated measurements", "TEST", 126, 147], ["unintentional Valsalva maneuver", "TREATMENT", 194, 225], ["cornea", "ANATOMY", 157, 163]]], ["Another reason is that TP measures IOP instantaneously and has a very short contact time resulting in a greater variation of IOP especially in patients with a wider ocular pulse pressure [26].DiscussionIn terms of safety, in this study, there were no sight-threatening complications and allergic reaction for both OF and PW.", [["ocular", "ANATOMY", 165, 171], ["allergic reaction", "DISEASE", 287, 304], ["TP", "GENE_OR_GENE_PRODUCT", 23, 25], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 143, 151], ["TP measures", "TREATMENT", 23, 34], ["IOP", "TEST", 35, 38], ["IOP", "PROBLEM", 125, 128], ["a wider ocular pulse pressure", "TEST", 157, 186], ["this study", "TEST", 225, 235], ["sight-threatening complications", "PROBLEM", 251, 282], ["allergic reaction", "PROBLEM", 287, 304]]], ["There were only a few participants from PW and OF groups that developed PEE post-measurements.", [["PEE", "DISEASE", 72, 75], ["participants", "SPECIES", 22, 34], ["few", "OBSERVATION_MODIFIER", 18, 21]]], ["This might be explained by the mechanical damage from multiple measurements.", [["the mechanical damage", "PROBLEM", 27, 48], ["might be explained", "UNCERTAINTY", 5, 23], ["mechanical", "OBSERVATION_MODIFIER", 31, 41], ["damage", "OBSERVATION", 42, 48], ["multiple", "OBSERVATION_MODIFIER", 54, 62]]], ["Furthermore, the contact area of TP was small (2.36 mm2) compared to GAT (7.35 mm2), and the contact time was very short.", [["TP", "GENE_OR_GENE_PRODUCT", 33, 35], ["TP", "TEST", 33, 35], ["GAT", "TEST", 69, 72], ["TP", "ANATOMY", 33, 35], ["small", "OBSERVATION_MODIFIER", 40, 45]]], ["None of the participants with PEE required revisiting or further treatment.", [["PEE", "DISEASE", 30, 33], ["participants", "ORGANISM", 12, 24], ["participants", "SPECIES", 12, 24], ["further treatment", "TREATMENT", 57, 74]]], ["Thus, PW was safe for IOP measurement.DiscussionPW has many advantages.", [["PW", "TEST", 6, 8], ["IOP measurement", "TEST", 22, 37]]], ["PW tip cover can be easily prepared in any hospital with a significant cost reduction compared to the commercial product.", [["PW tip", "TREATMENT", 0, 6], ["a significant cost reduction", "TREATMENT", 57, 85], ["tip", "OBSERVATION_MODIFIER", 3, 6], ["significant", "OBSERVATION_MODIFIER", 59, 70], ["cost", "OBSERVATION", 71, 75]]], ["The cost minimization analysis found that the cost of PW was approximately 8-times lower than the cost for OF.", [["The cost minimization analysis", "TEST", 0, 30], ["PW", "TEST", 54, 56]]], ["Consequently, PW can be used in post-operative patients where sterility is of concern.", [["PW", "SIMPLE_CHEMICAL", 14, 16], ["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["sterility", "PROBLEM", 62, 71]]], ["The sterilization process with ethylene oxide is commonly used and has high efficiency in eradicating microorganisms without deleterious effects on the plastic material [27].", [["ethylene oxide", "CHEMICAL", 31, 45], ["ethylene oxide", "CHEMICAL", 31, 45], ["ethylene oxide", "SIMPLE_CHEMICAL", 31, 45], ["The sterilization process", "TREATMENT", 0, 25], ["ethylene oxide", "TREATMENT", 31, 45], ["high efficiency", "PROBLEM", 71, 86], ["eradicating microorganisms", "PROBLEM", 90, 116], ["deleterious effects", "PROBLEM", 125, 144], ["ethylene oxide", "OBSERVATION", 31, 45], ["high efficiency", "OBSERVATION_MODIFIER", 71, 86]]], ["In addition, compared to OF, PW can be used safely in patients with latex allergy.", [["latex allergy", "DISEASE", 68, 81], ["PW", "SIMPLE_CHEMICAL", 29, 31], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["latex allergy", "PROBLEM", 68, 81]]], ["This method may also be suitable for a situation of high demand of use due to a concern of cross contamination like the recent outbreak of coronavirus disease 2019 (COVID-19).DiscussionThere were some limitations in this study.", [["coronavirus disease", "DISEASE", 139, 158], ["cross contamination", "PROBLEM", 91, 110], ["coronavirus disease", "PROBLEM", 139, 158], ["COVID", "TEST", 165, 170], ["this study", "TEST", 216, 226], ["coronavirus disease", "OBSERVATION", 139, 158]]], ["Firstly, most of the participants had IOP within normal range.", [["participants", "ORGANISM", 21, 33], ["participants", "SPECIES", 21, 33], ["IOP", "TEST", 38, 41], ["normal range", "OBSERVATION", 49, 61]]], ["TP has lower accuracy when the patients have an extreme IOP [28].", [["TP", "CHEMICAL", 0, 2], ["TP", "GENE_OR_GENE_PRODUCT", 0, 2], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["an extreme IOP", "TEST", 45, 59], ["lower", "OBSERVATION_MODIFIER", 7, 12]]], ["In addition, our previous study found greater MD and wider LOA in the eye model with higher IOP range compared to the lower ones [13].", [["eye", "ANATOMY", 70, 73], ["eye", "ORGAN", 70, 73], ["our previous study", "TEST", 13, 31], ["greater", "OBSERVATION_MODIFIER", 38, 45], ["wider", "OBSERVATION_MODIFIER", 53, 58], ["LOA", "OBSERVATION", 59, 62], ["eye", "ANATOMY", 70, 73], ["higher", "OBSERVATION_MODIFIER", 85, 91], ["IOP range", "OBSERVATION", 92, 101]]], ["Future studies are required to validate the agreement between PF and OF tip cover in eyes with higher IOP range.", [["eyes", "ANATOMY", 85, 89], ["eyes", "ORGAN", 85, 89], ["Future studies", "TEST", 0, 14], ["tip cover in eyes", "TREATMENT", 72, 89], ["tip", "OBSERVATION_MODIFIER", 72, 75], ["eyes", "ANATOMY", 85, 89], ["IOP range", "OBSERVATION", 102, 111]]], ["Secondly, the efficacy of TP has high variation, thus, it would be better to compare the performance of both tip covers against another reliable instrument with less variability such as GAT and manometer.", [["TP", "CHEMICAL", 26, 28], ["TP", "GENE_OR_GENE_PRODUCT", 26, 28], ["TP", "PROBLEM", 26, 28], ["GAT and manometer", "TEST", 186, 203], ["high variation", "OBSERVATION", 33, 47], ["tip", "OBSERVATION_MODIFIER", 109, 112]]], ["Furthermore, the central corneal thickness (CCT) was not measured in our study because we made a comparison within the same eye of the individual.", [["central corneal", "ANATOMY", 17, 32], ["eye", "ANATOMY", 124, 127], ["central corneal", "TISSUE", 17, 32], ["eye", "ORGAN", 124, 127], ["the central corneal thickness (CCT)", "TEST", 13, 48], ["our study", "TEST", 69, 78], ["central", "ANATOMY_MODIFIER", 17, 24], ["corneal", "ANATOMY", 25, 32], ["thickness", "OBSERVATION_MODIFIER", 33, 42]]], ["However, the difference in CCT might affect the accuracy of the measurement [29].", [["CCT", "PROTEIN", 27, 30], ["CCT", "TEST", 27, 30]]], ["We also did not measure the PW thickness after gas sterilization.", [["gas sterilization", "TREATMENT", 47, 64], ["gas sterilization", "OBSERVATION", 47, 64]]], ["The thickness may have been altered and become uneven after sterilization which could affect the IOP measurement.ConclusionsPW tip cover was safe and demonstrated acceptable intra-observer repeatability, inter-observer reproducibility, with good agreement compared to OF tip cover for IOP measurement with Tono-Pen in normotensive eyes.", [["eyes", "ANATOMY", 331, 335], ["eyes", "ORGAN", 331, 335], ["sterilization", "TREATMENT", 60, 73], ["the IOP measurement", "TEST", 93, 112], ["IOP measurement", "TEST", 285, 300], ["Tono", "TEST", 306, 310], ["altered", "OBSERVATION_MODIFIER", 28, 35], ["uneven", "OBSERVATION_MODIFIER", 47, 53], ["eyes", "ANATOMY", 331, 335]]], ["PW could be used as an alternative tip cover for Tono-Pen.", [["PW", "SIMPLE_CHEMICAL", 0, 2], ["PW", "TREATMENT", 0, 2], ["an alternative tip cover", "TREATMENT", 20, 44]]]], "PMC7267598": [["Unmet needsIf there is one element that the existing COVID\u201019 pandemic response plans agree upon, it is the need for broadly accessible and implementable testing that enables case detection, contact tracing, and the \u201cflattening of the curve\u201d of the pandemic spread (McClellan et al, 2020; Organisation for Economic Co\u2010operation and Development, 2020).", [["pandemic", "DISEASE", 249, 257], ["implementable testing", "TEST", 140, 161], ["contact tracing", "TEST", 191, 206], ["the \u201cflattening of the curve", "PROBLEM", 212, 240], ["the pandemic spread", "PROBLEM", 245, 264]]], ["Testing, both for viral load (virologic testing) and for antibodies against SARS\u2010CoV\u20102 developed by previously infected individuals (serologic assessment), will be fundamental for the \u201cre\u2010opening\u201d of public spaces and safe return of workforces in regions where SARS\u2010CoV\u20102 is already widespread and to track and contain emergence/re\u2010emergence where the prevalence of the virus is lower.", [["SARS", "DISEASE", 76, 80], ["SARS", "DISEASE", 261, 265], ["antibodies", "PROTEIN", 57, 67], ["Testing", "TEST", 0, 7], ["viral load (virologic testing", "TEST", 18, 47], ["antibodies", "TEST", 57, 67], ["SARS", "PROBLEM", 76, 80], ["previously infected individuals", "PROBLEM", 100, 131], ["serologic assessment", "TEST", 133, 153], ["SARS", "PROBLEM", 261, 265], ["the virus", "PROBLEM", 366, 375], ["virus", "OBSERVATION", 370, 375]]], ["From February 2020 through the date of this publication, the global public and private sectors have invested in the development and distribution of new affordable and accessible tests, sample collection swabs, and reagents for clinical testing centers.", [["accessible tests", "TEST", 167, 183], ["sample collection swabs", "TEST", 185, 208], ["clinical testing centers", "TEST", 227, 251]]], ["Regulatory agencies such as the US FDA provided added regulatory flexibility to promote rapid adoption of new methods.", [["the US FDA", "TEST", 28, 38], ["regulatory flexibility", "TREATMENT", 54, 76], ["new methods", "TREATMENT", 106, 117]]], ["Despite these efforts, the capacity for testing and test processing (at local, national, and global levels) is failing to meet current and anticipated needs.", [["the capacity", "TEST", 23, 35], ["testing", "TEST", 40, 47], ["test processing", "TEST", 52, 67]]], ["The reasons are diverse and include lack of availability of test kits or components, limited labor to run the tests, limited number of testing facilities, shortages or uneven distribution of consumables and reagents for processing, shortages in swabs and personal protective equipment for sampling, and lack of clarity about how to interpret or act on a test result.", [["test kits", "TEST", 60, 69], ["limited labor", "PROBLEM", 85, 98], ["the tests", "TEST", 106, 115], ["personal protective equipment", "TREATMENT", 255, 284], ["a test result", "TEST", 352, 365]]], ["The net impact of these limitations is that a substantial portion of the population that could/should be tested will not be tested.", [["net", "OBSERVATION_MODIFIER", 4, 7], ["impact", "OBSERVATION_MODIFIER", 8, 14], ["substantial", "OBSERVATION_MODIFIER", 46, 57], ["portion", "OBSERVATION_MODIFIER", 58, 65]]], ["Additionally, and perhaps just as concerning, limited virologic test availability has delayed timelines for testing.", [["limited virologic test", "TEST", 46, 68], ["testing", "TEST", 108, 115]]], ["As viral shedding appears to happen most significantly in the earlier stages of infection, unduly delayed testing can result in a higher false\u2010negative rate depending on a given test's sensitivity.", [["infection", "DISEASE", 80, 89], ["viral shedding", "PROBLEM", 3, 17], ["infection", "PROBLEM", 80, 89], ["unduly delayed testing", "PROBLEM", 91, 113], ["a higher false\u2010negative rate", "PROBLEM", 128, 156], ["test's sensitivity", "TEST", 178, 196], ["infection", "OBSERVATION", 80, 89]]], ["The unfortunate synergy of these factors impacts both the ability for a clinician to advise an individual patient and for governments and health agencies to monitor and manage their population health.", [["patient", "ORGANISM", 106, 113], ["patient", "SPECIES", 106, 113]]], ["The ability to make informed decisions about personal or public health protection has been untenably affected by a lack of data on personal/local risk as well as regional caseloads and transmission rates (Fig 1).", [["transmission rates", "TEST", 185, 203]]], ["Concurrently, untapped capacities for testing or analysis in public and private sectors at a global scale are available and justify the pragmatic proposals discussed in this paper.Unmet needsJust as the reasons for sampling and testing insufficiency are multifaceted and expansive, so too must be our solutions for addressing them.", [["insufficiency", "DISEASE", 236, 249], ["untapped capacities", "PROBLEM", 14, 33], ["testing", "TEST", 38, 45], ["analysis", "TEST", 49, 57], ["a global scale", "TEST", 91, 105], ["sampling", "TEST", 215, 223], ["testing insufficiency", "PROBLEM", 228, 249], ["insufficiency", "OBSERVATION", 236, 249], ["expansive", "OBSERVATION_MODIFIER", 271, 280]]], ["To further stem the spread of COVID\u201019, a series of systematic and innovative implementation approaches to the design and execution of virologic testing are necessary.", [["innovative implementation approaches", "TREATMENT", 67, 103], ["virologic testing", "TEST", 135, 152]]], ["Such approaches should be tailored for broad adoption (or ready adaptation) as a means to simultaneously, comprehensively, and pragmatically address current hurdles to providing public access to adequate testing for COVID\u201019.", [["COVID\u2010", "TREATMENT", 216, 222]]], ["As a first step, the proposals outlined here focus primarily on the role of virologic testing as a coordinated first line of assessment with the recognition that serologic testing will ultimately play a critical role in longer\u2010term monitoring and control measures.Unmet needsThis communication defines four key pillars for action and a supporting conceptual model of implementation to promote a scalable and \u201call in\u201d approach to virologic testing.", [["virologic testing", "TEST", 76, 93], ["assessment", "TEST", 125, 135], ["serologic testing", "TEST", 162, 179], ["longer\u2010term monitoring", "TEST", 220, 242], ["virologic testing", "TEST", 429, 446]]], ["The uniqueness of our approach lies in four simultaneous elements.", [["simultaneous elements", "OBSERVATION", 44, 65]]], ["Specifically, this approach:\u2022Is adaptable for use at a local or international level;\u2022Is not specific to any one health care or public health system or structure;\u2022Addresses testing accuracy and processing capacity as well as test availability; and\u2022Proposes efficient and pragmatic approaches to testing implementation and subsequent public health action.", [["testing accuracy", "TEST", 172, 188], ["testing implementation", "TEST", 294, 316]]]], "687c700d5047b9a1f7f0a2158a3f4f8cc4669668": [["whether they were likely or possibly essential during the COVID-19 pandemic and the frequency of exposure to infections and close proximity to others by occupation.", [["infections", "DISEASE", 109, 119], ["the COVID", "TEST", 54, 63], ["infections", "PROBLEM", 109, 119], ["infections", "OBSERVATION", 109, 119]]]], "PMC2836320": [["BackgroundThe German standing commission for immunisation, along with other authorities [1-3] currently recommends that healthcare workers (HCWs) be vaccinated against seasonal influenza.", [["influenza", "DISEASE", 177, 186], ["immunisation", "TREATMENT", 45, 57], ["seasonal influenza", "PROBLEM", 168, 186]]], ["Two reasons are cited: firstly that HCWs can be a source of infection for vulnerable people under their care [1-3], and secondly that HCWs are at increased risk for contracting influenza [1].", [["infection", "DISEASE", 60, 69], ["influenza", "DISEASE", 177, 186], ["HCWs", "ORGANISM", 36, 40], ["people", "ORGANISM", 85, 91], ["HCWs", "ORGANISM", 134, 138], ["people", "SPECIES", 85, 91], ["infection", "PROBLEM", 60, 69], ["contracting influenza", "PROBLEM", 165, 186]]], ["Vaccination of HCWs should theoretically reduce the risk of influenza infection both in themselves and their patients.", [["influenza infection", "DISEASE", 60, 79], ["HCWs", "ORGANISM", 15, 19], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["Vaccination of HCWs", "TREATMENT", 0, 19], ["influenza infection", "PROBLEM", 60, 79], ["influenza", "OBSERVATION", 60, 69]]], ["There is evidence to support the first reason for vaccination, the protection of patients.", [["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["vaccination", "TREATMENT", 50, 61]]], ["HCWs can transmit influenza to those under their care during both outbreaks and non-outbreak situations [4-7].", [["influenza", "DISEASE", 18, 27], ["HCWs", "ORGANISM", 0, 4], ["influenza", "PROBLEM", 18, 27]]], ["Low vaccination rates in HCWs have been associated with nosocomial outbreaks [4,8], and higher vaccination rates with reduced nosocomial influenza incidences [7].BackgroundHCWs may transmit influenza to those under their care, but is there evidence that their occupational exposures (to patients, relatives, colleagues and the hospital environment) confer an increased risk of influenza compared to the general population?", [["influenza", "DISEASE", 137, 146], ["influenza", "DISEASE", 190, 199], ["influenza", "DISEASE", 377, 386], ["patients", "ORGANISM", 287, 295], ["patients", "SPECIES", 287, 295], ["Low vaccination rates", "PROBLEM", 0, 21], ["nosocomial outbreaks", "PROBLEM", 56, 76], ["higher vaccination rates", "PROBLEM", 88, 112], ["reduced nosocomial influenza incidences", "PROBLEM", 118, 157], ["influenza", "PROBLEM", 190, 199], ["influenza", "PROBLEM", 377, 386], ["influenza", "OBSERVATION", 377, 386]]], ["Influenza serological attack rates in HCWs of 23% (single season, [9]) and 14% (an average of two seasons, [10]) have been documented.", [["Influenza", "DISEASE", 0, 9], ["Influenza serological attack rates", "TEST", 0, 34], ["HCWs", "TEST", 38, 42]]], ["However, as serological attack rates of influenza may vary considerably from season to season as well as from location to location, without the inclusion of a comparison group of non-HCWs neither study could demonstrate an increased risk.BackgroundAnother aspect of influenza in HCWs is that many HCWs argue that they withdraw from work when they become ill with influenza-like illness to reduce their risk of transmitting influenza to their patients.", [["influenza", "DISEASE", 40, 49], ["influenza", "DISEASE", 266, 275], ["influenza-like illness", "DISEASE", 363, 385], ["influenza", "DISEASE", 423, 432], ["HCWs", "ORGANISM", 297, 301], ["patients", "ORGANISM", 442, 450], ["patients", "SPECIES", 442, 450], ["serological attack rates", "TEST", 12, 36], ["influenza", "PROBLEM", 40, 49], ["non-HCWs neither study", "TEST", 179, 201], ["an increased risk", "PROBLEM", 220, 237], ["influenza", "PROBLEM", 266, 275], ["influenza", "PROBLEM", 363, 372], ["transmitting influenza", "PROBLEM", 410, 432], ["increased", "OBSERVATION_MODIFIER", 223, 232], ["influenza", "OBSERVATION", 266, 275]]], ["However, not all serologically diagnosed influenza infections experience an influenza-like illness, and a proportion will be asymptomatic.", [["influenza infections", "DISEASE", 41, 61], ["influenza-like illness", "DISEASE", 76, 98], ["influenza infections", "PROBLEM", 41, 61], ["an influenza-like illness", "PROBLEM", 73, 98], ["asymptomatic", "PROBLEM", 125, 137], ["influenza", "OBSERVATION", 76, 85]]], ["The frequency of asymptomatic influenza infection in HCWs has been assessed in volunteer studies (33%, [11]), a cohort study (28%, [9]) and one randomised controlled study (42%, [10]).BackgroundThe objective of this study was to address the question of whether HCWs in the acute care hospital setting have a higher risk of serologically confirmed influenza infections (SCII) than non-HCWs, and to assess the proportion of individuals with SCII who experience either any respiratory symptoms or an influenza-like illness.Inclusion and exclusion criteria ::: MethodsHCW in our context were defined as people working on a daily basis with unwell patients in an acute hospital setting, including nurses (trainee and qualified) and doctors.", [["respiratory", "ANATOMY", 470, 481], ["influenza infection", "DISEASE", 30, 49], ["influenza infections", "DISEASE", 347, 367], ["SCII", "DISEASE", 369, 373], ["SCII", "DISEASE", 439, 443], ["respiratory symptoms", "DISEASE", 470, 490], ["influenza-like illness", "DISEASE", 497, 519], ["people", "ORGANISM", 599, 605], ["patients", "ORGANISM", 643, 651], ["people", "SPECIES", 599, 605], ["patients", "SPECIES", 643, 651], ["asymptomatic influenza infection", "PROBLEM", 17, 49], ["volunteer studies", "TEST", 79, 96], ["a cohort study", "TEST", 110, 124], ["one randomised controlled study", "TEST", 140, 171], ["this study", "TEST", 211, 221], ["influenza infections", "PROBLEM", 347, 367], ["any respiratory symptoms", "PROBLEM", 466, 490], ["an influenza-like illness", "PROBLEM", 494, 519], ["asymptomatic", "OBSERVATION_MODIFIER", 17, 29], ["influenza", "OBSERVATION_MODIFIER", 30, 39], ["infection", "OBSERVATION", 40, 49], ["influenza", "OBSERVATION", 347, 356], ["influenza", "OBSERVATION", 497, 506]]], ["Non-HCW were those working or studying at the study sites, or attending the blood donation centres, who did not fit the definition of HCW.Inclusion and exclusion criteria ::: MethodsExclusions (applied to both HCWs and non-HCWs) were: people with patient contact in the community (such as community doctors and nurses, dentists, and pharmacists); people working in care homes; laboratory workers who had contact with respiratory samples or with influenza virus; people who planned to be away from Berlin for more than two weeks during the projected season (January to April); and people who did not wish to be contacted weekly by mobile phone Short Message System (SMS) or email.Inclusion and exclusion criteria ::: MethodsFor the analysis of serologically-confirmed infections, we excluded vaccinated individuals where the baseline serum sample was taken fewer than 14 days after vaccination, or where a later second sample was not obtainable (see recruitment above).", [["blood", "ANATOMY", 76, 81], ["respiratory samples", "ANATOMY", 417, 436], ["serum sample", "ANATOMY", 833, 845], ["influenza virus", "DISEASE", 445, 460], ["infections", "DISEASE", 767, 777], ["blood", "ORGANISM_SUBSTANCE", 76, 81], ["people", "ORGANISM", 235, 241], ["patient", "ORGANISM", 247, 254], ["people", "ORGANISM", 347, 353], ["people", "ORGANISM", 462, 468], ["people", "ORGANISM", 580, 586], ["serum", "ORGANISM_SUBSTANCE", 833, 838], ["people", "SPECIES", 235, 241], ["patient", "SPECIES", 247, 254], ["people", "SPECIES", 347, 353], ["influenza virus", "SPECIES", 445, 460], ["people", "SPECIES", 462, 468], ["people", "SPECIES", 580, 586], ["MethodsExclusions", "TREATMENT", 175, 192], ["influenza virus", "PROBLEM", 445, 460], ["Methods", "TREATMENT", 716, 723], ["the analysis", "TEST", 727, 739], ["serologically", "PROBLEM", 743, 756], ["infections", "PROBLEM", 767, 777], ["vaccinated individuals", "PROBLEM", 791, 813], ["the baseline serum sample", "TEST", 820, 845], ["vaccination", "TREATMENT", 881, 892], ["infections", "OBSERVATION", 767, 777]]], ["These participants were excluded from the serological analyses as any titre rise could have been caused by vaccination and not infection.Inclusion and exclusion criteria ::: MethodsBecause pigs can carry influenza viruses, and participants with pig contact were associated with SCII, participants reporting contact with pigs were excluded.Active surveillance for respiratory infections during influenza season ::: MethodsIn order to document weekly occurrences of respiratory infections during the influenza season, we contacted all participants weekly through SMS or through email, asking them if they had experienced a \"new\" respiratory infection during the previous 7 days.", [["respiratory", "ANATOMY", 363, 374], ["respiratory", "ANATOMY", 464, 475], ["respiratory", "ANATOMY", 627, 638], ["infection", "DISEASE", 127, 136], ["influenza viruses", "DISEASE", 204, 221], ["SCII", "DISEASE", 278, 282], ["respiratory infections", "DISEASE", 363, 385], ["influenza", "DISEASE", 393, 402], ["respiratory infections", "DISEASE", 464, 486], ["respiratory infection", "DISEASE", 627, 648], ["participants", "ORGANISM", 6, 18], ["pigs", "ORGANISM", 189, 193], ["pig", "ORGANISM", 245, 248], ["pigs", "ORGANISM", 320, 324], ["participants", "SPECIES", 6, 18], ["pigs", "SPECIES", 189, 193], ["participants", "SPECIES", 227, 239], ["pig", "SPECIES", 245, 248], ["participants", "SPECIES", 284, 296], ["pigs", "SPECIES", 320, 324], ["participants", "SPECIES", 533, 545], ["pigs", "SPECIES", 189, 193], ["pig", "SPECIES", 245, 248], ["pigs", "SPECIES", 320, 324], ["the serological analyses", "TEST", 38, 62], ["any titre rise", "PROBLEM", 66, 80], ["vaccination", "PROBLEM", 107, 118], ["infection", "PROBLEM", 127, 136], ["influenza viruses", "PROBLEM", 204, 221], ["respiratory infections", "PROBLEM", 363, 385], ["Methods", "TREATMENT", 414, 421], ["respiratory infections", "PROBLEM", 464, 486], ["a \"new\" respiratory infection", "PROBLEM", 619, 648], ["infection", "OBSERVATION", 127, 136], ["respiratory", "ANATOMY", 464, 475], ["infections", "OBSERVATION", 476, 486], ["respiratory", "ANATOMY", 627, 638], ["infection", "OBSERVATION", 639, 648]]], ["Where participants answered \"yes\", they were contacted by telephone and details of their infection were obtained using an illness questionnaire.Active surveillance for respiratory infections during influenza season ::: MethodsWeekly surveillance for respiratory infections covered the period from January 13, 2007 to March 30, 2007, a period chosen to coincide with the influenza season.", [["respiratory", "ANATOMY", 168, 179], ["respiratory", "ANATOMY", 250, 261], ["infection", "DISEASE", 89, 98], ["respiratory infections", "DISEASE", 168, 190], ["influenza", "DISEASE", 198, 207], ["respiratory infections", "DISEASE", 250, 272], ["influenza", "DISEASE", 370, 379], ["participants", "SPECIES", 6, 18], ["their infection", "PROBLEM", 83, 98], ["respiratory infections", "PROBLEM", 168, 190], ["respiratory infections", "PROBLEM", 250, 272], ["respiratory", "ANATOMY", 250, 261], ["infections", "OBSERVATION", 262, 272]]], ["This strategy was employed in order to maximise the predictive value of a positive answer.Postseason follow-up ::: MethodsAfter the influenza season, participants were recalled by SMS or email.", [["participants", "ORGANISM", 150, 162], ["participants", "SPECIES", 150, 162]]], ["They gave a second serum sample and completed a further questionnaire, including repeat questions on vaccination status and employment type; number of patient contacts on a typical day between January 13 and April 6, 2007; broad age classification of patient contacts (adults (>17 years) and children (<18 years); clinical specialty and usage of facemasks (for HCWs); daily professional and household contacts; use of public transport and car ownership; contact with pigs (for veterinary students); and vaccination in previous years.", [["serum sample", "ANATOMY", 19, 31], ["serum", "ORGANISM_SUBSTANCE", 19, 24], ["patient", "ORGANISM", 151, 158], ["patient", "ORGANISM", 251, 258], ["children", "ORGANISM", 292, 300], ["pigs", "ORGANISM", 467, 471], ["patient", "SPECIES", 151, 158], ["patient", "SPECIES", 251, 258], ["children", "SPECIES", 292, 300], ["pigs", "SPECIES", 467, 471], ["a second serum sample", "TEST", 10, 31]]], ["Participants were asked again if they had had respiratory infections over the period January 13, 2007 to 6th April 2007, extending the period of surveillance to one week after the last weekly SMS was sent.Postseason follow-up ::: MethodsContact was defined as either touching or having a two way conversation with someone close by, or (for patient contact only) examining or giving care to a patient.", [["respiratory", "ANATOMY", 46, 57], ["respiratory infections", "DISEASE", 46, 68], ["patient", "ORGANISM", 340, 347], ["patient", "ORGANISM", 392, 399], ["Participants", "SPECIES", 0, 12], ["patient", "SPECIES", 340, 347], ["patient", "SPECIES", 392, 399], ["respiratory infections", "PROBLEM", 46, 68], ["the last weekly SMS", "TEST", 176, 195], ["MethodsContact", "TREATMENT", 230, 244], ["infections", "OBSERVATION", 58, 68]]], ["Participants were asked to estimate the number of contacts made during a typical day in household and work settings.Laboratory investigations ::: MethodsThe paired blood samples were defrosted and antibody titres were determined on the same day using the haemagglutination inhibition test to determine infection in any of the two A subtypes or the two B lineages.", [["blood samples", "ANATOMY", 164, 177], ["infection", "DISEASE", 302, 311], ["blood samples", "ORGANISM_SUBSTANCE", 164, 177], ["B lineages", "CELL", 352, 362], ["B lineages", "CELL_TYPE", 352, 362], ["Participants", "SPECIES", 0, 12], ["Laboratory investigations", "TEST", 116, 141], ["Methods", "TREATMENT", 146, 153], ["The paired blood samples", "TEST", 153, 177], ["antibody titres", "TEST", 197, 212], ["the haemagglutination inhibition test", "TEST", 251, 288], ["infection", "PROBLEM", 302, 311]]], ["We tested for antibody to the following strains:Laboratory investigations ::: MethodsA/H1: A/New Caledonia/20/1999 (H1N1)Laboratory investigations ::: MethodsA/H3: A/Wisconsin/67/2005 (H3N2), and A/California/07/2004 (H3N2)Laboratory investigations ::: MethodsB, Victoria lineage: B/Malaysia/2506/2004Laboratory investigations ::: MethodsB, Yamagata lineage: B/Jiangsu/10/2003.Laboratory investigations ::: MethodsTitres of below 10 were assigned the value of 5 in order to allow calculation of the titre rise.", [["New Caledonia", "ORGANISM", 93, 106], ["20/1999", "ORGANISM", 107, 114], ["Wisconsin/67/2005 (H3N2", "ORGANISM", 166, 189], ["California/07/2004", "ORGANISM", 198, 216], ["A/California/07/2004 (H3N2", "SPECIES", 196, 222], ["Jiangsu/10/2003", "SPECIES", 361, 376], ["Laboratory investigations", "TEST", 301, 326], ["MethodsTitres", "TEST", 407, 420]]], ["SCII was defined as a fourfold or greater titre rise between pre- and post-season samples, with a postseason titre of at least 40.", [["a postseason titre", "TEST", 96, 114]]], ["As A/Wisconsin/67/2005 (H3N2) and A/California/07/2004 (H3N2) were closely related a titre rise to either of these strains was considered as a single SCII due to A/H3N2.Outcomes ::: MethodsThe primary outcome was evidence of SCII by any of the above strains.Outcomes ::: MethodsThe clinical outcomes were influenza-like-illness (ILI), defined as an illness with an acute onset, self-reported fever, cough, and head or body pains; and acute respiratory infection (ARI), defined as any reported infection with coryza (nasal discharge) or cough.", [["head", "ANATOMY", 410, 414], ["body", "ANATOMY", 418, 422], ["respiratory", "ANATOMY", 440, 451], ["nasal", "ANATOMY", 516, 521], ["SCII", "DISEASE", 150, 154], ["SCII", "DISEASE", 225, 229], ["influenza-like-illness", "DISEASE", 305, 327], ["ILI", "DISEASE", 329, 332], ["fever", "DISEASE", 392, 397], ["cough", "DISEASE", 399, 404], ["head or body pains", "DISEASE", 410, 428], ["acute respiratory infection", "DISEASE", 434, 461], ["ARI", "DISEASE", 463, 466], ["infection", "DISEASE", 493, 502], ["coryza", "DISEASE", 508, 514], ["cough", "DISEASE", 536, 541], ["A/Wisconsin/67/2005 (H3N2)", "ORGANISM", 3, 29], ["A/California/07/2004 (H3N2", "ORGANISM", 34, 60], ["A/H3N2", "ORGANISM", 162, 168], ["head", "ORGANISM_SUBDIVISION", 410, 414], ["body", "ORGANISM_SUBDIVISION", 418, 422], ["nasal", "ORGANISM_SUBDIVISION", 516, 521], ["A/Wisconsin/67/2005 (H3N2)", "SPECIES", 3, 29], ["A/California/07/2004 (H3N2", "SPECIES", 34, 60], ["A/H3N2", "SPECIES", 162, 168], ["H3N2", "PROBLEM", 24, 28], ["H3N2", "PROBLEM", 56, 60], ["a titre rise", "PROBLEM", 83, 95], ["these strains", "PROBLEM", 109, 122], ["H3N2", "PROBLEM", 164, 168], ["Methods", "TREATMENT", 182, 189], ["SCII", "PROBLEM", 225, 229], ["the above strains", "PROBLEM", 240, 257], ["influenza", "PROBLEM", 305, 314], ["fever", "PROBLEM", 392, 397], ["cough", "PROBLEM", 399, 404], ["head or body pains", "PROBLEM", 410, 428], ["acute respiratory infection (ARI)", "PROBLEM", 434, 467], ["any reported infection", "PROBLEM", 480, 502], ["coryza (nasal discharge", "PROBLEM", 508, 531], ["cough", "PROBLEM", 536, 541], ["acute", "OBSERVATION_MODIFIER", 365, 370], ["head", "ANATOMY", 410, 414], ["body", "ANATOMY", 418, 422], ["pains", "OBSERVATION", 423, 428], ["acute", "OBSERVATION_MODIFIER", 434, 439], ["respiratory", "ANATOMY", 440, 451], ["infection", "OBSERVATION", 452, 461], ["infection", "OBSERVATION", 493, 502], ["cough", "OBSERVATION", 536, 541]]], ["Clinical outcomes were based only on completed illness questionnaires or postseason illness reports, not on SMS or email replies, the latter being used only as the prompt for collection of illness data.Outcomes ::: MethodsWhere illness was reported over more than one week, symptoms for each week were combined to produce a single illness episode.", [["illness", "DISEASE", 47, 54], ["illness", "DISEASE", 84, 91], ["illness", "DISEASE", 189, 196], ["illness", "DISEASE", 228, 235], ["illness data", "TEST", 189, 201], ["Methods", "TREATMENT", 215, 222], ["symptoms", "PROBLEM", 274, 282], ["a single illness episode", "PROBLEM", 322, 346]]], ["To produce an epidemic curve of SCII with any ILI, or in its absence, another ARI, the respective dates of illness onset were plotted.", [["SCII", "DISEASE", 32, 36], ["ILI", "DISEASE", 46, 49], ["ARI", "DISEASE", 78, 81], ["illness", "DISEASE", 107, 114], ["SCII", "CANCER", 32, 36], ["any ILI", "PROBLEM", 42, 49], ["another ARI", "PROBLEM", 70, 81]]], ["Where more than one illness episode was reported, we used the onset date of the episode closest to the peak, on the assumption that this episode was the most likely to be due to influenza virus.Statistical analysis ::: MethodsWe undertook bivariate analyses for all binary exposure variables and calculated risk ratios (RR), their 95% confidence interval and p-values.", [["influenza", "DISEASE", 178, 187], ["influenza virus", "ORGANISM", 178, 193], ["influenza virus", "SPECIES", 178, 193], ["the episode", "PROBLEM", 76, 87], ["this episode", "PROBLEM", 132, 144], ["influenza virus", "PROBLEM", 178, 193], ["bivariate analyses", "TEST", 239, 257], ["all binary exposure variables", "PROBLEM", 262, 291], ["calculated risk ratios", "PROBLEM", 296, 318], ["RR", "TEST", 320, 322], ["p-values", "TEST", 359, 367], ["most likely to be due to", "UNCERTAINTY", 153, 177], ["influenza virus", "OBSERVATION", 178, 193]]], ["For the comparison of the exposure groups (HCW vs. non-HCW) continuous variables were analysed using the Kruskal-Wallis test.", [["the Kruskal-Wallis test", "TEST", 101, 124]]], ["For the analysis of the association with SCII continuous variables were explored by grouping them in categories.", [["the analysis", "TEST", 4, 16], ["SCII continuous variables", "TREATMENT", 41, 66]]], ["We regarded a p-value of less than 0.05 as statistically significant.", [["a p-value", "TEST", 12, 21]]], ["We then constructed a multivariate logistic regression model (logistic command, STATA [StataCorp.", [["STATA [StataCorp", "TREATMENT", 80, 96]]], ["College Station, TX: Statacorp LP]) using variables which were associated with the outcome with a p-value of less than 0.1 in the bivariate analysis.", [["a p-value", "TEST", 96, 105], ["the bivariate analysis", "TEST", 126, 148]]], ["Variables with p values between 0.1 and 0.2, along with healthcare worker status, were also tested in the final model.Statistical analysis ::: MethodsIn order to determine whether the site of recruitment had any group-level effects on the model, we constructed a random-effects logistic regression model with the same variables as the standard model plus study site as the grouping variable, and a likelihood ratio test for the proportion of variance attributable to the group level (rho) was performed (xtlogit, STATA).Data protection and ethical approval ::: MethodsThe data protection protocol was approved by both state and national data protection offices in Berlin, and shared with all study partners.", [["rho", "GENE_OR_GENE_PRODUCT", 484, 487], ["p values", "TEST", 15, 23], ["Methods", "TREATMENT", 143, 150], ["the standard model plus study site", "TEST", 331, 365], ["a likelihood ratio test", "TEST", 396, 419], ["Methods", "TREATMENT", 561, 568], ["The data protection protocol", "TEST", 568, 596], ["recruitment", "OBSERVATION", 192, 203]]], ["Ethical approval for the study was obtained from the University of Berlin, faculty of medicine (Charit\u00e9) ethics committee.Recruitment and follow-up ::: ResultsWe recruited 1044 participants, of which 736 (71%) were included in the analysis with SCII as outcome, and 866 (93%) for the clinical outcome analysis (Figure 1).Recruitment and follow-up ::: ResultsThose not included in the study were of younger age (38 vs 34, p < 0.01 Kruskall-Wallis) and were more likely to be HCW at recruitment (42% vs 34%, p < 0.01), but there were no significant differences in sex, current immunisation, smoking status, car ownership or use of public transport in excluded versus non-excluded participants.Comparison of study participants by healthcare worker status ::: ResultsOf the 736 participants included in the analysis with the outcome SCII 250 (34%) were HCWs and 486 (66%) were non-HCWs.", [["participants", "SPECIES", 177, 189], ["participants", "SPECIES", 678, 690], ["participants", "SPECIES", 711, 723], ["participants", "SPECIES", 774, 786], ["the study", "TEST", 21, 30], ["the clinical outcome analysis", "TEST", 280, 309], ["the study", "TEST", 380, 389], ["vs", "TEST", 414, 416], ["p", "TEST", 421, 422], ["p", "TEST", 506, 507], ["significant differences in sex", "PROBLEM", 535, 565], ["public transport", "TEST", 629, 645], ["HCWs", "TEST", 849, 853], ["more likely to be", "UNCERTAINTY", 456, 473], ["no", "UNCERTAINTY", 532, 534], ["significant", "OBSERVATION_MODIFIER", 535, 546]]], ["Most participants (71%) were female.", [["participants", "ORGANISM", 5, 17], ["participants", "SPECIES", 5, 17]]], ["The age distribution was bimodal, with peaks in the age groups 20-29 years and 40-49 years both in HCWs and non-HCWs.Comparison of study participants by healthcare worker status ::: ResultsOf the 250 healthcare workers, 41 (16%) were doctors, 97 (39%) were trainee nurses and 112 (45%) were qualified nurses.", [["participants", "SPECIES", 137, 149]]], ["In 88/486 (18%) the occupation was not stated or unclear.Comparison of study participants by healthcare worker status ::: ResultsTable 1 compares study characteristics in the exposure group (HCW) and control group (non-HCW).", [["participants", "SPECIES", 77, 89]]], ["HCWs were significantly younger than controls (35.7 versus 39.2, Kruskal-Wallis test, p < 0.01).", [["HCWs", "ORGANISM", 0, 4], ["Kruskal-Wallis test", "TEST", 65, 84], ["p", "TEST", 86, 87]]], ["They were also significantly more likely to be current smokers, female, vaccinated in the current season, and to own a car.Comparison of study participants by healthcare worker status ::: ResultsHealthcare workers had significantly more non-patient contacts at work (mean 14.3 versus 13.8, p = 0.021) but fewer contacts at home (mean 2.7 versus 3.5, P < 0.01) There were no significant differences in immunisation in the previous three seasons, or in household exposure to children.", [["children", "ORGANISM", 473, 481], ["participants", "SPECIES", 143, 155], ["children", "SPECIES", 473, 481], ["no", "UNCERTAINTY", 371, 373], ["significant", "OBSERVATION_MODIFIER", 374, 385], ["differences", "OBSERVATION_MODIFIER", 386, 397]]], ["HCWs were significantly less likely to have a titer of <40 against A/California/07/2004, the A/H3N2-strain of the previous season.Serologically confirmed influenza infection and ILI/ARI ::: ResultsIn total there were 82 titer rises among 78 participants.", [["influenza infection", "DISEASE", 154, 173], ["HCWs", "ORGANISM", 0, 4], ["A/H3N2", "ORGANISM", 93, 99], ["participants", "SPECIES", 241, 253], ["A/California/07/2004", "SPECIES", 67, 87], ["influenza infection", "PROBLEM", 154, 173], ["influenza infection", "OBSERVATION", 154, 173]]], ["Of these, 13 (16%) were due to A/New Caledonia/20/1999 (H1N1), 64 (78%) due to either of the two A/H3N2-strains tested, two (2%) due to B/Malaysia/2506/2004 and three (4%) due to B/Jiangsu/10/2003.", [["A/H3N2-strains", "ORGANISM", 97, 111], ["A/New Caledonia/20/1999 (H1N1)", "SPECIES", 31, 61], ["B/Malaysia/2506/2004", "SPECIES", 136, 156], ["B/Jiangsu/10/2003", "SPECIES", 179, 196], ["New", "OBSERVATION_MODIFIER", 33, 36], ["Caledonia", "OBSERVATION", 37, 46]]], ["There were four double-infections, three with H3N2/H1N1 co-infections and one with titre rises to both B strains.Serologically confirmed influenza infection and ILI/ARI ::: ResultsTable 2 shows SCII and reported infections by healthcare worker status.", [["infections", "DISEASE", 23, 33], ["H3N2/H1N1 co-infections", "DISEASE", 46, 69], ["influenza infection", "DISEASE", 137, 156], ["infections", "DISEASE", 212, 222], ["H3N2/H1N1", "ORGANISM", 46, 55], ["SCII", "CANCER", 194, 198], ["four double-infections", "PROBLEM", 11, 33], ["H3N2", "PROBLEM", 46, 50], ["H1N1 co-infections", "PROBLEM", 51, 69], ["titre rises", "PROBLEM", 83, 94], ["influenza infection", "PROBLEM", 137, 156], ["SCII", "PROBLEM", 194, 198], ["four", "OBSERVATION_MODIFIER", 11, 15], ["double", "OBSERVATION_MODIFIER", 16, 22], ["infections", "OBSERVATION", 23, 33], ["influenza infection", "OBSERVATION", 137, 156], ["infections", "OBSERVATION", 212, 222]]], ["The overall attack rate for SCII was 10.6% (78/736).", [["SCII", "DISEASE", 28, 32], ["The overall attack rate", "TEST", 0, 23], ["SCII", "TEST", 28, 32]]], ["Of the 78 people with evidence of SCII, 23 (30%) reported neither ARI nor ILI, 33 (42%) reported at least one ARI but no ILI, and 22 (28%) reported at least one ILI.Bivariate analysis: risk factors for SCII ::: ResultsHCWs did not have a significantly higher risk of SCII than non-HCWs (RR 1.09, p = 0.70).", [["SCII", "DISEASE", 34, 38], ["ARI", "DISEASE", 66, 69], ["ILI", "DISEASE", 74, 77], ["ARI", "DISEASE", 110, 113], ["ILI", "DISEASE", 121, 124], ["ILI", "DISEASE", 161, 164], ["SCII", "DISEASE", 267, 271], ["non-HCWs", "DISEASE", 277, 285], ["people", "ORGANISM", 10, 16], ["people", "SPECIES", 10, 16], ["SCII", "TEST", 34, 38], ["neither ARI", "PROBLEM", 58, 69], ["ILI", "TEST", 74, 77], ["ILI", "PROBLEM", 121, 124], ["RR", "TEST", 287, 289], ["p", "TEST", 296, 297], ["no", "UNCERTAINTY", 118, 120], ["ILI", "OBSERVATION", 121, 124]]], ["In addition, neither working as a nurse (RR = 0.94, p = 0.82) nor as a doctor was significant (RR = 1.76, p = 0.13).", [["RR", "TEST", 41, 43], ["RR", "TEST", 95, 97], ["p", "TEST", 106, 107]]], ["There was also no significant difference in the risk of SCII between HCWs and controls after stratification by vaccination status, car ownership, having children, or regular use of public transport.Bivariate analysis: risk factors for SCII ::: ResultsThere were three exposures with p-values below 0.1: vaccination, having a car in the household and having three or more children at home (Table 3).", [["SCII", "DISEASE", 56, 60], ["children", "ORGANISM", 153, 161], ["children", "ORGANISM", 371, 379], ["children", "SPECIES", 153, 161], ["children", "SPECIES", 371, 379], ["vaccination", "TREATMENT", 303, 314], ["no", "UNCERTAINTY", 15, 17], ["significant", "OBSERVATION_MODIFIER", 18, 29], ["difference", "OBSERVATION_MODIFIER", 30, 40]]], ["Household contacts increased the unadjusted risk of SCII (Figure 2).", [["SCII", "DISEASE", 52, 56]]], ["Attack rates were lowest in those living alone (4%), intermediate in those living with adults but no children (10%) or one or two children (12%), and highest in those with three or more children in the household (24%).", [["children", "ORGANISM", 130, 138], ["children", "ORGANISM", 186, 194], ["children", "SPECIES", 101, 109], ["children", "SPECIES", 130, 138], ["children", "SPECIES", 186, 194], ["Attack rates", "PROBLEM", 0, 12]]], ["In a stratified analysis, the effect of car ownership was significant when participants did not live with children (RR = 2.77, p = 0.01), but not for participants who lived in a household with children (RR = 0.98, p = 1.00).Multivariate model ::: ResultsVariables significantly associated with SCII were the type of household contact environment, car ownership, and vaccination status (Table 4).", [["SCII", "DISEASE", 294, 298], ["children", "ORGANISM", 106, 114], ["children", "ORGANISM", 193, 201], ["participants", "SPECIES", 75, 87], ["children", "SPECIES", 106, 114], ["participants", "SPECIES", 150, 162], ["children", "SPECIES", 193, 201], ["a stratified analysis", "TEST", 3, 24], ["RR", "TEST", 116, 118], ["RR", "TEST", 203, 205]]], ["Living with children was associated with an increased risk of SCII, with an overall odds ratio of 3.7 (p < 0.01, separate model without stratification of household contacts).", [["SCII", "DISEASE", 62, 66], ["children", "ORGANISM", 12, 20], ["children", "SPECIES", 12, 20], ["an increased risk of SCII", "PROBLEM", 41, 66], ["an overall odds ratio", "TEST", 73, 94], ["increased", "OBSERVATION_MODIFIER", 44, 53]]], ["Three or more children in the household (OR13.8, p < 0.01) were a greater risk than one or two children (OR 5.3, p = 0.02).Multivariate model ::: ResultsHousehold car ownership was a significant risk factor only among persons living in households without children and had an odds ratio for SCII of 3.0 (p = 0.02), while owning a car in households with children was not statistically significant (OR = 0.95; p = 0.94) and so was not included in the final model.Multivariate model ::: ResultsImmunisation against influenza was associated with an OR of 0.50 (p = 0.02).", [["influenza", "DISEASE", 511, 520], ["children", "ORGANISM", 14, 22], ["children", "ORGANISM", 95, 103], ["persons", "ORGANISM", 218, 225], ["children", "ORGANISM", 255, 263], ["children", "ORGANISM", 352, 360], ["children", "SPECIES", 14, 22], ["children", "SPECIES", 95, 103], ["persons", "SPECIES", 218, 225], ["children", "SPECIES", 255, 263], ["children", "SPECIES", 352, 360], ["influenza", "PROBLEM", 511, 520]]], ["Vaccine effectiveness against SCII was therefore 50% (95%CI 12-71%).", [["SCII", "CANCER", 30, 34], ["Vaccine effectiveness", "TREATMENT", 0, 21], ["CI", "TEST", 57, 59]]], ["Effectiveness against SCII with a reported ILI was higher at 73% (95%CI 6-92%; p = 0.04).Multivariate model ::: ResultsOther variables were added to the multivariate model, but were found not to be significant at the p < 0.2 level.", [["SCII", "DISEASE", 22, 26], ["ILI", "DISEASE", 43, 46], ["SCII", "CANCER", 22, 26], ["CI", "TEST", 69, 71], ["p", "TEST", 79, 80], ["the multivariate model", "TEST", 149, 171], ["not to be", "UNCERTAINTY", 188, 197]]], ["These were being a doctor; having 7 or more child patient contacts; and being a healthcare worker.", [["patient", "ORGANISM", 50, 57], ["patient", "SPECIES", 50, 57]]], ["Addition of a group-level variance term for recruitment site to the random-effects model was not statistically significant (p(rho = 0) > = 0.498).Risk factors for any ARI ::: ResultsThe four variables with a p-value < 0.2 in the bivariate analysis were age below 51 (p = 0.02), female sex (p = 0.03), HCW (p = 0.03) and smoking (p = 0.12).", [["a group-level variance term", "TREATMENT", 12, 39], ["recruitment site", "PROBLEM", 44, 60], ["a p-value", "TEST", 206, 215], ["the bivariate analysis", "TEST", 225, 247]]], ["In the multivariate model (n = 850) all except female sex (p = 0.054) were significant, and the effect of smoking became statistically significant.", [["smoking", "CHEMICAL", 106, 113]]], ["Age below 51 (OR 1.44, p = 0.04), female sex (OR 1.36, p = 0.05) and HCW status (OR 1.34, p = 0.04) had an OR above 1, and smoking had an OR below 1 (OR 0.72, p = 0.04).Temporal progression of influenza cases ::: ResultsFigure 3 shows the distribution of dates of onset for all SCII where an episode of ARI or ILI was reported.", [["influenza", "DISEASE", 193, 202], ["SCII", "DISEASE", 278, 282], ["ARI", "DISEASE", 303, 306], ["ILI", "DISEASE", 310, 313], ["p", "TEST", 23, 24], ["HCW status", "TEST", 69, 79], ["ARI", "PROBLEM", 303, 306], ["ILI", "PROBLEM", 310, 313], ["influenza", "OBSERVATION", 193, 202]]], ["The peak seen in week 9 corresponded with the peak number of positive influenza tests from Berlin patients performed at the national reference laboratory for influenza, from patient samples collected through the German influenza sentinel surveillance system [12].DiscussionWe found no significant association between being a healthcare worker in acute hospital care and serogically confirmed influenza infection.", [["influenza", "DISEASE", 158, 167], ["influenza infection", "DISEASE", 392, 411], ["patients", "ORGANISM", 98, 106], ["patient", "ORGANISM", 174, 181], ["patients", "SPECIES", 98, 106], ["patient", "SPECIES", 174, 181], ["The peak", "TEST", 0, 8], ["positive influenza tests", "PROBLEM", 61, 85], ["influenza", "PROBLEM", 158, 167], ["patient samples", "TEST", 174, 189], ["influenza infection", "PROBLEM", 392, 411], ["peak", "OBSERVATION_MODIFIER", 4, 8], ["infection", "OBSERVATION", 402, 411]]], ["Instead we identified household contacts, in particular children, and car ownership, as important risk factors for SCII.", [["SCII", "DISEASE", 115, 119], ["children", "ORGANISM", 56, 64], ["children", "SPECIES", 56, 64]]], ["30% of participants with SCII reported no symptoms, and only around one-quarter of those reporting influenza-like illness also had SCII.DiscussionWe did not demonstrate a strongly increased risk of influenza infection in HCWs in acute hospital care.", [["SCII", "DISEASE", 25, 29], ["influenza-like illness", "DISEASE", 99, 121], ["SCII", "DISEASE", 131, 135], ["influenza infection", "DISEASE", 198, 217], ["participants", "ORGANISM", 7, 19], ["participants", "SPECIES", 7, 19], ["symptoms", "PROBLEM", 42, 50], ["influenza", "PROBLEM", 99, 108], ["influenza infection", "PROBLEM", 198, 217], ["acute hospital care", "TREATMENT", 229, 248], ["influenza", "OBSERVATION_MODIFIER", 198, 207], ["infection", "OBSERVATION", 208, 217], ["acute", "OBSERVATION_MODIFIER", 229, 234]]], ["As HCWs do appear to have an increased risk for ARI (OR = 1.3) it would be plausible to expect an effect of similar order for influenza infections.", [["ARI", "DISEASE", 48, 51], ["influenza infections", "DISEASE", 126, 146], ["ARI", "PROBLEM", 48, 51], ["influenza infections", "PROBLEM", 126, 146], ["increased", "OBSERVATION_MODIFIER", 29, 38]]], ["Although study limitations might have led to a failure to detect a true increase, it is unlikely that we have missed a large difference in the risk of influenza.DiscussionWhy might HCWs in hospital not have a higher risk of influenza?", [["influenza", "DISEASE", 151, 160], ["influenza", "DISEASE", 224, 233], ["a failure", "PROBLEM", 45, 54], ["a true increase", "PROBLEM", 65, 80], ["influenza", "PROBLEM", 151, 160], ["influenza", "PROBLEM", 224, 233], ["failure", "OBSERVATION", 47, 54], ["increase", "OBSERVATION_MODIFIER", 72, 80], ["large", "OBSERVATION_MODIFIER", 119, 124], ["influenza", "OBSERVATION", 151, 160], ["influenza", "OBSERVATION", 224, 233]]], ["The prevalence of infectious influenza in patients may have been low, either due to the absence of influenza patients or because patients admitted later in the course of illness might have been less infectious.", [["influenza", "DISEASE", 29, 38], ["influenza", "DISEASE", 99, 108], ["illness", "DISEASE", 170, 177], ["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 109, 117], ["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 109, 117], ["patients", "SPECIES", 129, 137], ["infectious influenza", "PROBLEM", 18, 38], ["influenza", "PROBLEM", 99, 108], ["illness", "PROBLEM", 170, 177], ["infectious", "OBSERVATION_MODIFIER", 18, 28], ["influenza", "OBSERVATION", 29, 38], ["less", "OBSERVATION_MODIFIER", 194, 198], ["infectious", "OBSERVATION", 199, 209]]], ["Also, infection control measures such as use of personal protective equipment and individual or cohort isolation might have reduced the risks of infection in HCWs.", [["infection", "DISEASE", 6, 15], ["infection", "DISEASE", 145, 154], ["infection control measures", "TREATMENT", 6, 32], ["personal protective equipment", "TREATMENT", 48, 77], ["cohort isolation", "TREATMENT", 96, 112], ["infection", "PROBLEM", 145, 154], ["infection", "OBSERVATION", 6, 15], ["infection", "OBSERVATION", 145, 154]]], ["HCWs were less likely than non-HCWs to be susceptible (preseason titer of less than 40) to A/California/07/2004 (H3N2), which was the A/H3N2 strain of the previous season and related to A/Wisconsin/67/2005 (H3N2), the dominant strain in the 2006/07 season.DiscussionAs most influenza patients admitted to hospitals are children or older people, one might expect to find an increased risk for SCII in HCWs who work with these patient groups.", [["influenza", "DISEASE", 274, 283], ["SCII", "DISEASE", 392, 396], ["HCWs", "ORGANISM", 0, 4], ["California/07/2004 (H3N2", "ORGANISM", 93, 117], ["A/H3N2", "ORGANISM", 134, 140], ["Wisconsin/67/2005 (H3N2", "ORGANISM", 188, 211], ["influenza", "ORGANISM", 274, 283], ["patients", "ORGANISM", 284, 292], ["children", "ORGANISM", 319, 327], ["people", "ORGANISM", 337, 343], ["patient", "ORGANISM", 425, 432], ["patients", "SPECIES", 284, 292], ["children", "SPECIES", 319, 327], ["people", "SPECIES", 337, 343], ["patient", "SPECIES", 425, 432], ["A/California/07/2004 (H3N2", "SPECIES", 91, 117], ["A/H3N2", "SPECIES", 134, 140], ["A/Wisconsin/67/2005 (H3N2)", "SPECIES", 186, 212], ["preseason titer", "TEST", 55, 70], ["H3N2", "PROBLEM", 113, 117], ["the A/H3N2 strain", "PROBLEM", 130, 147], ["H3N2", "PROBLEM", 207, 211], ["the dominant strain", "PROBLEM", 214, 233], ["less likely", "UNCERTAINTY", 10, 21], ["dominant", "OBSERVATION_MODIFIER", 218, 226], ["strain", "OBSERVATION_MODIFIER", 227, 233]]], ["Our finding of an elevated odds ratio for HCWs with more frequent contact with child patients, albeit not significant in this setting, would be consistent with this supposition.", [["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["an elevated odds ratio", "PROBLEM", 15, 37], ["elevated", "OBSERVATION_MODIFIER", 18, 26]]], ["Another study focusing on this hypothesis is needed to investigate it further.DiscussionHousehold contacts, and in particular children in the home, were the main significant risk factors identified in this study.", [["children", "ORGANISM", 126, 134], ["children", "SPECIES", 126, 134], ["Another study", "TEST", 0, 13], ["this study", "TEST", 201, 211]]], ["This finding is similar to that in another droplet-transmitted infection, meningitis, where household contacts constitute by far the most important risk group [13].", [["infection", "DISEASE", 63, 72], ["meningitis", "DISEASE", 74, 84], ["transmitted infection", "PROBLEM", 51, 72], ["meningitis", "PROBLEM", 74, 84], ["infection", "OBSERVATION", 63, 72], ["meningitis", "OBSERVATION", 74, 84]]], ["The role of children as the main sources of influenza transmission has been suggested in several studies [14-17].", [["influenza transmission", "DISEASE", 44, 66], ["children", "ORGANISM", 12, 20], ["children", "SPECIES", 12, 20], ["influenza transmission", "PROBLEM", 44, 66]]], ["Adult household contacts may play a role analogous, but possibly less marked, to that of children.DiscussionWhilst public transport usage was not associated with SCII, car ownership was a significant risk factor, albeit only in households without children.", [["children", "ORGANISM", 89, 97], ["children", "ORGANISM", 247, 255], ["children", "SPECIES", 89, 97], ["children", "SPECIES", 247, 255], ["less marked", "OBSERVATION_MODIFIER", 65, 76]]], ["For this reason, further details on passengers, frequency or duration of car use were not obtained in the study.DiscussionPossession of a car has not previously been recognised as a risk factor for influenza acquisition.", [["influenza", "DISEASE", 198, 207], ["the study", "TEST", 102, 111], ["influenza acquisition", "PROBLEM", 198, 219]]], ["In one observational study on risk factors for SARS in China \"using a taxi more than once a week\" was identified as independent risk factor for SARS infection with an increased odds ratio close to significance (p = 0.07).", [["SARS", "DISEASE", 47, 51], ["SARS infection", "DISEASE", 144, 158], ["SARS", "PROBLEM", 47, 51], ["SARS infection", "PROBLEM", 144, 158], ["an increased odds ratio", "PROBLEM", 164, 187]]], ["Furthermore, this variable was kept in the multivariate model while \"riding a bus\" and \"taking the subway\" (who were significant in bivariate analysis) were not [19].", [["bivariate analysis", "TEST", 132, 150]]], ["Ownership of a car may also be a marker for having a greater number of social contacts, perhaps including children.", [["children", "ORGANISM", 106, 114], ["children", "SPECIES", 106, 114]]], ["Car users are also exposed to air pollution from other vehicles, and this may predispose users to respiratory infections.", [["respiratory", "ANATOMY", 98, 109], ["respiratory infections", "DISEASE", 98, 120], ["respiratory infections", "PROBLEM", 98, 120], ["air pollution", "OBSERVATION", 30, 43], ["respiratory", "ANATOMY", 98, 109], ["infections", "OBSERVATION", 110, 120]]], ["Despite the unexpected nature of this finding, it is possible that car usage is indeed a risk factor and should be explored through further studies.DiscussionWe did not find an increased risk of influenza in the 58% of participants who were regular users of public transport.", [["influenza", "DISEASE", 195, 204], ["participants", "SPECIES", 219, 231], ["further studies", "TEST", 132, 147], ["influenza", "PROBLEM", 195, 204], ["public transport", "TREATMENT", 258, 274], ["increased", "OBSERVATION_MODIFIER", 177, 186], ["influenza", "OBSERVATION", 195, 204]]], ["Public transport usage has been cited as a possible risk factor for influenza infection, particularly in the context of pandemic planning [20].", [["influenza infection", "DISEASE", 68, 87], ["influenza infection", "PROBLEM", 68, 87], ["pandemic planning", "TREATMENT", 120, 137], ["infection", "OBSERVATION", 78, 87]]], ["In a recent international survey of precautionary behaviour for pandemic influenza, 75% of respondents said that they would avoid public transport [21].", [["influenza", "DISEASE", 73, 82], ["pandemic influenza", "PROBLEM", 64, 82]]], ["Both rail and air travel have been associated with respiratory infection transmission [22,23].", [["respiratory", "ANATOMY", 51, 62], ["respiratory infection", "DISEASE", 51, 72], ["respiratory infection transmission", "PROBLEM", 51, 85], ["air", "OBSERVATION", 14, 17], ["respiratory", "OBSERVATION_MODIFIER", 51, 62], ["infection", "OBSERVATION", 63, 72]]], ["Whilst it is possible to contract influenza on public transport, our results suggest that, at least in Berlin, using public transport does not increase a person's risk of influenza.", [["influenza", "DISEASE", 34, 43], ["influenza", "DISEASE", 171, 180], ["person", "SPECIES", 154, 160], ["influenza", "PROBLEM", 34, 43], ["influenza", "PROBLEM", 171, 180], ["influenza", "OBSERVATION", 171, 180]]], ["In Berlin, crowding on public transport is infrequent and not extreme, so this result may not be generalisable to cities with different conditions.DiscussionVaccine uptake was relatively high both in HCWs (42%) and non-HCWs (32%).", [["DiscussionVaccine uptake", "TEST", 147, 171], ["crowding", "OBSERVATION_MODIFIER", 11, 19]]], ["In non-HCWs, the participation of a federal public health institute where influenza vaccination is freely offered to employees may account for the high vaccination rate.", [["influenza", "DISEASE", 74, 83], ["influenza vaccination", "TREATMENT", 74, 95], ["the high vaccination rate", "TREATMENT", 143, 168]]], ["High vaccination uptake limited the number of SCII and reduced the study power.", [["High vaccination uptake", "PROBLEM", 0, 23], ["the study power", "TEST", 63, 78]]], ["Vaccination effectiveness was 50% against SCII and reached 73% for a more severe outcome, SCII with reported ILI.DiscussionOnly 28% of participants with SCII reported an ILI, the majority reporting no symptoms or more minor respiratory illness.", [["respiratory", "ANATOMY", 224, 235], ["SCII", "DISEASE", 42, 46], ["SCII", "DISEASE", 90, 94], ["ILI", "DISEASE", 109, 112], ["SCII", "DISEASE", 153, 157], ["ILI", "DISEASE", 170, 173], ["respiratory illness", "DISEASE", 224, 243], ["participants", "ORGANISM", 135, 147], ["participants", "SPECIES", 135, 147], ["Vaccination effectiveness", "TREATMENT", 0, 25], ["a more severe outcome", "PROBLEM", 67, 88], ["symptoms", "PROBLEM", 201, 209], ["more minor respiratory illness", "PROBLEM", 213, 243], ["respiratory illness", "OBSERVATION", 224, 243]]], ["The proportion of asymptomatic infections (30% or more) was substantial and similar to that reported by Elder (28%,[9] and consistent with an estimated proportion of 33% obtained from pooled challenge studies [10].", [["infections", "DISEASE", 31, 41], ["asymptomatic infections", "PROBLEM", 18, 41], ["pooled challenge studies", "TEST", 184, 208], ["asymptomatic", "OBSERVATION_MODIFIER", 18, 30], ["infections", "OBSERVATION", 31, 41], ["consistent with", "UNCERTAINTY", 123, 138]]], ["In addition, only 26% of persons with an ILI had evidence of an influenza infection.", [["ILI", "DISEASE", 41, 44], ["influenza infection", "DISEASE", 64, 83], ["persons", "ORGANISM", 25, 32], ["persons", "SPECIES", 25, 32], ["an ILI", "PROBLEM", 38, 44], ["an influenza infection", "PROBLEM", 61, 83], ["influenza", "OBSERVATION_MODIFIER", 64, 73], ["infection", "OBSERVATION", 74, 83]]], ["Thus, the ILI-syndrome was a poor marker for influenza infections.", [["ILI-syndrome", "DISEASE", 10, 22], ["influenza infections", "DISEASE", 45, 65], ["the ILI-syndrome", "PROBLEM", 6, 22], ["influenza infections", "PROBLEM", 45, 65]]], ["Unvaccinated HCWs who intend to withdraw from work when they become ill with influenza-typical symptoms may overlook many (symptomatic or asymptomatic) influenza infections, putting patients at unnecessary risk.DiscussionThe association of HCW status and ARI may reflect the fact that HCWs communicate with or care for a large number of people including patients, colleagues, and relatives, and are thus exposed to a wide variety of respiratory pathogens.", [["respiratory", "ANATOMY", 433, 444], ["influenza", "DISEASE", 77, 86], ["influenza infections", "DISEASE", 152, 172], ["ARI", "DISEASE", 255, 258], ["respiratory pathogens", "DISEASE", 433, 454], ["HCWs", "ORGANISM", 13, 17], ["patients", "ORGANISM", 182, 190], ["people", "ORGANISM", 337, 343], ["patients", "ORGANISM", 354, 362], ["patients", "SPECIES", 182, 190], ["people", "SPECIES", 337, 343], ["patients", "SPECIES", 354, 362], ["influenza", "PROBLEM", 77, 86], ["typical symptoms", "PROBLEM", 87, 103], ["asymptomatic) influenza infections", "PROBLEM", 138, 172], ["ARI", "PROBLEM", 255, 258], ["respiratory pathogens", "PROBLEM", 433, 454], ["respiratory pathogens", "OBSERVATION", 433, 454]]], ["The reduced risk for ARI in people aged over 50 years might be explained by their cumulative immune experience or a lower contact rate.", [["ARI", "DISEASE", 21, 24], ["people", "ORGANISM", 28, 34], ["people", "SPECIES", 28, 34], ["ARI", "PROBLEM", 21, 24], ["reduced", "OBSERVATION_MODIFIER", 4, 11]]], ["The apparent protective effect of smoking could be due to lower ascertainment of ARI in this group, where a background of smoking-related symptoms may have masked the onset of an additional, mild infectious respiratory illness.", [["respiratory", "ANATOMY", 207, 218], ["smoking", "CHEMICAL", 34, 41], ["ARI", "DISEASE", 81, 84], ["smoking", "CHEMICAL", 122, 129], ["respiratory illness", "DISEASE", 207, 226], ["ARI", "PROBLEM", 81, 84], ["related symptoms", "PROBLEM", 130, 146], ["an additional, mild infectious respiratory illness", "PROBLEM", 176, 226], ["protective effect", "OBSERVATION_MODIFIER", 13, 30], ["ARI", "OBSERVATION", 81, 84], ["mild", "OBSERVATION_MODIFIER", 191, 195], ["infectious", "OBSERVATION_MODIFIER", 196, 206], ["respiratory illness", "OBSERVATION", 207, 226]]], ["Conversely, respiratory symptoms due to non-infectious causes may be over-reported in non-smokers.DiscussionWhat significance does this study have for the current H1N1v pandemic?", [["respiratory", "ANATOMY", 12, 23], ["respiratory symptoms", "DISEASE", 12, 32], ["respiratory symptoms", "PROBLEM", 12, 32], ["non-infectious causes", "PROBLEM", 40, 61], ["this study", "TEST", 131, 141], ["non-infectious", "OBSERVATION", 40, 54]]], ["As pandemic influenza should result in a higher attack rate than seasonal influenza, the prevalence of influenza in hospital inpatients and staff is likely to be higher than for seasonal influenza, so increasing the risk of exposure and infection for HCWs compared to that described here.", [["influenza", "DISEASE", 12, 21], ["influenza", "DISEASE", 74, 83], ["influenza", "DISEASE", 103, 112], ["influenza", "DISEASE", 187, 196], ["infection", "DISEASE", 237, 246], ["pandemic influenza", "PROBLEM", 3, 21], ["a higher attack rate", "PROBLEM", 39, 59], ["seasonal influenza", "PROBLEM", 65, 83], ["influenza", "PROBLEM", 103, 112], ["seasonal influenza", "PROBLEM", 178, 196], ["infection", "PROBLEM", 237, 246], ["HCWs", "PROBLEM", 251, 255], ["infection", "OBSERVATION", 237, 246]]], ["For the same reasons, the risk in HCWs and non-HCWs from their household contacts would also be higher than for seasonal influenza.", [["influenza", "DISEASE", 121, 130], ["seasonal influenza", "PROBLEM", 112, 130], ["influenza", "OBSERVATION", 121, 130]]], ["Therefore even if a repeat study during pandemic conditions identified a significant occupational risk for HCWs, household exposures might still be more strongly associated with influenza infection.DiscussionThis study was subject to a number of limitations.", [["influenza infection", "DISEASE", 178, 197], ["a repeat study", "TEST", 18, 32], ["pandemic conditions", "PROBLEM", 40, 59], ["influenza infection", "PROBLEM", 178, 197], ["This study", "TEST", 208, 218], ["infection", "OBSERVATION", 188, 197]]], ["As recruiting at the hospital and one administrative study site was done through the occupational health departments, only a small proportion (fewer than 10%) of the HCWs at these sites were enrolled in the study.", [["the study", "TEST", 203, 212], ["small", "OBSERVATION_MODIFIER", 125, 130]]], ["Selection bias could have concealed any actual relationship between HCWs status and influenza infection, if HCWs with a lower risk of influenza than their non-recruited colleagues were to have enrolled, or if non-HCWs with a higher risk of influenza enrolled.", [["influenza infection", "DISEASE", 84, 103], ["influenza", "DISEASE", 134, 143], ["influenza", "DISEASE", 240, 249], ["Selection bias", "TEST", 0, 14], ["influenza infection", "PROBLEM", 84, 103], ["influenza", "PROBLEM", 134, 143], ["influenza", "PROBLEM", 240, 249], ["influenza", "OBSERVATION", 134, 143], ["influenza", "OBSERVATION", 240, 249]]], ["It is possible that HCWs with a higher number of patient contacts and, therefore in theory a higher risk of influenza, would be less likely to participate due to pressure of work.", [["influenza", "DISEASE", 108, 117], ["patient", "ORGANISM", 49, 56], ["patient", "SPECIES", 49, 56], ["influenza", "PROBLEM", 108, 117], ["influenza", "OBSERVATION", 108, 117]]], ["Alternatively, HCWs who were concerned about their higher risk of influenza may have protected themselves better and may have been more likely than other HCWs to participate, which would tend to decrease the relative risk in this group.DiscussionLoss of recruited participants, mostly due to losses to follow up (despite repeated attempts to contact) and to the timing of vaccination, reduced the effective power of the study and may have worsened selection bias, although excluded participants did not differ significantly with respect to variables found to influence the outcome.DiscussionAlthough there were differences between the two comparison groups with respect to sex, recent immunisation, smoking and use of public transport, the logistic regression methods should have adjusted for these where they had an effect on the outcome (in particular immunisation).", [["influenza", "DISEASE", 66, 75], ["participants", "SPECIES", 264, 276], ["participants", "SPECIES", 482, 494], ["influenza", "PROBLEM", 66, 75], ["vaccination", "TREATMENT", 372, 383], ["the study", "TEST", 416, 425], ["public transport", "TREATMENT", 718, 734], ["the logistic regression methods", "TREATMENT", 736, 767], ["influenza", "OBSERVATION", 66, 75]]], ["The lower average age and higher proportion of females in the HCW group is likely to be due to recruitment among trainee nurses in the larger hospitals.DiscussionSerological testing for influenza infection alone, rather than molecular testing methods, may have underestimated the true number of influenza infections [24].", [["influenza infection", "DISEASE", 186, 205], ["influenza infections", "DISEASE", 295, 315], ["Serological testing", "TEST", 162, 181], ["influenza infection", "PROBLEM", 186, 205], ["molecular testing methods", "TEST", 225, 250], ["influenza infections", "PROBLEM", 295, 315], ["lower", "OBSERVATION_MODIFIER", 4, 9], ["average", "OBSERVATION_MODIFIER", 10, 17], ["higher", "OBSERVATION_MODIFIER", 26, 32], ["proportion", "OBSERVATION_MODIFIER", 33, 43], ["likely to be due to", "UNCERTAINTY", 75, 94], ["recruitment", "OBSERVATION", 95, 106], ["influenza", "OBSERVATION", 295, 304]]], ["This, along with the relatively high vaccination uptake, will have reduced the number of SCII and thus the effective study power.", [["SCII", "DISEASE", 89, 93], ["the relatively high vaccination uptake", "PROBLEM", 17, 55]]], ["With an attack rate of 10% in non-healthcare workers, the sample size of 736 analysed would not have been sufficient to detect a relative risk below 1.8 (80% power, 5% significance).DiscussionWe explored the possibility of influenza clustering due to site-level group influences or localized influenza outbreaks.", [["influenza", "DISEASE", 292, 301], ["the sample size", "TEST", 54, 69], ["influenza clustering", "PROBLEM", 223, 243], ["level group influences", "PROBLEM", 256, 278], ["localized influenza outbreaks", "PROBLEM", 282, 311], ["influenza", "OBSERVATION", 292, 301]]], ["Analysis of symptom onset dates revealed no evidence of separate site-specific outbreaks, but instead the epidemic curves at each study site followed the overall trend.", [["symptom onset dates", "TEST", 12, 31], ["separate site", "PROBLEM", 56, 69], ["specific outbreaks", "PROBLEM", 70, 88], ["the epidemic curves at each study site", "PROBLEM", 102, 140], ["no evidence of", "UNCERTAINTY", 41, 55]]], ["In addition the multilevel analysis suggested that there were no significant group-level influences on the outcome.ConclusionsOur study results suggest that HCWs in an acute hospital care setting are at no higher risk of influenza than the general public, or that if they are, the increased risk is modest.", [["influenza", "DISEASE", 221, 230], ["the multilevel analysis", "TEST", 12, 35], ["significant group-level influences", "PROBLEM", 65, 99], ["Our study", "TEST", 126, 135], ["influenza", "PROBLEM", 221, 230], ["the increased risk", "PROBLEM", 277, 295], ["no", "UNCERTAINTY", 62, 64], ["significant", "OBSERVATION_MODIFIER", 65, 76], ["influenza", "OBSERVATION", 221, 230], ["modest", "OBSERVATION_MODIFIER", 299, 305]]], ["Household contacts, particularly children, play an important role with individuals with three or more children being at highest risk.", [["children", "ORGANISM", 33, 41], ["children", "ORGANISM", 102, 110], ["children", "SPECIES", 33, 41], ["children", "SPECIES", 102, 110]]], ["Use of public transport does not increase the risk of influenza, whereas (in the absence of household children) car ownership does seem to significantly increase the risk for influenza infection, although the mechanism is unclear.", [["influenza", "DISEASE", 54, 63], ["influenza infection", "DISEASE", 175, 194], ["children", "ORGANISM", 102, 110], ["children", "SPECIES", 102, 110], ["public transport", "TREATMENT", 7, 23], ["influenza", "PROBLEM", 54, 63], ["influenza infection", "PROBLEM", 175, 194], ["influenza", "OBSERVATION", 54, 63], ["influenza", "OBSERVATION", 175, 184]]], ["Further research would help to clarify the role of household contacts of different age groups, the relevance of car ownership, and whether subgroups of hospital HCWs - or HCWs in other settings, such as in primary care, - are at increased risk for influenza infection.", [["influenza infection", "DISEASE", 248, 267], ["influenza infection", "PROBLEM", 248, 267], ["influenza infection", "OBSERVATION", 248, 267]]], ["Finally, the ILI-syndrome is a poor marker for influenza infection, suggesting that HCWs cannot rely on this syndrome if they wish to confidently protect their patients but, should instead be vaccinated.Authors' contributionsCW, under the supervision of UB, led the study design, conducted the analysis and drafted and updated the manuscript.", [["ILI-syndrome", "DISEASE", 13, 25], ["influenza infection", "DISEASE", 47, 66], ["patients", "ORGANISM", 160, 168], ["patients", "SPECIES", 160, 168], ["the ILI-syndrome", "PROBLEM", 9, 25], ["influenza infection", "PROBLEM", 47, 66], ["this syndrome", "PROBLEM", 104, 117], ["the study", "TEST", 262, 271], ["the analysis", "TEST", 290, 302]]], ["CW had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.Authors' contributionsBS supervised laboratory testing and participated in manuscript review.", [["the study", "TEST", 38, 47], ["the data analysis", "TEST", 123, 140], ["laboratory testing", "TEST", 177, 195]]], ["GD participated in the conduct of the study and the manuscript review.", [["GD", "DISEASE", 0, 2], ["the study", "TEST", 34, 43]]], ["FG assisted with the study execution and critically reviewed the manuscript.", [["the study execution", "TEST", 17, 36]]], ["FH participated in the design of the study, participated in the execution of the study and critically reviewed the manuscript.", [["FH", "DISEASE", 0, 2], ["the study", "TEST", 33, 42], ["the study", "TEST", 77, 86]]], ["GK participated in the planning, methodological concepts, interpretation of results and manuscript review.", [["GK", "ORGANISM", 0, 2]]], ["AN participated in the conduct of the study and the manuscript review.", [["the study", "TEST", 34, 43]]], ["UB designed the study, obtained funding, supervised and assisted with its execution, supervised analysis and interpretation of data, and critically reviewed the manuscript.Authors' contributionsAll authors confirmed that they have seen and approved the final version and have no conflicts of interest.Pre-publication historyThe pre-publication history for this paper can be accessed here:Pre-publication historyhttp://www.biomedcentral.com/1471-2334/10/8/prepub", [["Pre-publication", "DISEASE", 301, 316], ["pre-publication", "DISEASE", 328, 343], ["Pre-publication", "DISEASE", 388, 403], ["the study", "TEST", 12, 21], ["supervised analysis", "TEST", 85, 104]]]], "PMC3887892": [["INTRODUCTIONGraphene, a one-atom-thick nanomaterial with sp2 carbons arranged in a two-dimensional honeycomb structure, has received much attention recently as an emerging material with a variety of potential applications based on its unique mechanical, electrical, optical, and biological properties (Zhu et al., 2010).", [["carbons", "CHEMICAL", 61, 68], ["sp2 carbons", "SIMPLE_CHEMICAL", 57, 68], ["INTRODUCTIONGraphene", "TREATMENT", 0, 20], ["sp2 carbons", "TREATMENT", 57, 68], ["potential applications", "TREATMENT", 199, 221]]], ["The oxidized form of graphene, or graphene oxide (GO, Fig. 1), has been extensively explored in both basic and biomedical research largely because of its good biocompatibility, colloidal dispersibility in aqueous solution, flexible surface chemistry, amphiphilicity, and superior fluorescence quenching capability (Loh et al., 2010; Morales-Narvaez et al., 2012).", [["surface", "ANATOMY", 232, 239], ["graphene", "CHEMICAL", 21, 29], ["graphene oxide", "CHEMICAL", 34, 48], ["graphene", "CHEMICAL", 21, 29], ["graphene oxide", "CHEMICAL", 34, 48], ["graphene", "SIMPLE_CHEMICAL", 21, 29], ["graphene oxide", "SIMPLE_CHEMICAL", 34, 48], ["The oxidized form of graphene", "TREATMENT", 0, 29], ["graphene oxide", "TREATMENT", 34, 48], ["colloidal dispersibility in aqueous solution", "TREATMENT", 177, 221], ["flexible surface chemistry", "TEST", 223, 249], ["amphiphilicity", "TEST", 251, 265], ["colloidal dispersibility", "OBSERVATION", 177, 201]]], ["Studies have demonstrated that the GO surface may interact through pi-pi stacking and hydrogen bonding interactions (Park et al., 2013) with various biomolecules, including thrombin (Chang et al., 2010), dopamine (Wang et al., 2009), nucleic acids (Lu et al., 2009), peptides (Wang et al., 2011a), proteins (Mu et al., 2012; Zhang et al., 2012), and lipids (Frost et al., 2012).INTRODUCTIONThese interactions are key to the use of GO for biological applications and enable the loading and release of various drug candidates (e.g., oligonucleotides and small molecules) and sensing probes.", [["GO surface", "ANATOMY", 35, 45], ["dopamine", "CHEMICAL", 204, 212], ["nucleic acids", "CHEMICAL", 234, 247], ["pi-pi", "CHEMICAL", 67, 72], ["hydrogen", "CHEMICAL", 86, 94], ["dopamine", "CHEMICAL", 204, 212], ["hydrogen", "SIMPLE_CHEMICAL", 86, 94], ["thrombin", "GENE_OR_GENE_PRODUCT", 173, 181], ["dopamine", "SIMPLE_CHEMICAL", 204, 212], ["nucleic acids", "SIMPLE_CHEMICAL", 234, 247], ["thrombin", "PROTEIN", 173, 181], ["Studies", "TEST", 0, 7], ["various biomolecules", "PROBLEM", 141, 161], ["thrombin", "TREATMENT", 173, 181], ["dopamine", "TREATMENT", 204, 212], ["nucleic acids", "TEST", 234, 247], ["biological applications", "TREATMENT", 438, 461], ["various drug candidates", "TREATMENT", 500, 523], ["oligonucleotides and small molecules)", "TREATMENT", 531, 568], ["sensing probes", "TREATMENT", 573, 587], ["hydrogen bonding", "OBSERVATION", 86, 102]]], ["Additionally, the fluorescence quenching property of GO leads to a wide range of active research and development of fluorescence resonance energy transfer (FRET) biosensors (Wang et al., 2010).", [["the fluorescence quenching", "PROBLEM", 14, 40], ["active", "OBSERVATION_MODIFIER", 81, 87]]], ["The nano-sized GO (nGO, 50\u2013300 nm) has been engineered, often by tuning GO preparation conditions, for use in intracellular delivery (Luo et al., 2010; Pan et al., 2011).", [["intracellular", "ANATOMY", 110, 123], ["nGO", "SIMPLE_CHEMICAL", 19, 22], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 110, 123], ["intracellular delivery", "TREATMENT", 110, 132]]], ["The mechanism underlying GO cellular uptake remains to be determined; however, endocytosis appears to be involved in the process.", [["cellular", "ANATOMY", 28, 36], ["cellular", "CELL", 28, 36], ["GO cellular uptake", "PROBLEM", 25, 43], ["endocytosis", "PROBLEM", 79, 90], ["cellular uptake", "OBSERVATION", 28, 43]]], ["Versatile covalent functionalization can be achieved through hydroxyl and carboxylic acid groups present on the GO surface to enhance its physiochemical, electrochemical, or biological properties depending on the application (Huang et al., 2011; Zhang et al., 2011).GO-BASED HELICASE BIOSENSORVarious GO-based enzymatic activity assay systems have been developed to target nucleases (Lee and Min, 2012), methyltransferases (Lee et al., 2011), and caspases (Wang et al., 2011b).", [["hydroxyl", "CHEMICAL", 61, 69], ["carboxylic acid", "CHEMICAL", 74, 89], ["hydroxyl", "CHEMICAL", 61, 69], ["carboxylic acid", "CHEMICAL", 74, 89], ["hydroxyl", "SIMPLE_CHEMICAL", 61, 69], ["carboxylic acid", "SIMPLE_CHEMICAL", 74, 89], ["caspases", "GENE_OR_GENE_PRODUCT", 447, 455], ["methyltransferases", "PROTEIN", 404, 422], ["caspases", "PROTEIN", 447, 455], ["Versatile covalent functionalization", "TREATMENT", 0, 36], ["hydroxyl and carboxylic acid groups", "TREATMENT", 61, 96], ["covalent functionalization", "OBSERVATION", 10, 36]]], ["Here, we focus on the first reported GO-based enzyme activity assay, namely the GO-based helicase activity assay (GOHA), and its use in identifying helicase nsP13 from the severe acute respiratory syndrome coronavirus (SARS CoV, SCV) (Jang et al., 2010).", [["acute respiratory syndrome coronavirus", "DISEASE", 179, 217], ["SARS", "DISEASE", 219, 223], ["helicase nsP13", "PROTEIN", 148, 162], ["severe acute respiratory syndrome coronavirus", "SPECIES", 172, 217], ["SARS CoV", "SPECIES", 219, 227], ["helicase nsP13", "TREATMENT", 148, 162], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 168, 217], ["severe", "OBSERVATION_MODIFIER", 172, 178], ["acute", "OBSERVATION_MODIFIER", 179, 184], ["respiratory syndrome coronavirus", "OBSERVATION", 185, 217], ["SCV", "ANATOMY", 229, 232]]], ["SARS is a viral respiratory disease in humans characterized by flu-like symptoms and high mortality rates.", [["respiratory", "ANATOMY", 16, 27], ["SARS", "DISEASE", 0, 4], ["viral respiratory disease", "DISEASE", 10, 35], ["flu-like symptoms", "DISEASE", 63, 80], ["humans", "ORGANISM", 39, 45], ["humans", "SPECIES", 39, 45], ["humans", "SPECIES", 39, 45], ["SARS", "PROBLEM", 0, 4], ["a viral respiratory disease in humans", "PROBLEM", 8, 45], ["flu-like symptoms", "PROBLEM", 63, 80], ["high mortality rates", "PROBLEM", 85, 105], ["viral", "OBSERVATION_MODIFIER", 10, 15], ["respiratory disease", "OBSERVATION", 16, 35], ["flu", "OBSERVATION", 63, 66]]], ["SCV helicases have been recognized as a primary target for direct-acting antiviral agents against SARS (Huang et al., 2008).", [["SARS", "DISEASE", 98, 102], ["SCV helicases", "PROTEIN", 0, 13], ["SCV helicases", "PROBLEM", 0, 13], ["direct-acting antiviral agents", "TREATMENT", 59, 89], ["SARS", "PROBLEM", 98, 102], ["helicases", "OBSERVATION", 4, 13]]], ["The GOHA platform relies on the preferential binding of GO to single-stranded DNA (ssDNA) over double-stranded DNA (dsDNA) and the quenching of DNA-conjugated fluorescent dyes when the GO and dyes are present in close proximity.", [["DNA", "CELLULAR_COMPONENT", 78, 81], ["ssDNA", "CELLULAR_COMPONENT", 83, 88], ["DNA", "CELLULAR_COMPONENT", 111, 114], ["dsDNA", "CELLULAR_COMPONENT", 116, 121], ["DNA", "CELLULAR_COMPONENT", 144, 147], ["conjugated fluorescent dyes", "SIMPLE_CHEMICAL", 148, 175], ["dyes", "SIMPLE_CHEMICAL", 192, 196], ["single-stranded DNA", "DNA", 62, 81], ["ssDNA", "DNA", 83, 88], ["double-stranded DNA", "DNA", 95, 114], ["single-stranded DNA (ssDNA", "TREATMENT", 62, 88], ["double-stranded DNA (dsDNA", "TREATMENT", 95, 121], ["the quenching of DNA", "TREATMENT", 127, 147], ["conjugated fluorescent dyes", "TREATMENT", 148, 175], ["dyes", "TREATMENT", 192, 196]]], ["Strong adsorption of single-stranded nucleotides to GO is mediated by pi-pi stacking interactions between the aromatic rings in the exposed bases that constitute single-stranded nucleotides and the sp2 hybridized hexagonal structure of GO (Liu et al., 2008; Varghese et al., 2009).", [["nucleotides", "CHEMICAL", 37, 48], ["pi-pi", "CHEMICAL", 70, 75], ["nucleotides", "CHEMICAL", 178, 189], ["sp2", "CHEMICAL", 198, 201], ["single-stranded nucleotides", "TREATMENT", 21, 48], ["the aromatic rings", "TREATMENT", 106, 124], ["single-stranded nucleotides", "PROBLEM", 162, 189], ["aromatic rings", "OBSERVATION", 110, 124], ["bases", "ANATOMY_MODIFIER", 140, 145], ["stranded nucleotides", "OBSERVATION", 169, 189], ["hexagonal", "OBSERVATION_MODIFIER", 213, 222]]], ["Contrary to ssDNA, dsDNA cannot interact with GO because the bases of dsDNA are located inside the double helix within the negatively charged phosphate backbone (He et al., 2010).", [["phosphate", "CHEMICAL", 142, 151], ["phosphate", "CHEMICAL", 142, 151], ["ssDNA", "CELLULAR_COMPONENT", 12, 17], ["dsDNA", "CELLULAR_COMPONENT", 19, 24], ["dsDNA", "CELLULAR_COMPONENT", 70, 75], ["dsDNA", "PROTEIN", 19, 24], ["ssDNA", "TREATMENT", 12, 17], ["dsDNA", "TREATMENT", 19, 24], ["dsDNA", "PROBLEM", 70, 75]]], ["Unwinding of dsDNA is initiated by addition of SCV helicases to a mixture of fluorescence-labeled substrate dsDNA and GO.", [["dsDNA", "CELLULAR_COMPONENT", 13, 18], ["dsDNA", "CELLULAR_COMPONENT", 108, 113], ["SCV helicases", "PROTEIN", 47, 60], ["Unwinding of dsDNA", "PROBLEM", 0, 18], ["SCV helicases", "TREATMENT", 47, 60], ["dsDNA", "OBSERVATION", 13, 18]]], ["As the helicase reaction proceeds, the fluorescence intensity decreases due to the energy transfer-mediated quenching that occurs upon binding of unwound ssDNA to the GO surface (Fig. 1).", [["GO surface", "ANATOMY", 167, 177], ["ssDNA", "CELLULAR_COMPONENT", 154, 159], ["GO surface", "CELLULAR_COMPONENT", 167, 177], ["the helicase reaction", "PROBLEM", 3, 24], ["the fluorescence intensity", "PROBLEM", 35, 61], ["mediated quenching", "PROBLEM", 99, 117], ["unwound ssDNA", "TREATMENT", 146, 159]]], ["The GOHA platform is a good example of a GO-based enzymatic biosensor due to its highly selective adsorption to ssDNA and exceptionally high fluorescence quenching ability.", [["ssDNA", "CELLULAR_COMPONENT", 112, 117]]], ["Further application of GOHA for more pathophysiological relevance has been extensively studied including a robust and cost-effective drug discovery platform.HEPATITIS C VIRUS NS3 HELICASE AND mGOHA FOR DRUG DISCOVERYHepatitis C is an infectious liver disease that affects more than 170 million people worldwide.", [["liver", "ANATOMY", 245, 250], ["GOHA", "CHEMICAL", 23, 27], ["infectious liver disease", "DISEASE", 234, 258], ["GOHA", "SIMPLE_CHEMICAL", 23, 27], ["liver", "ORGAN", 245, 250], ["people", "ORGANISM", 294, 300], ["GOHA", "PROTEIN", 23, 27], ["people", "SPECIES", 294, 300], ["HEPATITIS C VIRUS NS3 HELICASE", "PROBLEM", 157, 187], ["an infectious liver disease", "PROBLEM", 231, 258], ["infectious", "OBSERVATION_MODIFIER", 234, 244], ["liver", "ANATOMY", 245, 250], ["disease", "OBSERVATION", 251, 258]]], ["Chronic infection with hepatitis C virus (HCV) leads to severe liver disease, including cirrhosis and hepatocarcinoma (Choo et al., 1989; Francesco et al., 2005).", [["liver", "ANATOMY", 63, 68], ["hepatocarcinoma", "ANATOMY", 102, 117], ["Chronic infection", "DISEASE", 0, 17], ["hepatitis C", "DISEASE", 23, 34], ["liver disease", "DISEASE", 63, 76], ["cirrhosis", "DISEASE", 88, 97], ["hepatocarcinoma", "DISEASE", 102, 117], ["hepatitis C virus", "ORGANISM", 23, 40], ["HCV", "ORGANISM", 42, 45], ["liver", "ORGAN", 63, 68], ["hepatocarcinoma", "CANCER", 102, 117], ["hepatitis C virus", "SPECIES", 23, 40], ["hepatitis C virus", "SPECIES", 23, 40], ["HCV", "SPECIES", 42, 45], ["Chronic infection", "PROBLEM", 0, 17], ["hepatitis C virus (HCV)", "PROBLEM", 23, 46], ["severe liver disease", "PROBLEM", 56, 76], ["cirrhosis", "PROBLEM", 88, 97], ["hepatocarcinoma", "PROBLEM", 102, 117], ["infection", "OBSERVATION", 8, 17], ["hepatitis", "OBSERVATION", 23, 32], ["severe", "OBSERVATION_MODIFIER", 56, 62], ["liver", "ANATOMY", 63, 68], ["disease", "OBSERVATION", 69, 76], ["cirrhosis", "OBSERVATION", 88, 97], ["hepatocarcinoma", "OBSERVATION", 102, 117]]], ["At present, a combination of PEG-conjugated interferon-\u03b1 and ribavirin is routinely prescribed for treating hepatitis C infection.", [["PEG-conjugated interferon-\u03b1", "CHEMICAL", 29, 56], ["ribavirin", "CHEMICAL", 61, 70], ["hepatitis C infection", "DISEASE", 108, 129], ["PEG", "CHEMICAL", 29, 32], ["ribavirin", "CHEMICAL", 61, 70], ["PEG-conjugated interferon-\u03b1", "SIMPLE_CHEMICAL", 29, 56], ["ribavirin", "SIMPLE_CHEMICAL", 61, 70], ["hepatitis C", "ORGANISM", 108, 119], ["interferon", "PROTEIN", 44, 54], ["hepatitis C", "SPECIES", 108, 119], ["PEG-conjugated interferon-\u03b1", "TREATMENT", 29, 56], ["ribavirin", "TREATMENT", 61, 70], ["hepatitis C infection", "PROBLEM", 108, 129], ["hepatitis", "OBSERVATION", 108, 117], ["infection", "OBSERVATION", 120, 129]]], ["Interferon-\u03b1 is an immune booster and ribavirin is a nucleoside-mimicking derivative that causes lethal mutations in the virus during RNA replication and indirectly contributes to sustaining the immune response against HCV genotypes 1, 2, and 3.", [["Interferon-\u03b1", "CHEMICAL", 0, 12], ["ribavirin", "CHEMICAL", 38, 47], ["nucleoside", "CHEMICAL", 53, 63], ["ribavirin", "CHEMICAL", 38, 47], ["nucleoside", "CHEMICAL", 53, 63], ["Interferon-\u03b1", "GENE_OR_GENE_PRODUCT", 0, 12], ["ribavirin", "SIMPLE_CHEMICAL", 38, 47], ["nucleoside", "SIMPLE_CHEMICAL", 53, 63], ["HCV", "ORGANISM", 219, 222], ["3", "GENE_OR_GENE_PRODUCT", 243, 244], ["Interferon-\u03b1", "PROTEIN", 0, 12], ["HCV", "SPECIES", 219, 222], ["Interferon", "TREATMENT", 0, 10], ["an immune booster", "TREATMENT", 16, 33], ["ribavirin", "TREATMENT", 38, 47], ["a nucleoside", "TREATMENT", 51, 63], ["mimicking derivative", "TREATMENT", 64, 84], ["lethal mutations", "PROBLEM", 97, 113], ["the virus", "PROBLEM", 117, 126], ["RNA replication", "TREATMENT", 134, 149], ["HCV genotypes", "PROBLEM", 219, 232]]], ["However, this pharmacological intervention has showed only limited efficacy with significant side effects, including hemolytic anemia, depression, and fatigue.", [["hemolytic anemia", "DISEASE", 117, 133], ["depression", "DISEASE", 135, 145], ["fatigue", "DISEASE", 151, 158], ["this pharmacological intervention", "TEST", 9, 42], ["significant side effects", "PROBLEM", 81, 105], ["hemolytic anemia", "PROBLEM", 117, 133], ["depression", "PROBLEM", 135, 145], ["fatigue", "PROBLEM", 151, 158], ["hemolytic", "OBSERVATION_MODIFIER", 117, 126], ["anemia", "OBSERVATION", 127, 133], ["depression", "OBSERVATION", 135, 145]]], ["Frequent genetic mutations in HCV and drug resistance also significantly limit the effectiveness of current hepatitis treatments.", [["hepatitis", "DISEASE", 108, 117], ["HCV", "ORGANISM", 30, 33], ["HCV", "SPECIES", 30, 33], ["Frequent genetic mutations", "PROBLEM", 0, 26], ["HCV", "PROBLEM", 30, 33], ["drug resistance", "PROBLEM", 38, 53], ["current hepatitis treatments", "TREATMENT", 100, 128], ["mutations", "OBSERVATION", 17, 26], ["HCV", "OBSERVATION", 30, 33], ["drug resistance", "OBSERVATION", 38, 53], ["hepatitis", "OBSERVATION", 108, 117]]], ["For higher therapeutic efficacy, new drugs have been anticipated to target more genetically conserved proteins of HCV such as proteases.", [["HCV", "ORGANISM", 114, 117], ["genetically conserved proteins", "PROTEIN", 80, 110], ["proteases", "PROTEIN", 126, 135], ["HCV", "SPECIES", 114, 117], ["new drugs", "TREATMENT", 33, 42], ["HCV", "PROBLEM", 114, 117]]], ["Direct-acting antiviral agents targeting the non-structural protein 3-4A serine protease (NS3-4A) (Lee et al., 2012) and non-structural protein 5B RNA-dependent RNA polymerase (NS5B RdRp) (Farnik and Zeuzem, 2012) in the viral replication cycle have been reported to be more effective than conventional therapy.", [["serine", "CHEMICAL", 73, 79], ["non-structural protein 3-4A serine protease", "GENE_OR_GENE_PRODUCT", 45, 88], ["NS3-4A", "GENE_OR_GENE_PRODUCT", 90, 96], ["non-structural protein 5B RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 121, 175], ["non-structural protein 3-4A serine protease", "PROTEIN", 45, 88], ["NS3", "PROTEIN", 90, 93], ["non-structural protein 5B RNA-dependent RNA polymerase", "PROTEIN", 121, 175], ["NS5B RdRp", "PROTEIN", 177, 186], ["Direct-acting antiviral agents", "TREATMENT", 0, 30], ["the non-structural protein", "TEST", 41, 67], ["A serine protease", "TREATMENT", 71, 88], ["NS3", "TEST", 90, 93], ["non-structural protein 5B RNA", "TEST", 121, 150], ["dependent RNA polymerase", "PROBLEM", 151, 175], ["NS5B RdRp", "TEST", 177, 186], ["the viral replication cycle", "TREATMENT", 217, 244], ["conventional therapy", "TREATMENT", 290, 310], ["viral replication", "OBSERVATION", 221, 238]]], ["Two inhibitors of the NS3-4A protease, telaprevir (Vertex) and boceprevir (Merck), were recently approved by the United States Food and Drug Administration (FDA) for treating HCV infection.HEPATITIS C VIRUS NS3 HELICASE AND mGOHA FOR DRUG DISCOVERYThe HCV NS3 protein contains a C-terminal RNA helicase domain that hydrolyzes ATP to catalyze the unwinding of dsDNA or dsRNA into single-stranded forms.", [["telaprevir", "CHEMICAL", 39, 49], ["boceprevir", "CHEMICAL", 63, 73], ["HCV infection", "DISEASE", 175, 188], ["ATP", "CHEMICAL", 326, 329], ["telaprevir", "CHEMICAL", 39, 49], ["boceprevir", "CHEMICAL", 63, 73], ["C", "CHEMICAL", 279, 280], ["ATP", "CHEMICAL", 326, 329], ["NS3-4A", "GENE_OR_GENE_PRODUCT", 22, 28], ["telaprevir", "SIMPLE_CHEMICAL", 39, 49], ["Vertex", "SIMPLE_CHEMICAL", 51, 57], ["boceprevir", "SIMPLE_CHEMICAL", 63, 73], ["Merck", "SIMPLE_CHEMICAL", 75, 80], ["HCV", "ORGANISM", 175, 178], ["HCV NS3", "ORGANISM", 252, 259], ["ATP", "SIMPLE_CHEMICAL", 326, 329], ["dsDNA", "CELLULAR_COMPONENT", 359, 364], ["NS3", "PROTEIN", 22, 25], ["NS3", "PROTEIN", 207, 210], ["HCV NS3 protein", "PROTEIN", 252, 267], ["C-terminal RNA helicase domain", "PROTEIN", 279, 309], ["HCV", "SPECIES", 175, 178], ["HCV", "SPECIES", 252, 255], ["Two inhibitors", "TREATMENT", 0, 14], ["the NS3", "TREATMENT", 18, 25], ["4A protease", "TREATMENT", 26, 37], ["telaprevir (Vertex)", "TREATMENT", 39, 58], ["boceprevir (Merck)", "TREATMENT", 63, 81], ["HCV infection", "PROBLEM", 175, 188], ["HEPATITIS C VIRUS NS3 HELICASE", "PROBLEM", 189, 219], ["DRUG DISCOVERYThe HCV NS3 protein", "TREATMENT", 234, 267], ["a C-terminal RNA helicase domain", "TREATMENT", 277, 309], ["hydrolyzes ATP", "TREATMENT", 315, 329], ["dsDNA", "PROBLEM", 359, 364], ["dsRNA", "PROBLEM", 368, 373], ["infection", "OBSERVATION", 179, 188]]], ["The N-terminal serine protease domain cleaves the HCV polyprotein and, consequently, releases mature proteins.", [["N", "CHEMICAL", 4, 5], ["serine", "CHEMICAL", 15, 21], ["N-terminal serine protease domain", "PROTEIN", 4, 37], ["HCV polyprotein", "PROTEIN", 50, 65], ["mature proteins", "PROTEIN", 94, 109], ["HCV", "SPECIES", 50, 53], ["The N-terminal serine protease domain", "TREATMENT", 0, 37], ["the HCV polyprotein", "TREATMENT", 46, 65]]], ["The HCV NS3 helicase is one of the essential enzymes of HCV along with NS3-4A serine protease and NS5B RdRp, which are required for processing HCV proteins and viral replication.", [["serine", "CHEMICAL", 78, 84], ["HCV NS3", "ORGANISM", 4, 11], ["HCV", "ORGANISM", 56, 59], ["NS3-4A serine protease", "GENE_OR_GENE_PRODUCT", 71, 93], ["NS5B", "GENE_OR_GENE_PRODUCT", 98, 102], ["HCV", "ORGANISM", 143, 146], ["HCV NS3 helicase", "PROTEIN", 4, 20], ["NS3-4A serine protease", "PROTEIN", 71, 93], ["NS5B RdRp", "PROTEIN", 98, 107], ["HCV proteins", "PROTEIN", 143, 155], ["HCV", "SPECIES", 4, 7], ["HCV", "SPECIES", 56, 59], ["HCV", "SPECIES", 143, 146], ["The HCV NS3 helicase", "TREATMENT", 0, 20], ["HCV", "PROBLEM", 56, 59], ["NS3", "TREATMENT", 71, 74], ["4A serine protease", "TREATMENT", 75, 93], ["NS5B RdRp", "TREATMENT", 98, 107], ["processing HCV proteins", "TREATMENT", 132, 155], ["viral replication", "TREATMENT", 160, 177], ["HCV", "OBSERVATION", 4, 7], ["NS3 helicase", "OBSERVATION", 8, 20], ["HCV", "OBSERVATION", 56, 59], ["NS5B RdRp", "OBSERVATION", 98, 107], ["viral replication", "OBSERVATION", 160, 177]]], ["The HCV NS3 helicase has long been considered another important target for the development of hepatitis C therapeutics (Borowski et al., 2002; Frick, 2007); however, identification of potent inhibitors using chemical library screening has been challenging because the available helicase assay systems are incompatible with high-throughput formats.HEPATITIS C VIRUS NS3 HELICASE AND mGOHA FOR DRUG DISCOVERYNumerous technologies have been developed to measure helicase activity in vitro, including fluorescence and radiolabeled gel electrophoresis (Kwong and Risano, 1998), scintillation proximity assay (SPA) (Kyono et al., 1998), FlashPlate (Hicham Alaoui-Ismaili et al., 2000), electrochemiluminescence (ECL) (Zhang et al., 2001), enzyme-linked immunosorbent assay (ELISA) (Hsu et al., 1998), FRET (Porter et al., 1998), time-resolving resonance energy transfer (TR-RET) (Earnshaw et al., 1999), and molecular beacon helicase assay (MBHA) (Belon and Frick, 2008) (Table 1).", [["hepatitis C", "DISEASE", 94, 105], ["HCV NS3", "ORGANISM", 4, 11], ["hepatitis C", "ORGANISM", 94, 105], ["HCV NS3 helicase", "PROTEIN", 4, 20], ["HCV", "SPECIES", 4, 7], ["The HCV NS3 helicase", "TREATMENT", 0, 20], ["hepatitis C therapeutics", "PROBLEM", 94, 118], ["potent inhibitors", "TREATMENT", 184, 201], ["chemical library screening", "TEST", 208, 234], ["the available helicase assay systems", "TEST", 264, 300], ["HEPATITIS C VIRUS NS3 HELICASE", "PROBLEM", 347, 377], ["DRUG DISCOVERYNumerous technologies", "TREATMENT", 392, 427], ["fluorescence", "TEST", 497, 509], ["radiolabeled gel electrophoresis", "TEST", 514, 546], ["FlashPlate", "TEST", 631, 641], ["enzyme", "TEST", 733, 739], ["hepatitis", "OBSERVATION", 94, 103]]], ["Some assay methods have contributed significantly to unveiling the helicase reaction mechanism at the molecular level.", [["Some assay methods", "PROBLEM", 0, 18]]], ["However, according to the NIH screen data (Mukherjee et al., 2012), some antiviral candidates identified by currently available helicase assays exhibited poor activity in cell-based analysis and even turned out to interfere with the assay itself and produced false positives.HEPATITIS C VIRUS NS3 HELICASE AND mGOHA FOR DRUG DISCOVERYRecently, our laboratory reported a multiplexed helicase assay platform based on GO (called mGOHA) that exhibits robust sensibility and high-throughput compatibility (Jang et al., 2013) (Fig. 2).", [["cell", "ANATOMY", 171, 175], ["cell", "CELL", 171, 175], ["the NIH screen data", "TEST", 22, 41], ["some antiviral candidates", "TREATMENT", 68, 93], ["helicase assays", "TEST", 128, 143], ["the assay", "TEST", 229, 238], ["false positives", "PROBLEM", 259, 274], ["HEPATITIS C VIRUS NS3 HELICASE", "PROBLEM", 275, 305], ["a multiplexed helicase assay platform", "TEST", 368, 405], ["robust sensibility", "PROBLEM", 447, 465], ["false positives", "OBSERVATION", 259, 274], ["high", "OBSERVATION_MODIFIER", 470, 474]]], ["Briefly, mGOHA employs SCV helicase and HCV NS3 helicase in a single mixed solution with DNA substrates labeled with two distinct fluorescent dyes, Cy3 and Cy5, respectively.", [["mGOHA", "CHEMICAL", 9, 14], ["mGOHA", "SIMPLE_CHEMICAL", 9, 14], ["SCV", "GENE_OR_GENE_PRODUCT", 23, 26], ["HCV NS3", "ORGANISM", 40, 47], ["DNA", "CELLULAR_COMPONENT", 89, 92], ["fluorescent dyes", "SIMPLE_CHEMICAL", 130, 146], ["Cy3", "SIMPLE_CHEMICAL", 148, 151], ["Cy5", "SIMPLE_CHEMICAL", 156, 159], ["mGOHA", "PROTEIN", 9, 14], ["SCV helicase", "PROTEIN", 23, 35], ["HCV NS3 helicase", "PROTEIN", 40, 56], ["HCV", "SPECIES", 40, 43], ["SCV helicase", "TREATMENT", 23, 35], ["HCV NS3 helicase", "TREATMENT", 40, 56], ["a single mixed solution with DNA substrates", "TREATMENT", 60, 103], ["fluorescent dyes", "OBSERVATION", 130, 146]]], ["The substrates were designed to selectively recognize each helicase to ensure orthogonal reactivity.", [["helicase", "PROTEIN", 59, 67], ["orthogonal reactivity", "OBSERVATION", 78, 99]]], ["Approximately 10,000 small molecules underwent a high-throughput screen using the mGOHA platform to identify potent inhibitors of target helicases (Fig. 3).", [["mGOHA", "SIMPLE_CHEMICAL", 82, 87], ["target helicases", "PROTEIN", 130, 146], ["the mGOHA platform", "TREATMENT", 78, 96], ["potent inhibitors", "TREATMENT", 109, 126]]], ["After the primary and secondary screens, five inhibitors specific to each helicase and five inhibitors active towards both helicases were identified.", [["helicase", "PROTEIN", 74, 82], ["secondary screens", "TEST", 22, 39], ["five inhibitors", "TREATMENT", 41, 56], ["each helicase", "TREATMENT", 69, 82], ["five inhibitors", "TREATMENT", 87, 102]]], ["The inhibitors exhibited 50\u2013500 \u03bcM of IC50 values on target helicases.", [["target helicases", "PROTEIN", 53, 69], ["The inhibitors", "TEST", 0, 14], ["IC50 values", "TEST", 38, 49]]], ["Furthermore, most directly inhibited the ATPase activity of the target helicase.", [["ATPase", "GENE_OR_GENE_PRODUCT", 41, 47], ["ATPase", "PROTEIN", 41, 47], ["target helicase", "PROTEIN", 64, 79]]], ["Among the five compounds identified as HCV NS3 helicase inhibitors, two compounds showed a considerable inhibitory effect on HCV gene replication following infection of the human liver cell line Huh-7.", [["liver cell line Huh-7", "ANATOMY", 179, 200], ["HCV NS3", "ORGANISM", 39, 46], ["HCV", "ORGANISM", 125, 128], ["human", "ORGANISM", 173, 178], ["liver cell line Huh-7", "CELL", 179, 200], ["HCV NS3 helicase", "PROTEIN", 39, 55], ["human liver cell line Huh-7", "CELL_LINE", 173, 200], ["human", "SPECIES", 173, 178], ["HCV", "SPECIES", 39, 42], ["HCV", "SPECIES", 125, 128], ["human", "SPECIES", 173, 178], ["HCV NS3 helicase inhibitors", "TREATMENT", 39, 66], ["a considerable inhibitory effect", "PROBLEM", 89, 121], ["HCV gene replication", "TREATMENT", 125, 145], ["Huh", "TEST", 195, 198], ["liver", "ANATOMY", 179, 184], ["cell line", "OBSERVATION", 185, 194]]], ["Collectively, mGOHA was demonstrated to be a successful high-throughput screening method that yields highly potent antiviral candidates without interfering with the assay itself and producing false positives.", [["mGOHA", "CHEMICAL", 14, 19], ["mGOHA", "SIMPLE_CHEMICAL", 14, 19], ["the assay", "TEST", 161, 170], ["false positives", "PROBLEM", 192, 207], ["false positives", "OBSERVATION", 192, 207]]], ["This novel assay also overcame the limitations of existing assay methods by providing reliable, reproducible, real-time quantitative monitoring of helicase activity.CONCLUSIONA helicase assay based on GO, called GOHA, was developed and successfully implemented in multiplexed high-throughput chemical screening to identify potent helicase inhibitors, which are potentially of clinical interest to treat hepatitis C and SARS.", [["hepatitis C", "DISEASE", 403, 414], ["SARS", "DISEASE", 419, 423], ["helicase", "PROTEIN", 147, 155], ["This novel assay", "TEST", 0, 16], ["existing assay methods", "TEST", 50, 72], ["helicase activity", "TREATMENT", 147, 164], ["helicase assay", "TEST", 177, 191], ["chemical screening", "TEST", 292, 310], ["potent helicase inhibitors", "TREATMENT", 323, 349], ["hepatitis C", "PROBLEM", 403, 414], ["SARS", "PROBLEM", 419, 423], ["helicase activity", "OBSERVATION", 147, 164]]], ["The new assay enables quantitative, reliable, and real-time monitoring of helicase activity by simply tracking changes in fluorescence intensity.", [["helicase", "PROTEIN", 74, 82], ["The new assay", "TEST", 0, 13], ["tracking changes in fluorescence intensity", "PROBLEM", 102, 144]]], ["The ability to perform multiplexed screening is also advantageous because it reduces costs and labor while providing near instantaneous information on the relative selectivity of the identified inhibitors.CONCLUSIONTo effectively treat HCV infection, direct-acting antiviral agents should be developed to complement the standard interferon-\u03b1 and ribavirin treatments.", [["HCV infection", "DISEASE", 236, 249], ["ribavirin", "CHEMICAL", 346, 355], ["ribavirin", "CHEMICAL", 346, 355], ["HCV", "ORGANISM", 236, 239], ["interferon-\u03b1", "GENE_OR_GENE_PRODUCT", 329, 341], ["ribavirin", "SIMPLE_CHEMICAL", 346, 355], ["interferon", "PROTEIN", 329, 339], ["HCV", "SPECIES", 236, 239], ["multiplexed screening", "TEST", 23, 44], ["labor", "PROBLEM", 95, 100], ["HCV infection", "PROBLEM", 236, 249], ["direct-acting antiviral agents", "TREATMENT", 251, 281], ["the standard interferon-\u03b1", "TREATMENT", 316, 341], ["ribavirin treatments", "TREATMENT", 346, 366], ["infection", "OBSERVATION", 240, 249]]], ["In this regard, discovery of new inhibitors of HCV NS3 helicase will be a great addition to existing options for direct-acting antiviral agents.", [["HCV NS3", "ORGANISM", 47, 54], ["HCV NS3 helicase", "PROTEIN", 47, 63], ["HCV", "SPECIES", 47, 50], ["new inhibitors", "TREATMENT", 29, 43], ["HCV NS3 helicase", "TREATMENT", 47, 63], ["direct-acting antiviral agents", "TREATMENT", 113, 143]]], ["The GOHA will be further harnessed to identify other helicase inhibitors to treat additional viral infections in the future.", [["viral infections", "DISEASE", 93, 109], ["GOHA", "SIMPLE_CHEMICAL", 4, 8], ["helicase inhibitors", "TREATMENT", 53, 72], ["additional viral infections", "PROBLEM", 82, 109], ["viral", "OBSERVATION_MODIFIER", 93, 98], ["infections", "OBSERVATION", 99, 109]]]], "7308ae143d6b9fa8bb488ba9d92cfac37dd0fc7b": [["Conclusion:This document provides recommendations and guidance with analysis of the risks relative to the benefits of various models of NP care during the COVID-19 pandemic.", [["NP care", "TREATMENT", 136, 143], ["the COVID", "TEST", 151, 160]]], ["Keywords: Neuropsychological assessment; Teleneuropsychology; Coronavirus; COVID-19; Recommendations; Models of care; In-clinicGoals of the Models of Care Recommendation and GuidanceClinical neuropsychologists globally are trying to determine how to provide neuropsychological (NP) services while minimizing risks of the COVID-19 illness and novel coronavirus transmission as lockdown orders are lifted and ambulatory clinical services resume in many settings.", [["coronavirus", "DISEASE", 348, 359], ["coronavirus", "ORGANISM", 348, 359], ["Neuropsychological assessment", "TEST", 10, 39], ["Teleneuropsychology", "TEST", 41, 60], ["Coronavirus", "PROBLEM", 62, 73], ["COVID", "TEST", 75, 80], ["neuropsychological (NP) services", "TREATMENT", 258, 290], ["the COVID", "TEST", 317, 326], ["novel coronavirus transmission", "TREATMENT", 342, 372], ["ambulatory clinical services", "TREATMENT", 407, 435]]], ["To do so rationally requires analysis of the risks relative to the benefits of various models of NP care.", [["NP care", "TREATMENT", 97, 104]]], ["Readers are referred to the IOPC Recommendations/Guidance for Teleneuropsychology (TeleNP) in Response to the COVID-19 Pandemic (Bilder et al., 2020) , which was developed to provide guidance for TeleNP in the context of the disruption in the usual face-to-face interpersonal contact that characterizes NP assessments.", [["Pandemic", "DISEASE", 119, 127], ["TeleNP", "TREATMENT", 196, 202], ["disruption", "OBSERVATION", 225, 235]]], ["This additional guidance first outlines the benefits of NP assessment, then surveys the risks of conducting NP assessments in the context of the novel coronavirus pandemic, and finally reviews the options for conducting NP exams in several ways, including standard in-person NP exams and several modified NP exam formats including mitigated in-person, in-clinic TeleNP, and in-home TeleNP.", [["coronavirus pandemic", "DISEASE", 151, 171], ["coronavirus", "ORGANISM", 151, 162], ["person", "SPECIES", 344, 350], ["NP assessment", "TEST", 56, 69], ["conducting NP assessments", "TEST", 97, 122], ["conducting NP exams", "TEST", 209, 228], ["NP exams", "TEST", 275, 283], ["modified NP exam formats", "TEST", 296, 320]]], ["Models for informed consent procedures and suggestions for documentation are included.Goals of the Models of Care Recommendation and GuidanceThis material is provided to help readers consider options and risk-benefit ratios of different strategies for NP care during the COVID-19 pandemic.", [["documentation", "TEST", 59, 72], ["NP care", "TREATMENT", 252, 259], ["the COVID", "TEST", 267, 276], ["pandemic", "PROBLEM", 280, 288]]], ["Given wide regional variation in risks of coronavirus infection or transmission, and wide variation in individual patient risk characteristics and practice settings, no uniform guidance or set of recommendations is likely to be appropriate across clinical settings, and \"hybrid\" or \"blended\" models may best balance risks and benefits.", [["coronavirus infection", "DISEASE", 42, 63], ["coronavirus", "ORGANISM", 42, 53], ["patient", "ORGANISM", 114, 121], ["patient", "SPECIES", 114, 121], ["coronavirus", "SPECIES", 42, 53], ["wide regional variation", "PROBLEM", 6, 29], ["coronavirus infection", "PROBLEM", 42, 63], ["wide variation", "PROBLEM", 85, 99], ["practice settings", "TREATMENT", 147, 164], ["regional variation", "OBSERVATION", 11, 29], ["coronavirus infection", "OBSERVATION", 42, 63], ["wide", "OBSERVATION_MODIFIER", 85, 89], ["variation", "OBSERVATION_MODIFIER", 90, 99]]], ["It is assumed that all psychologists will adhere to respective federal and state rules and regulations, the American Psychological Association's Ethical Standards (APA, 2017) , and the Standards for Educational and Psychological Testing (American Educational Research Association et al., 2014) .Benefits of NP AssessmentEmerging literature supports the incremental validity of NP assessment above and beyond other demographic, medical, and diagnostic variables; NP assessment enhances diagnostic decision-making and prediction of outcomes and reduces costs (Braun et al., 2011; Donders, 2020; Watt & Crowe, 2018) .", [["NP assessment", "TEST", 377, 390], ["NP assessment", "TEST", 462, 475]]], ["These benefits have almost always exceeded risks because the typical risks of NP assessment are so low.", [["NP assessment", "TEST", 78, 91]]], ["Now that the novel coronavirus pandemic has made in-person clinical encounters subject to nonnegligible risks described in the next section, it is valuable to specify the benefits of NP exams so that these can be weighed against potential risks.Benefits of NP AssessmentMany benefits of NP assessment can be understood as assisting in differential diagnosis or characterization of brain function that affects treatment or other interventions (Braun et al., 2011) .", [["brain", "ANATOMY", 381, 386], ["coronavirus pandemic", "DISEASE", 19, 39], ["coronavirus", "ORGANISM", 19, 30], ["brain", "ORGAN", 381, 386], ["the novel coronavirus pandemic", "PROBLEM", 9, 39], ["NP exams", "TEST", 183, 191], ["NP Assessment", "TEST", 257, 270], ["NP assessment", "TEST", 287, 300]]], ["A nonexhaustive list of interventions that are often guided by NP exams is as follows: In addition to direct impacts on interventions, NP exams may provide differential diagnoses and/or characterization of patient functioning that affects patient and/or caregiver understanding.", [["patient", "ORGANISM", 206, 213], ["patient", "ORGANISM", 239, 246], ["patient", "SPECIES", 206, 213], ["patient", "SPECIES", 239, 246], ["interventions", "TREATMENT", 24, 37], ["NP exams", "TEST", 63, 71], ["interventions", "TREATMENT", 120, 133], ["NP exams", "TEST", 135, 143]]], ["For example, it may be of high importance to a patient and family members to know how likely it is that their loved one has dementia or that their symptoms are better understood as a response to stressors or isolation during the pandemic.", [["dementia", "DISEASE", 124, 132], ["patient", "ORGANISM", 47, 54], ["patient", "SPECIES", 47, 54], ["dementia", "PROBLEM", 124, 132], ["their symptoms", "PROBLEM", 141, 155], ["isolation", "TREATMENT", 208, 217], ["the pandemic", "PROBLEM", 225, 237]]], ["By identifying appropriate treatments and increasing understanding, NP assessments also reduce costs, including direct financial costs (through reduction in suboptimal treatment utilization) and other human costs (through productivity loss, treatment of ancillary disorders, caregiver burden, and other indirect impacts).Benefits of NP AssessmentThe benefits of NP assessment need to be determined with respect to time.", [["human", "ORGANISM", 201, 206], ["human", "SPECIES", 201, 206], ["human", "SPECIES", 201, 206], ["appropriate treatments", "TREATMENT", 15, 37], ["NP assessments", "TEST", 68, 82], ["suboptimal treatment utilization", "TREATMENT", 157, 189], ["ancillary disorders", "PROBLEM", 254, 273], ["caregiver burden", "PROBLEM", 275, 291], ["NP Assessment", "TEST", 333, 346], ["NP assessment", "TEST", 362, 375]]], ["This weighs particularly on decisions to delay exams considering the benefits of earlier intervention and understanding versus the risks of delayed interventions and understanding.", [["delay exams", "TEST", 41, 52], ["earlier intervention", "TREATMENT", 81, 101], ["delayed interventions", "TREATMENT", 140, 161]]], ["The distinctions between \"emergency,\" \"urgent,\" and \"elective\" procedures are often unclear, 2 and it is more accurate to consider \"urgency\" as a dimension or continuum rather than classify the potential scenarios that can arise for patients given specific syndromes, ages, and other contextual factors.Benefits of NP Assessment\u2022 A patient who has epilepsy surgery delayed because NP information is not available may have adverse consequences of ongoing recurrent seizures during that waiting period. \u2022 A patient who has a cardiac or other major organ transplant (e.g., kidney, liver) delayed because NP information is not available may experience severe medical consequences or even death. \u2022 A patient with Parkinson's disease who has a deep brain stimulation surgery delayed because NP information is not available may experience adverse consequences such as a fall and poor adaptive functioning during that waiting period, hindering his/her ability to live independently. \u2022 A patient with suspected dementia who is living alone, driving, and/or working may experience adverse consequences of continuing these activities without intervention, potentially endangering self and others. \u2022 An immigrant could be denied asylum because NP information is not available, and this could result in deportation and possible lethal consequences on return to their country of origin. \u2022 A child with a learning disorder may not receive appropriate instruction, and their educational progress and potential placements may be affected adversely.", [["cardiac", "ANATOMY", 523, 530], ["organ", "ANATOMY", 546, 551], ["kidney", "ANATOMY", 570, 576], ["liver", "ANATOMY", 578, 583], ["brain", "ANATOMY", 743, 748], ["epilepsy", "DISEASE", 348, 356], ["seizures", "DISEASE", 464, 472], ["death", "DISEASE", 684, 689], ["Parkinson's disease", "DISEASE", 708, 727], ["dementia", "DISEASE", 1002, 1010], ["learning disorder", "DISEASE", 1390, 1407], ["patients", "ORGANISM", 233, 241], ["patient", "ORGANISM", 332, 339], ["patient", "ORGANISM", 505, 512], ["organ", "ORGAN", 546, 551], ["kidney", "ORGAN", 570, 576], ["liver", "ORGAN", 578, 583], ["patient", "ORGANISM", 695, 702], ["brain", "ORGAN", 743, 748], ["patient", "ORGANISM", 979, 986], ["patients", "SPECIES", 233, 241], ["patient", "SPECIES", 332, 339], ["patient", "SPECIES", 505, 512], ["patient", "SPECIES", 695, 702], ["patient", "SPECIES", 979, 986], ["child", "SPECIES", 1377, 1382], ["\"elective\" procedures", "TREATMENT", 52, 73], ["urgency", "PROBLEM", 132, 139], ["specific syndromes", "PROBLEM", 248, 266], ["NP Assessment", "TEST", 315, 328], ["epilepsy surgery", "TREATMENT", 348, 364], ["ongoing recurrent seizures", "PROBLEM", 446, 472], ["other major organ transplant", "TREATMENT", 534, 562], ["severe medical consequences", "PROBLEM", 648, 675], ["even death", "PROBLEM", 679, 689], ["Parkinson's disease", "PROBLEM", 708, 727], ["a deep brain stimulation surgery", "TREATMENT", 736, 768], ["adverse consequences", "PROBLEM", 832, 852], ["a fall", "PROBLEM", 861, 867], ["suspected dementia", "PROBLEM", 992, 1010], ["intervention", "TREATMENT", 1131, 1143], ["lethal consequences", "PROBLEM", 1315, 1334], ["a learning disorder", "PROBLEM", 1388, 1407], ["potential placements", "TREATMENT", 1484, 1504], ["seizures", "OBSERVATION", 464, 472], ["cardiac", "ANATOMY", 523, 530], ["transplant", "OBSERVATION", 552, 562], ["kidney", "ANATOMY", 570, 576], ["liver", "ANATOMY", 578, 583], ["deep", "ANATOMY_MODIFIER", 738, 742], ["brain", "ANATOMY", 743, 748], ["dementia", "OBSERVATION", 1002, 1010]]], ["The risks for adverse impacts of not receiving appropriate educational support and intervention may be magnified in the context of homeschool or hybrid homeschool models prior to full return to school conditions (which may not occur in some areas until a vaccine is widely available). \u2022 A child with autism spectrum disorder or attention-deficit/hyperactivity disorder with significant behavioral dysregulation may not receive appropriate interventions such as applied behavior analysis or psychiatric management.", [["autism spectrum disorder", "DISEASE", 300, 324], ["attention-deficit/hyperactivity disorder", "DISEASE", 328, 368], ["behavioral dysregulation", "DISEASE", 386, 410], ["psychiatric", "DISEASE", 490, 501], ["child", "SPECIES", 289, 294], ["appropriate educational support", "TREATMENT", 47, 78], ["intervention", "TREATMENT", 83, 95], ["hybrid homeschool models", "TREATMENT", 145, 169], ["a vaccine", "TREATMENT", 253, 262], ["autism spectrum disorder", "PROBLEM", 300, 324], ["deficit", "PROBLEM", 338, 345], ["hyperactivity disorder", "PROBLEM", 346, 368], ["significant behavioral dysregulation", "PROBLEM", 374, 410], ["appropriate interventions", "TREATMENT", 427, 452], ["behavior analysis", "TEST", 469, 486], ["psychiatric management", "TREATMENT", 490, 512]]], ["As a result, the child's condition may worsen and require more intensive and costly interventions.", [["child", "SPECIES", 17, 22], ["costly interventions", "TREATMENT", 77, 97]]], ["The child may no longer be appropriate for school placement, and this could have negative downstream effects for both the child and the family system (e.g., parental stress; job loss). \u2022 A patient with a major comorbid mood disorder may not receive an appropriate diagnosis and treatment plan, increasing the risk for suicide.Health RisksThe primary risks of conducting in-person or in-clinic assessments during the pandemic are health risks, including:Health Risks\u2022 Patient risk of contracting COVID-19Health Risks2 It is generally agreed that these three terms are to be interpreted in descending order of immediacy but the boundaries separating the conditions may be unclear, and there are multiple frameworks for understanding the level of urgency.", [["job loss", "DISEASE", 174, 182], ["mood disorder", "DISEASE", 219, 232], ["child", "ORGANISM", 4, 9], ["patient", "ORGANISM", 189, 196], ["child", "SPECIES", 4, 9], ["patient", "SPECIES", 189, 196], ["Patient", "SPECIES", 467, 474], ["school placement", "TREATMENT", 43, 59], ["a major comorbid mood disorder", "PROBLEM", 202, 232], ["treatment plan", "TREATMENT", 278, 292], ["suicide", "PROBLEM", 318, 325], ["urgency", "PROBLEM", 744, 751], ["no longer", "UNCERTAINTY", 14, 23]]], ["See for example https://bit.ly/ ElectiveRecs \u2022 Examiner(s) risk of contracting COVID-19 \u2022 Risk of transmission of coronavirus to patient, examiner(s), and/or community \u2022 Risks of exam validity being undermined by illness anxiety, which may be manifested by both examinees and examiners.Health RisksWith regard to health risks, it should be noted that for Phase I and Phase II reopening as defined by White House/CDC criteria, \"vulnerable persons\" (i.e., individuals with serious underlying health conditions, including high blood pressure, chronic lung disease, diabetes, obesity, asthma, and those whose immune system is compromised, such as by chemotherapy for cancer and other conditions requiring such therapy) are instructed to continue to follow \"safer-at-home\" orders.", [["blood", "ANATOMY", 524, 529], ["lung", "ANATOMY", 548, 552], ["cancer", "ANATOMY", 663, 669], ["coronavirus", "DISEASE", 114, 125], ["illness anxiety", "DISEASE", 213, 228], ["chronic lung disease", "DISEASE", 540, 560], ["diabetes", "DISEASE", 562, 570], ["obesity", "DISEASE", 572, 579], ["asthma", "DISEASE", 581, 587], ["cancer", "DISEASE", 663, 669], ["coronavirus", "ORGANISM", 114, 125], ["patient", "ORGANISM", 129, 136], ["persons", "ORGANISM", 438, 445], ["blood", "ORGANISM_SUBSTANCE", 524, 529], ["lung", "ORGAN", 548, 552], ["cancer", "CANCER", 663, 669], ["patient", "SPECIES", 129, 136], ["persons", "SPECIES", 438, 445], ["contracting COVID", "TEST", 67, 84], ["coronavirus", "PROBLEM", 114, 125], ["exam validity", "TEST", 179, 192], ["anxiety", "PROBLEM", 221, 228], ["Phase I and Phase II reopening", "PROBLEM", 355, 385], ["serious underlying health conditions", "PROBLEM", 471, 507], ["high blood pressure", "PROBLEM", 519, 538], ["chronic lung disease", "PROBLEM", 540, 560], ["diabetes", "PROBLEM", 562, 570], ["obesity", "PROBLEM", 572, 579], ["asthma", "PROBLEM", 581, 587], ["chemotherapy", "TREATMENT", 646, 658], ["cancer", "PROBLEM", 663, 669], ["other conditions", "PROBLEM", 674, 690], ["such therapy", "TREATMENT", 701, 713], ["chronic", "OBSERVATION_MODIFIER", 540, 547], ["lung", "ANATOMY", 548, 552], ["disease", "OBSERVATION", 553, 560]]], ["For more details: https:// www.whitehouse.gov/openingamerica/#criteria.Legal RisksIt should be recognized that the risks are not limited to health risks as noted earlier but also entail legal risks, including (a) exposure to litigation that may arise if an examinee's or employee's health is compromised, (b) exposure to litigation if the conclusions of the examination are questioned or considered invalid, and (c) possibility that the clinician's or practice's insurance coverage may not include practice under these circumstances (which may interact with other state, county, or city regulations imposed at the time; e.g., if the practice is not considered appropriate under \"reopening\" guidelines in effect within that jurisdiction).", [["litigation", "TREATMENT", 225, 235], ["the examination", "TEST", 354, 369], ["practice's insurance coverage", "TREATMENT", 452, 481]]], ["Most carriers offer individual consultations for this purpose.Legal RisksThe Trust has developed a statement https://bit.ly/TrustGuidelines (https://bit.ly/TrustGuidelines; Parma Trust Insurance, 2020) on in-person psychological services during the COVID-19 crisis, which is a useful reference and highlights the importance of each psychologist considering, among other factors, all relevant institutional, regional, state, and federal regulations in effect within their jurisdiction in considering risk management strategies.Models for Conducting NP AssessmentsThe following models are summarized to help provide options that may be considered by those planning reopening.", [["risk management strategies", "TREATMENT", 499, 525], ["Conducting NP Assessments", "TEST", 537, 562]]], ["It is assumed that no single model is best and that each practitioner needs to select elements from different models to maximize benefits and minimize risks.Standard in-person administrationIn-person or \"in-clinic\" assessment without mitigation procedures is the pre-COVID-19 \"gold standard\" against which other procedures are compared.", [["person", "SPECIES", 169, 175], ["person", "SPECIES", 193, 199], ["mitigation procedures", "TREATMENT", 234, 255]]], ["These are also generally the conditions under which normative and standardization studies were conducted, so deviation from this may be considered nonstandard administration.Modified in-person administration (using mitigation procedures to minimize the risk of coronavirus infection and/or transmission)The risks of in-person assessment are reduced by mitigation strategies (e.g., use of PPE, physical distancing), but some of these strategies may also potentially increase patient anxiety and represent an alteration in standard administration practices and therefore may affect the validity and increase the risk of inaccurate diagnoses.", [["coronavirus infection", "DISEASE", 261, 282], ["anxiety", "DISEASE", 482, 489], ["coronavirus", "ORGANISM", 261, 272], ["patient", "ORGANISM", 474, 481], ["patient", "SPECIES", 474, 481], ["standardization studies", "TEST", 66, 89], ["mitigation procedures", "TREATMENT", 215, 236], ["coronavirus infection", "PROBLEM", 261, 282], ["person assessment", "TEST", 319, 336], ["PPE", "TREATMENT", 388, 391], ["patient anxiety", "PROBLEM", 474, 489], ["standard administration practices", "TREATMENT", 521, 554]]], ["Note that significant deviation from standard assessment procedures affects scores in unknown ways and therefore reduces the reliability of score interpretation (American Educational Research Association et al., 2014).", [["significant deviation", "PROBLEM", 10, 31], ["standard assessment procedures", "TEST", 37, 67], ["significant", "OBSERVATION_MODIFIER", 10, 21], ["deviation", "OBSERVATION", 22, 31]]], ["We do not currently have a clear understanding of the point at which a virus mitigation measure becomes a significant departure from standardized administration.", [["a virus mitigation", "TREATMENT", 69, 87], ["clear", "OBSERVATION", 27, 32]]], ["There are currently no studies of potential threats to validity in the context of in-person viral mitigation strategies.Modified in-person administration (using mitigation procedures to minimize the risk of coronavirus infection and/or transmission)See below for a discussion of mitigation procedures.", [["coronavirus infection", "DISEASE", 207, 228], ["coronavirus", "ORGANISM", 207, 218], ["validity", "TEST", 55, 63], ["viral mitigation strategies", "TREATMENT", 92, 119], ["mitigation procedures", "TREATMENT", 161, 182], ["coronavirus infection", "PROBLEM", 207, 228], ["mitigation procedures", "TREATMENT", 279, 300]]], ["The following is a nonexhaustive list of procedures that are designed to reduce the risk of exposure but differ from standard practice and may affect test performance or interpretation:Modified in-person administration (using mitigation procedures to minimize the risk of coronavirus infection and/or transmission)\u2022 Screening procedures to determine that the patient (and the examiner) do not have symptoms or recent exposure, discussion of potential risk as part of an informed consent process, and visible signs of mitigation (e.g., masks, gloves, plexiglass barriers, warning signs) may increase patient anxiety to a degree that interferes with test performance.", [["coronavirus infection", "DISEASE", 272, 293], ["anxiety", "DISEASE", 607, 614], ["coronavirus", "ORGANISM", 272, 283], ["patient", "ORGANISM", 359, 366], ["patient", "ORGANISM", 599, 606], ["patient", "SPECIES", 359, 366], ["patient", "SPECIES", 599, 606], ["procedures", "TREATMENT", 41, 51], ["mitigation procedures", "TREATMENT", 226, 247], ["coronavirus infection", "PROBLEM", 272, 293], ["Screening procedures", "TEST", 316, 336], ["symptoms", "PROBLEM", 398, 406], ["gloves", "TREATMENT", 542, 548], ["patient anxiety", "PROBLEM", 599, 614], ["test performance", "TEST", 648, 664]]], ["Lack of physical contact between the patient and office staff or examiners may also have a general anxiety-provoking effect and reduce the level of support patients experience from interpersonal contact.", [["anxiety", "DISEASE", 99, 106], ["patient", "ORGANISM", 37, 44], ["patients", "ORGANISM", 156, 164], ["patient", "SPECIES", 37, 44], ["patients", "SPECIES", 156, 164], ["a general anxiety", "PROBLEM", 89, 106]]], ["Even if examiner behavior and office practices do not raise anxiety, there is a risk that the examinee may have increased anxiety or other symptoms secondary to health, social, and/or financial concerns related to COVID-19.", [["anxiety", "DISEASE", 60, 67], ["anxiety", "DISEASE", 122, 129], ["anxiety", "PROBLEM", 60, 67], ["increased anxiety", "PROBLEM", 112, 129], ["other symptoms", "PROBLEM", 133, 147], ["COVID", "TEST", 214, 219]]], ["A standardized assessment (e.g., Coronavirus Anxiety Scale; National Institute of Health Office of Behavioral & Social Sciences Research, 2020) may help assess the severity of COVID-specific concerns and supplement the usual clinical interview and standard instruments customarily used to assess the current emotional state effects on NP exam results. \u2022 Use of masks, gloves, or other personal protective equipment (PPE) by examiners and/or examinees may have additional adverse impacts on validity.", [["COVID", "DISEASE", 176, 181], ["A standardized assessment", "TEST", 0, 25], ["standard instruments", "TREATMENT", 248, 268], ["NP exam", "TEST", 335, 342], ["masks", "TREATMENT", 361, 366], ["gloves", "TREATMENT", 368, 374]]], ["Masks may be distracting to examinees and therefore affect performance on tests.", [["tests", "TEST", 74, 79]]], ["Masked verbalizations may be harder to understand for both examinee and examiner.", [["Masked verbalizations", "PROBLEM", 0, 21]]], ["This may be particularly problematic for tests where standard administration procedures do not allow repetition of items (e.g., Digit Span) and tests measuring the ability to distinguish sounds (e.g., items from a measure of phonological processing that are read aloud by the examiner).", [["tests", "TEST", 41, 46], ["standard administration procedures", "TREATMENT", 53, 87], ["tests", "TEST", 144, 149], ["phonological processing", "TREATMENT", 225, 248]]], ["Masks may also interfere with nonverbal communications including facial expressions and articulatory movements. \u2022 Increased distance between patient and examiner may make it more difficult for instructions to be delivered effectively and for examiners to record responses accurately.", [["facial", "ANATOMY", 65, 71], ["patient", "ORGANISM", 141, 148], ["patient", "SPECIES", 141, 148], ["facial expressions", "TEST", 65, 83], ["articulatory movements", "TEST", 88, 110], ["distance", "OBSERVATION_MODIFIER", 124, 132]]], ["Although some recommendations focus on a distance of \"six feet\" between examiner and examinee, considerations include the configuration of the space, ventilation, and how long the exposure lasts.Modified in-person administration (using mitigation procedures to minimize the risk of coronavirus infection and/or transmission)In some settings, novel physical barriers may be put in place between patients and office staff and/or examiners (e.g., plexiglass shields at reception desks or within exam rooms) when closer seating arrangements are unavoidable, but in those situations airflow and filtration must be considered carefully, and their impact on test performance has not been evaluated. \u2022 Restricted use of manipulatives and other articles that are \"high contact\" during testing.", [["coronavirus infection", "DISEASE", 282, 303], ["coronavirus", "ORGANISM", 282, 293], ["patients", "ORGANISM", 394, 402], ["patients", "SPECIES", 394, 402], ["ventilation", "TREATMENT", 150, 161], ["mitigation procedures", "TREATMENT", 236, 257], ["coronavirus infection", "PROBLEM", 282, 303], ["novel physical barriers", "TREATMENT", 342, 365], ["filtration", "TREATMENT", 590, 600], ["test performance", "TEST", 651, 667]]], ["Procedures that involve the patient and the examiner touching the same materials (e.g., blocks, pegs, tapping devices, pencils) may be minimized and alternatives identified.In-clinic TeleNPIn this model, both the clinician and the patient are in a clinic but in separate rooms using videoconferencing methods to conduct the NP assessment.", [["patient", "ORGANISM", 28, 35], ["patient", "ORGANISM", 231, 238], ["patient", "SPECIES", 28, 35], ["patient", "SPECIES", 231, 238], ["Procedures", "TREATMENT", 0, 10], ["blocks, pegs, tapping devices", "TREATMENT", 88, 117], ["the NP assessment", "TEST", 320, 337]]], ["In some circumstances, the rooms are in different clinic locations (e.g., a patient in a satellite clinic in a rural area and a neuropsychologist in a main clinic in a city center), and in other models, the rooms are in the same building.", [["patient", "ORGANISM", 76, 83], ["patient", "SPECIES", 76, 83]]], ["Having patients in a separate room further reduces the risk of patient and clinician exposure to coronavirus as compared to direct in-person mitigated assessment.", [["coronavirus", "DISEASE", 97, 108], ["patients", "ORGANISM", 7, 15], ["patient", "ORGANISM", 63, 70], ["coronavirus", "ORGANISM", 97, 108], ["patients", "SPECIES", 7, 15], ["patient", "SPECIES", 63, 70], ["coronavirus", "PROBLEM", 97, 108], ["mitigated assessment", "TEST", 141, 161]]], ["Clinicians control the quality of the TeleNP platform and equipment, are available to troubleshoot, can control the testing environment, and typically have greater ability to monitor patients.In-clinic TeleNPMost TeleNP research has been conducted in the context of in-clinic TeleNP, and because of the larger research base, the inclinic method is generally better validated than in-home TeleNP assessments.", [["patients", "ORGANISM", 183, 191], ["patients", "SPECIES", 183, 191], ["TeleNP assessments", "TEST", 388, 406]]], ["The existing literature for in-clinic TeleNP suggests that at least for some measures the actual difference between in-person and in-clinic TeleNP modalities is small (e.g., Hedges g = 0.033 or 1/33 SD; Bilder et al., 2020) .", [["Hedges g", "TEST", 174, 182], ["small", "OBSERVATION_MODIFIER", 161, 166]]], ["However, validation and equivalence studies are lacking for many measures and a wide array of patient populations.", [["patient", "ORGANISM", 94, 101], ["patient", "SPECIES", 94, 101], ["validation and equivalence studies", "TEST", 9, 43], ["a wide array of patient populations", "TREATMENT", 78, 113]]], ["The \"Computerized Neuropsychological Assessment Devices: Joint Position Paper of the American Academy of Clinical Neuropsychology and the National Academy of Neuropsychology\" (Bauer et al., 2012) clarifies that \"a computerized test adapted from an examiner administered test is a new test\".", [["Joint", "ANATOMY", 57, 62]]], ["As a result, it is essential that new normative data with adjustments for the pertinent demographic variables be established for computerized tests.", [["computerized tests", "TEST", 129, 147]]], ["Utilizing an in-clinic TeleNP model with tests that have not yet been validated in this context will reduce the validity of diagnostic conclusions.In-home TeleNP assessments (patient at home)The NP evaluation is conducted with the patient in their own home or other remote location via audio or videoconferencing technology (Bilder et al., 2020) .", [["patient", "ORGANISM", 175, 182], ["patient", "ORGANISM", 231, 238], ["patient", "SPECIES", 175, 182], ["patient", "SPECIES", 231, 238], ["tests", "TEST", 41, 46], ["The NP evaluation", "TEST", 191, 208]]], ["Most of the TeleNP research has not been conducted in this context, where examiners do not have control over the availability or quality of the telehealth platforms, cannot guarantee the availability of a distraction free testing environment, cannot help troubleshoot technical problems, and have limited ability to monitor patients.", [["patients", "ORGANISM", 324, 332], ["patients", "SPECIES", 324, 332], ["a distraction free testing", "TEST", 203, 229]]], ["Note that the testing portion of the NP assessment may or may not be included in the episodes of neuropsychological care conducted via in-home TeleNP.", [["the NP assessment", "TEST", 33, 50], ["neuropsychological care", "TREATMENT", 97, 120]]], ["Interviews of patients and collaterals combined with a record review may provide sufficient information in some cases, and the clinician may decide there is not sufficient incremental validity of additional NP testing to justify risks to validity of nonstandard administration.In-home TeleNP assessments (patient at home)Several factors may limit the benefits of in-home TeleNP assessment in specific patient populations.", [["patients", "ORGANISM", 14, 22], ["collaterals", "MULTI-TISSUE_STRUCTURE", 27, 38], ["patient", "ORGANISM", 305, 312], ["patient", "ORGANISM", 401, 408], ["patients", "SPECIES", 14, 22], ["patient", "SPECIES", 305, 312], ["patient", "SPECIES", 401, 408], ["additional NP testing", "TEST", 196, 217], ["nonstandard administration", "TREATMENT", 250, 276], ["TeleNP assessment", "TEST", 371, 388]]], ["Reduced patient access to technology due to economic disparities and potentially widening health disparities is a significant problem.", [["patient", "ORGANISM", 8, 15], ["patient", "SPECIES", 8, 15], ["economic disparities", "PROBLEM", 44, 64], ["potentially widening health disparities", "PROBLEM", 69, 108], ["a significant problem", "PROBLEM", 112, 133], ["widening", "OBSERVATION_MODIFIER", 81, 89], ["significant", "OBSERVATION_MODIFIER", 114, 125], ["problem", "OBSERVATION", 126, 133]]], ["For example, a Pew Research study in 2015 found that 15% of Hispanic and 12% of Black Americans (vs. 4% of Whites) rely on smartphones and do not have internet access (Pew Research, 2015) .", [["a Pew Research study", "TEST", 13, 33], ["Hispanic", "TEST", 60, 68], ["Black Americans", "PROBLEM", 80, 95]]], ["Sixteen percent of persons in the USA aged 16-65 are not digitally literate, and adults who are not digitally literate are, on average, less educated, older, and more likely to be Black, Hispanic, or foreign born, compared to digitally literate adults (Pew Research, 2019).In-home TeleNP assessments (patient at home)Socioeconomic disparities may further result in patients having limited access to a quiet, distraction-free place to engage in-home TeleNP assessment.", [["persons", "ORGANISM", 19, 26], ["adults", "ORGANISM", 81, 87], ["patient", "ORGANISM", 301, 308], ["patients", "ORGANISM", 365, 373], ["persons", "SPECIES", 19, 26], ["patient", "SPECIES", 301, 308], ["patients", "SPECIES", 365, 373], ["Socioeconomic disparities", "PROBLEM", 317, 342], ["home TeleNP assessment", "TEST", 444, 466]]], ["Finally, few validation studies for TeleNP have been conducted for multilingual, non-European American patients.Combined, hybrid, or staged models (combining elements of TeleNP with elements of in-person face-to-face)Clinicians might blend elements of TeleNP (either in clinic or at home) with mitigated in-person assessment to maximize the benefits and minimize the risks of the overall assessment strategy.", [["TeleNP", "SIMPLE_CHEMICAL", 36, 42], ["patients", "ORGANISM", 103, 111], ["TeleNP", "DNA", 170, 176], ["patients", "SPECIES", 103, 111], ["person", "SPECIES", 197, 203], ["few validation studies", "TEST", 9, 31], ["hybrid", "PROBLEM", 122, 128], ["the overall assessment strategy", "TEST", 376, 407]]], ["By conducting some procedures via home or in-clinic TeleNP, it may be possible to narrow the scope of questions that must be addressed in person, thereby minimizing exam time and exposure to risks associated with the coronavirus.Combined, hybrid, or staged models (combining elements of TeleNP with elements of in-person face-to-face)For example, initial interviews, select testing measures, and feedback sessions might be conducted using telehealth platforms to reduce the number of hours an examinee needs to spend in a clinic.", [["coronavirus", "DISEASE", 217, 228], ["coronavirus", "ORGANISM", 217, 228], ["TeleNP", "DNA", 287, 293], ["person", "SPECIES", 138, 144], ["person", "SPECIES", 314, 320], ["the coronavirus", "PROBLEM", 213, 228], ["hybrid", "PROBLEM", 239, 245], ["select testing measures", "TEST", 367, 390], ["feedback sessions", "TREATMENT", 396, 413], ["telehealth platforms", "TREATMENT", 439, 459]]], ["There may be instruments that have been validated via in-clinic or in-home TeleNP with a particular patient population and those might be administered with confidence via in-clinic or in-home TeleNP.", [["patient", "ORGANISM", 100, 107], ["patient", "SPECIES", 100, 107]]], ["Other instruments lacking TeleNP validation might be administered in person.Stepped careThe primary care model of making medical treatment decisions based on a \"stepped-care\" approach can be applied to NP episodes of care (Lanca, 2018; Sobell & Sobell, 1999 , 2000 .", [["person", "SPECIES", 69, 75], ["Other instruments", "TREATMENT", 0, 17], ["TeleNP validation", "TREATMENT", 26, 43], ["medical treatment", "TREATMENT", 121, 138], ["a \"stepped-care\" approach", "TREATMENT", 158, 183]]], ["That is, a patient who may have had a full NP evaluation in the past may only require a briefer evaluation for continued monitoring or consultation in the future.", [["patient", "ORGANISM", 11, 18], ["patient", "SPECIES", 11, 18], ["a full NP evaluation", "TEST", 36, 56], ["a briefer evaluation", "TEST", 86, 106], ["continued monitoring", "TEST", 111, 131]]], ["This stepped model of care becomes even more relevant in the current COVID era since the benefit of stepped care increases the flexibility for modality of treatment and decreases the length of NP assessment, which decreases exposure time.Delaying the assessment until it is possible to see the patient in person without modificationsThe timeframe for the conditions under which this would again be safe (development and wide availability of vaccine) is currently unknown.", [["patient", "ORGANISM", 294, 301], ["patient", "SPECIES", 294, 301], ["person", "SPECIES", 305, 311], ["stepped care", "TREATMENT", 100, 112], ["modality of treatment", "TREATMENT", 143, 164], ["NP assessment", "TEST", 193, 206], ["the assessment", "TEST", 247, 261], ["vaccine", "TREATMENT", 441, 448]]], ["The risks of delaying neuropsychological care are described earlier.Patient Risk StratificationConsidering the benefits of NP assessment in the context of the risks of in-person practice during the pandemic, as mitigated by the various models for assessment noted earlier, is a complex process and involves at least four different factors (see Fig. 1 ).Patient Risk StratificationUrgency of care.", [["Patient", "SPECIES", 68, 75], ["Patient", "SPECIES", 353, 360], ["neuropsychological care", "TREATMENT", 22, 45], ["NP assessment", "TEST", 123, 136], ["assessment", "TEST", 247, 257]]], ["Practitioners should consider the urgency of the clinical condition/situation and the potential adverse consequences if NP assessment is delayed.", [["NP assessment", "TEST", 120, 133]]], ["Does the NP assessment have to occur prior to a surgical procedure?", [["the NP assessment", "TEST", 5, 22], ["a surgical procedure", "TREATMENT", 46, 66]]], ["Does the referral question involve the possibility that the patient may require increased levels of supervision or other treatments, without which there would be adverse consequences?Patient Risk StratificationSymptom acuity and impact.", [["patient", "ORGANISM", 60, 67], ["patient", "SPECIES", 60, 67], ["Patient", "SPECIES", 183, 190], ["increased levels of supervision", "TREATMENT", 80, 111], ["other treatments", "TREATMENT", 115, 131], ["StratificationSymptom acuity", "OBSERVATION", 196, 224]]], ["Practitioners should consider the severity of the presenting symptoms and the likelihood that the condition may cause harm if NP assessment information is lacking.", [["the presenting symptoms", "PROBLEM", 46, 69], ["the condition", "PROBLEM", 94, 107], ["NP assessment", "TEST", 126, 139]]], ["Is the patient experiencing high levels of depression or actively hallucinating?", [["depression", "DISEASE", 43, 53], ["patient", "ORGANISM", 7, 14], ["patient", "SPECIES", 7, 14], ["depression", "PROBLEM", 43, 53], ["actively hallucinating", "PROBLEM", 57, 79]]], ["Is the patient, per family report, engaging in dangerous activities (such as driving while cognitively compromised)?Patient Risk StratificationIncremental validity.", [["patient", "ORGANISM", 7, 14], ["patient", "SPECIES", 7, 14], ["Patient", "SPECIES", 116, 123], ["StratificationIncremental validity", "OBSERVATION", 129, 163]]], ["Practitioners should consider the incremental validity of different NP procedures to competently answer the primary referral question and make appropriate diagnoses and treatment recommendations for the patient.", [["patient", "ORGANISM", 203, 210], ["patient", "SPECIES", 203, 210], ["different NP procedures", "TREATMENT", 58, 81]]], ["A NP interview, collateral interview(s), and records review may be conducted using telehealth methods at very low risk of viral transmission, and higher risk in-person NP testing may only be well justified-in the context of risk of viral transmission-by determining the elements of the assessment that will provide incremental validity for the most pressing aspect of the referral question.", [["person", "SPECIES", 161, 167], ["telehealth methods", "TREATMENT", 83, 101], ["viral transmission", "PROBLEM", 122, 140], ["NP testing", "TEST", 168, 178], ["viral transmission", "PROBLEM", 232, 250], ["the assessment", "TEST", 282, 296], ["viral", "OBSERVATION", 232, 237]]], ["As an example, in the case of an 11-year-old child diagnosed with dyslexia the year prior via cognitive and academic achievement testing, where the primary referral question is whether continued reading intervention is necessary, a clinician might conclude that repeating a reading assessment adds considerable incremental validity to the most pressing aspect of the referral question but that repeating the rest of the battery might be delayed until extended face-to-face assessment is safer.Patient Risk StratificationAssessment of incremental validity should also consider the validity data supporting the chosen model of assessment.", [["dyslexia", "DISEASE", 66, 74], ["child", "ORGANISM", 45, 50], ["Patient", "SPECIES", 493, 500], ["dyslexia", "PROBLEM", 66, 74], ["academic achievement testing", "TEST", 108, 136], ["a reading assessment", "TEST", 272, 292], ["face assessment", "TEST", 468, 483], ["the validity data", "TEST", 576, 593], ["assessment", "TEST", 625, 635]]], ["For example, a visual memory test lacking validation evidence for in-home TeleNP may not have clear incremental validity.", [["a visual memory test", "TEST", 13, 33]]], ["The same test may have been validated using in-clinic TeleNP, so the incremental validity of administering the test via in-clinic TeleNP may be judged as higher.", [["the test", "TEST", 107, 115]]], ["The use of that same procedure in home TeleNP may also vary in validity depending on the technology, bandwidth, home setting, and comfort levels of both patient and clinician with the use of this technology.", [["patient", "ORGANISM", 153, 160], ["patient", "SPECIES", 153, 160], ["same procedure", "TREATMENT", 16, 30], ["this technology", "TREATMENT", 191, 206]]], ["These considerations highlight the complexity and context specificity of these decisions.Patient Risk StratificationIndividual health risk for Practitioners should consider whether the patient or a close family member of the patient has underlying health conditions that may increase the risk of serious complications from contracting the virus.", [["patient", "ORGANISM", 185, 192], ["patient", "ORGANISM", 225, 232], ["Patient", "SPECIES", 89, 96], ["patient", "SPECIES", 185, 192], ["patient", "SPECIES", 225, 232], ["underlying health conditions", "PROBLEM", 237, 265], ["serious complications", "PROBLEM", 296, 317], ["contracting the virus", "PROBLEM", 323, 344], ["serious", "OBSERVATION_MODIFIER", 296, 303], ["complications", "OBSERVATION", 304, 317]]], ["As noted earlier, for Phase I and Phase II reopening as defined by White House/CDC criteria, \"vulnerable persons\" (i.e., individuals with serious underlying health conditions, including high blood pressure, chronic lung disease, diabetes, obesity, asthma, and those whose immune system is compromised, such as by chemotherapy for cancer and other conditions requiring such therapy) are instructed to continue to follow \"safer-at-home\" orders.", [["blood", "ANATOMY", 191, 196], ["lung", "ANATOMY", 215, 219], ["cancer", "ANATOMY", 330, 336], ["chronic lung disease", "DISEASE", 207, 227], ["diabetes", "DISEASE", 229, 237], ["obesity", "DISEASE", 239, 246], ["asthma", "DISEASE", 248, 254], ["cancer", "DISEASE", 330, 336], ["persons", "ORGANISM", 105, 112], ["blood", "ORGANISM_SUBSTANCE", 191, 196], ["lung", "ORGAN", 215, 219], ["cancer", "CANCER", 330, 336], ["persons", "SPECIES", 105, 112], ["Phase II reopening", "TREATMENT", 34, 52], ["serious underlying health conditions", "PROBLEM", 138, 174], ["high blood pressure", "PROBLEM", 186, 205], ["chronic lung disease", "PROBLEM", 207, 227], ["diabetes", "PROBLEM", 229, 237], ["obesity", "PROBLEM", 239, 246], ["asthma", "PROBLEM", 248, 254], ["chemotherapy", "TREATMENT", 313, 325], ["cancer", "PROBLEM", 330, 336], ["other conditions", "PROBLEM", 341, 357], ["such therapy", "TREATMENT", 368, 380], ["chronic", "OBSERVATION_MODIFIER", 207, 214], ["lung", "ANATOMY", 215, 219], ["disease", "OBSERVATION", 220, 227]]], ["In addition to the above individual risk stratification, providers should consider larger issues of population risk.", [["population risk", "PROBLEM", 100, 115]]], ["What is the likelihood that the individual, if seen in person, might increase risks to the community or family from which they are coming and to which they will return?Patient Risk StratificationAs clinicians engage in a decision-making process, it may be helpful to consider a balance between competing threats (Fig. 2) .", [["person", "SPECIES", 55, 61], ["Patient", "SPECIES", 168, 175]]], ["Traditional nonmitigated NP practice may result in the fewest threats to validity, but greater risks to safety, depending on the health status of a particular patient and the community threat level.", [["patient", "ORGANISM", 159, 166], ["patient", "SPECIES", 159, 166], ["Traditional nonmitigated NP practice", "TREATMENT", 0, 36]]], ["In-home TeleNP may result in the fewest threats to safety but pose substantial risks to validity.Patient Risk StratificationIn this context, clinicians are encouraged to consider combined/staged or hybrid models where many aspects of the episode of NP care can be provided via TeleNP platforms and carefully consider the incremental validity of any proposed test administration if that is to be included in a larger assessment process.Mitigation ProceduresMultiple governmental agencies and professional organizations have released guidance on minimizing risk of patient and healthcare provider exposure.", [["patient", "ORGANISM", 563, 570], ["Patient", "SPECIES", 97, 104], ["patient", "SPECIES", 563, 570], ["combined/staged or hybrid models", "PROBLEM", 179, 211], ["NP care", "TREATMENT", 249, 256], ["any proposed test administration", "TREATMENT", 345, 377]]], ["Additionally, state and local government guidance regarding conditions of reopening as well as mitigation strategies should be consulted.", [["reopening", "TREATMENT", 74, 83], ["mitigation strategies", "TREATMENT", 95, 116]]], ["An outline/discussion of these essential infection mitigation processes is included below but is not meant to be exhaustive.", [["infection", "DISEASE", 41, 50], ["these essential infection mitigation processes", "PROBLEM", 25, 71], ["infection", "OBSERVATION", 41, 50]]], ["For an expanded discussion of mitigation procedures, see https://iopc.online.Mitigation ProceduresPrior to resuming in-person clinical care, it is important for clinicians to have infection mitigation plans in place, along with contingency plans for possible scenarios where the planned procedures cannot be followed.", [["infection", "DISEASE", 180, 189], ["mitigation procedures", "TREATMENT", 30, 51], ["infection mitigation plans", "TREATMENT", 180, 206], ["scenarios", "TREATMENT", 259, 268], ["the planned procedures", "TREATMENT", 275, 297]]], ["This means starting with a very low volume of patients, following the plan that was developed as literally as possible.", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54]]], ["Once a few patients are seen, the plan can be modified as needed based on real-time patient contact activities.", [["patients", "ORGANISM", 11, 19], ["patient", "ORGANISM", 84, 91], ["patients", "SPECIES", 11, 19], ["patient", "SPECIES", 84, 91]]], ["Increases in patient volume can occur incrementally, with maximum patient load determined by your setting and ability to follow pandemic mitigation processes.Prior to Reopening\u2022 Develop a model of care plan for patients.", [["patient", "ORGANISM", 13, 20], ["patient", "ORGANISM", 66, 73], ["patients", "ORGANISM", 211, 219], ["patient", "SPECIES", 13, 20], ["patient", "SPECIES", 66, 73], ["patients", "SPECIES", 211, 219], ["Increases in patient volume", "PROBLEM", 0, 27]]], ["In a lifespan practice, a separate plan might be developed for pediatric, adult, and geriatric patients.", [["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["a lifespan practice", "TREATMENT", 3, 22]]], ["The plan will ideally include multiple options that take into account risk stratification for each individual patient. \u2022 Create appropriate signage for waiting areas, treatment rooms, and in paper form outlining the policies/procedures for infection mitigation in your office(s). \u2022 Create a written plan for:Prior to Reopening-Pre-appointment screening for potential symptoms of COVID-19 (see https://iopc.online for example screening forms).Prior to ReopeningThe plan should include a clear policy regarding what happens if screening is failed. -Day-of-appointment screening policy for both patients and staff that might include temperature screens.", [["infection", "DISEASE", 240, 249], ["patient", "ORGANISM", 110, 117], ["patients", "ORGANISM", 592, 600], ["patient", "SPECIES", 110, 117], ["patients", "SPECIES", 592, 600], ["multiple options", "TREATMENT", 30, 46], ["treatment rooms", "TREATMENT", 167, 182], ["infection mitigation", "TREATMENT", 240, 260], ["Pre-appointment screening", "TEST", 327, 352], ["potential symptoms", "PROBLEM", 357, 375], ["COVID", "TEST", 379, 384], ["Reopening", "TREATMENT", 451, 460], ["screening", "TEST", 525, 534], ["temperature screens", "TEST", 630, 649], ["Reopening", "OBSERVATION", 451, 460]]], ["The plan should include a clear policy regarding what happens if screening is failed.Prior to Reopening-Personal protective equipment that staff and patients will be expected to use.", [["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["screening", "TEST", 65, 74], ["Reopening", "TREATMENT", 94, 103]]], ["This includes masks and might include (depending on the setting and risk level) gloves, face shields, goggles, or safety glasses that cover the eyes, use of scrubs, and gowns. -Maintaining appropriate social distancing.", [["eyes", "ANATOMY", 144, 148], ["eyes", "ORGAN", 144, 148], ["masks", "TREATMENT", 14, 19], ["gloves", "TREATMENT", 80, 86], ["goggles", "TREATMENT", 102, 109], ["safety glasses", "TREATMENT", 114, 128], ["scrubs", "TREATMENT", 157, 163], ["eyes", "ANATOMY", 144, 148], ["social distancing", "OBSERVATION", 201, 218]]], ["The plan may include * specific flow patterns through the office * limits on family members accompanying patients * use of virtual (parking lot) waiting rooms * removal of some chairs in waiting areas as needed area to promote social distancing * use of clear (plexiglass) barriers across a testing table with or without openings for stimuli to be presented (does not eliminate need for masks) * staggering appointment times to minimize patient contact and to allow for additional cleaning/ventilation time in between \u2022 Hand washing and/or use of hand sanitizer procedures to be used by all parties before and after any contact with a patient, caregiver, staff, or provider. \u2022 Cleaning/disinfecting office areas, furniture, surfaces, doors, and manipulative items (including writing utensils) before and after every patient contact.", [["hand", "ANATOMY", 547, 551], ["patients", "ORGANISM", 105, 113], ["patient", "ORGANISM", 437, 444], ["patient", "ORGANISM", 635, 642], ["patient", "ORGANISM", 816, 823], ["patients", "SPECIES", 105, 113], ["patient", "SPECIES", 437, 444], ["patient", "SPECIES", 635, 642], ["patient", "SPECIES", 816, 823], ["removal", "TREATMENT", 161, 168], ["clear (plexiglass)", "TREATMENT", 254, 272], ["a testing table", "TEST", 289, 304], ["additional cleaning/ventilation time", "TREATMENT", 470, 506], ["Hand washing", "TREATMENT", 520, 532], ["hand sanitizer procedures", "TREATMENT", 547, 572], ["washing", "OBSERVATION", 525, 532]]], ["(See https://iopc.online/ for sample checklists.) \u2022 Implementing structural mitigation procedures.", [["structural mitigation procedures", "TREATMENT", 65, 97]]], ["The plan might include: -Designation of \"clean\" (i.e., unexposed) materials, forms, etc. area and a separate area for \"dirty\" (i.e., exposed) materials so as avoid cross-contamination of items. -Use of HEPA air filters for a period of time prior to and after exam room use.", [["area", "ANATOMY", 89, 93], ["\"dirty\"", "PROBLEM", 118, 125], ["HEPA air filters", "TREATMENT", 202, 218], ["exam", "TEST", 259, 263], ["air filters", "OBSERVATION", 207, 218]]], ["HEPA filters can also be run on lower speeds during the assessment. -Changing fabric furniture to furniture that can be cleaned with recommended cleaning agents or covering fabric furniture with wipeable protective covers. -Use of foot-operated trash cans.Prior to Reopening\u2022 Obtain personal protective equipment including masks to be worn by patients, providers, and any office staff, as well as plexiglass barriers if these are part of the social distancing plan.Timeline of Infection Mitigation ActivitiesActivities prior to patient arrival.Timeline of Infection Mitigation Activities\u2022 COVID screening questionnaire administered at the time of scheduling and 48 hr prior to the appointment (either via phone contact or email). \u2022 Send link to electronic registration forms that can be completed and submitted online prior to arrival as well as written instructions regarding safety requirements for visit (masks, etc.) , any limitation on number of persons present (e.g., only one caregiver, no siblings), and specific instructions for a virtual waiting room if one is being used. \u2022 Clean rooms and materials (use of checklist with time and date recommended).", [["foot", "ORGANISM_SUBDIVISION", 231, 235], ["patients", "ORGANISM", 343, 351], ["patient", "ORGANISM", 528, 535], ["patients", "SPECIES", 343, 351], ["patient", "SPECIES", 528, 535], ["persons", "SPECIES", 951, 958], ["HEPA filters", "TREATMENT", 0, 12], ["the assessment", "TEST", 52, 66], ["Changing fabric furniture to furniture", "TREATMENT", 69, 107], ["cleaning agents", "TREATMENT", 145, 160], ["fabric furniture", "TREATMENT", 173, 189], ["wipeable protective covers", "TREATMENT", 195, 221], ["Reopening", "TREATMENT", 265, 274], ["personal protective equipment", "TREATMENT", 283, 312], ["Infection Mitigation", "TREATMENT", 556, 576], ["electronic registration", "TEST", 745, 768], ["filters", "OBSERVATION", 5, 12], ["foot", "ANATOMY", 231, 235], ["Infection", "OBSERVATION", 477, 486], ["Infection", "OBSERVATION", 556, 565]]], ["See https://iopc.online/ for an example that can be edited to fit individual clinic needs.Timeline of Infection Mitigation ActivitiesInitial entry.Timeline of Infection Mitigation Activities\u2022 Patient and visitors screened again for symptoms.", [["Patient", "SPECIES", 192, 199], ["symptoms", "PROBLEM", 232, 240], ["Infection", "OBSERVATION", 102, 111], ["Infection", "OBSERVATION", 159, 168]]], ["This may include temperature screening.Timeline of Infection Mitigation Activities\u2022 Review of mitigation/hygiene procedures with patients.Timeline of Infection Mitigation Activities\u2022 Hand sanitizer or hand washing upon arrival.Timeline of Infection Mitigation Activities\u2022 If forms cannot be completed electronically prior to arrival:Timeline of Infection Mitigation Activities-Complete forms in a controlled room rather than bringing forms from home -Consider use of verbal consent and related documentation -Use of \"clean\" and \"dirty\" folders or containers for forms.Timeline of Infection Mitigation ActivitiesInterview.Timeline of Infection Mitigation Activities\u2022 Consider patient and collateral interviews via in-home TeleNP to minimize time in office.Timeline of Infection Mitigation ActivitiesTesting activities.Timeline of Infection Mitigation Activities\u2022 Maximize efficiency of test session to minimize time in office.Timeline of Infection Mitigation Activities\u2022 Minimize testing where contact of materials is needed.Timeline of Infection Mitigation Activities\u2022 \"Clean\" versus \"dirty\" side of the room (including folders of paper-clean and dirty).Timeline of Infection Mitigation Activities-No touching of \"dirty\" forms for 24 hr or wash hands after handlingTimeline of Infection Mitigation Activities\u2022 Cleaning of manipulative stimuli with disinfecting wipes and/or separating them for cleaning after the assessment.Timeline of Infection Mitigation Activities\u2022 Repeated use of hand sanitizer and hand washing during the session as needed (e.g., if a person touches his or her face, sneezes, coughs, etc.). \u2022 If used, gloves should be discarded and replaced in any instance where hands would have been washed or sanitized (e.g., touching face, coughing into hands). \u2022 Laminate paper stimuli or cards or put them in plastic sheets for easy cleaning.Timeline of Infection Mitigation Activities\u2022 Consider using orally administered measures of visual information processing to maximize social distancing and minimize contact with materials. \u2022 Place garbage can close to the patient-foot-operated or open, with plastic liner for easy removal. \u2022 Separate pencils/pens for patients and examiner.End of session.\u2022 No hand shaking or physical contact.End of session.\u2022 Be mindful of social distancing as you leave the room.End of session.After the session.End of session.\u2022 Clean room, furniture, contact surfaces, materials, etc. (note that some disinfecting wipes require use of gloves).End of session.-Timing of cleaning-may benefit from at least a 30-min waiting period before cleaning, to minimize airborne droplets \u2022 Wash hands or use hand sanitizers after handling forms (e.g., when scoring) and/or allow a 24-hr waiting time before handling forms touched by the patient. \u2022 Engage room HEPA air filter system.Feedback options to consider\u2022 Feedback may be conducted where possible via in-home TeleNP. \u2022 Same day, in same room, immediately following the testing or after a short break. \u2022 If separate day in clinic, use the same precautions noted earlier for the return visit.", [["hand", "ANATOMY", 201, 205], ["hand", "ANATOMY", 1485, 1489], ["hand", "ANATOMY", 1504, 1508], ["hand", "ANATOMY", 2215, 2219], ["hand", "ANATOMY", 2636, 2640], ["Infection", "DISEASE", 1277, 1286], ["coughs", "DISEASE", 1599, 1605], ["patients", "ORGANISM", 129, 137], ["hand", "ORGANISM_SUBDIVISION", 201, 205], ["patient", "ORGANISM", 675, 682], ["hand", "ORGANISM_SUBDIVISION", 1485, 1489], ["hand", "ORGANISM_SUBDIVISION", 1504, 1508], ["hands", "ORGANISM_SUBDIVISION", 1687, 1692], ["patient", "ORGANISM", 2077, 2084], ["foot", "ORGANISM_SUBDIVISION", 2085, 2089], ["patients", "ORGANISM", 2173, 2181], ["patient", "ORGANISM", 2765, 2772], ["patients", "SPECIES", 129, 137], ["patient", "SPECIES", 675, 682], ["person", "SPECIES", 1558, 1564], ["patient", "SPECIES", 2077, 2084], ["patients", "SPECIES", 2173, 2181], ["patient", "SPECIES", 2765, 2772], ["temperature screening", "TEST", 17, 38], ["Infection Mitigation", "TREATMENT", 150, 170], ["Hand sanitizer", "TREATMENT", 183, 197], ["hand washing", "TREATMENT", 201, 213], ["Infection Mitigation", "TREATMENT", 767, 787], ["Infection Mitigation", "TREATMENT", 829, 849], ["Infection Mitigation", "TREATMENT", 937, 957], ["manipulative stimuli", "TREATMENT", 1322, 1342], ["disinfecting wipes", "TREATMENT", 1348, 1366], ["the assessment", "TEST", 1409, 1423], ["Infection Mitigation", "TREATMENT", 1436, 1456], ["hand sanitizer", "TREATMENT", 1485, 1499], ["hand washing", "TREATMENT", 1504, 1516], ["coughs", "PROBLEM", 1599, 1605], ["gloves", "TREATMENT", 1625, 1631], ["easy cleaning", "TREATMENT", 1841, 1854], ["Infection Mitigation", "TREATMENT", 1867, 1887], ["orally administered measures", "TREATMENT", 1915, 1943], ["visual information processing", "TREATMENT", 1947, 1976], ["plastic liner", "TREATMENT", 2113, 2126], ["easy removal", "TREATMENT", 2131, 2143], ["Separate pencils/pens", "TREATMENT", 2147, 2168], ["hand shaking", "PROBLEM", 2215, 2227], ["gloves", "TREATMENT", 2476, 2482], ["cleaning", "TREATMENT", 2510, 2518], ["airborne droplets", "TREATMENT", 2598, 2615], ["hand sanitizers", "TREATMENT", 2636, 2651], ["HEPA air filter system", "TREATMENT", 2788, 2810], ["Feedback options", "TREATMENT", 2811, 2827], ["the testing", "TEST", 2950, 2961], ["a short break", "PROBLEM", 2971, 2984], ["the same precautions", "TREATMENT", 3019, 3039], ["Infection", "OBSERVATION", 51, 60], ["Infection", "OBSERVATION", 150, 159], ["Infection", "OBSERVATION", 239, 248], ["Infection", "OBSERVATION", 345, 354], ["Infection", "OBSERVATION", 580, 589], ["Infection", "OBSERVATION", 633, 642], ["Infection", "OBSERVATION", 767, 776], ["Infection", "OBSERVATION", 829, 838], ["Infection", "OBSERVATION", 937, 946], ["Infection", "OBSERVATION", 1036, 1045], ["Infection", "OBSERVATION", 1166, 1175], ["Infection", "OBSERVATION", 1277, 1286], ["Infection", "OBSERVATION", 1436, 1445], ["Infection", "OBSERVATION", 1867, 1876], ["foot", "ANATOMY", 2085, 2089], ["hand", "ANATOMY", 2215, 2219], ["shaking", "OBSERVATION", 2220, 2227], ["air filter", "OBSERVATION", 2793, 2803]]], ["Regular monitoring of recommendations by the CDC, WHO, and other trusted sources is also recommended to stay as up-to-date as possible regarding infection mitigation strategies.", [["infection", "DISEASE", 145, 154], ["infection mitigation strategies", "TREATMENT", 145, 176]]], ["As clinicians, we are ethically mandated to engage patients in a consent process where both risks and benefits are clearly explained.", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59]]], ["This is likely to be a departure from the relatively straightforward consent conversations neuropsychologists are used to, where there are minimal risks to physical well-being and validity.", [["likely to be", "UNCERTAINTY", 8, 20]]], ["Additionally, neuropsychologists may be personally uncomfortable with proceeding with an assessment (whichever above model is chosen) without a clear-cut \"right answer\" and when each option holds its own risks to validity and/or safety.", [["an assessment", "TEST", 86, 99]]], ["The discomfort, if present, may create a barrier to a clear, thorough consent process.Informed ConsentIn most cases, a thorough consent conversation will need to include the benefits and risks of all three options (in-person, TeleNP and hybrid models), with a recommendation from the clinician regarding the best path forward.", [["person", "SPECIES", 218, 224], ["The discomfort", "PROBLEM", 0, 14], ["discomfort", "OBSERVATION", 4, 14]]], ["It is also important to not overstate clinicians' ability to \"take into account\" the impact of nonstandard assessment.Consent for TeleNPInformed consent for TeleNP has been described at length in the IOPC Recommendations/Guidance for Teleneuropsychology (TeleNP) in Response to the COVID-19 Pandemic (Bilder et al., 2020) .", [["TeleNP", "CHEMICAL", 157, 163], ["nonstandard assessment", "TEST", 95, 117]]], ["Key points to cover include:Consent for TeleNP\u2022 Modification of standard test administration affects results in ways that are so far unknown.", [["standard test administration", "TEST", 64, 92]]], ["This reduces confidence in the diagnostic conclusions and may affect recommendations for treatment. \u2022 Involvement of a caregiver, guardian, parent, and facilitator is a nonstandard condition for testing and also threatens confidence in diagnostic conclusions. \u2022 Error may be compounded with patients from culturally and linguistically diverse populations, patients who require an interpreter, or patients who have limited experience/comfort with the technology being used. \u2022 Some qualitative data usually obtained during an in-person exam will be lost, and this may reduce the richness of the clinical data and further limit conclusions and recommendations. \u2022 TeleNP may pose risks to privacy and confidentiality.Consent for TeleNP\u2022 Assessment results may not be acceptable by organizations for administrative purposes. \u2022 A discussion of the risks and benefits of in-person assessment, hybrid TeleNP, or no assessment as an alternative to TeleNP assessment. \u2022 Appropriate disclosure and referral to a provider who is conducting in-person assessments, if a factor in recommending TeleNP is a health condition of the clinician that makes in-person assessment risky to the provider.Consent for in-person assessmentsThe American Psychological Association has developed a sample informed consent form for resuming in-person services: https://bit.ly/APAconsent.", [["TeleNP", "CHEMICAL", 660, 666], ["TeleNP", "CHEMICAL", 1079, 1085], ["patients", "ORGANISM", 291, 299], ["patients", "ORGANISM", 356, 364], ["patients", "ORGANISM", 396, 404], ["patients", "SPECIES", 291, 299], ["patients", "SPECIES", 356, 364], ["patients", "SPECIES", 396, 404], ["treatment", "TREATMENT", 89, 98], ["testing", "TEST", 195, 202], ["the technology", "TREATMENT", 446, 460], ["person exam", "TEST", 527, 538], ["the clinical data", "TEST", 589, 606], ["TeleNP\u2022 Assessment", "TEST", 725, 743], ["administrative purposes", "TEST", 795, 818], ["person assessment", "TEST", 867, 884], ["assessment", "TEST", 907, 917], ["TeleNP assessment", "TEST", 939, 956]]], ["The document is largely geared toward psychotherapy services.", [["psychotherapy services", "TREATMENT", 38, 60]]], ["See IOPC.online for sample informed consents for return to in-person NP practice.", [["IOPC", "PROTEIN", 4, 8]]], ["Key points to cover include:Consent for in-person assessments\u2022 By coming to an office or hospital, patients have an increased risk of exposure to the virus compared with staying home. \u2022 A clear set of measures patients and their families need to agree to take to minimize the risk of exposure to others in the office (including staff and other patients). \u2022 A clear set of measures clinicians will take to minimize the risk of exposure for patients. \u2022 Explanation of any screening measures, including temperature checks, at the beginning of services and the expectation that individuals who are ill will be expected to leave the office. \u2022 A recognition that the procedures for minimizing risk may change over time and both parties will discuss necessary changes in procedure. \u2022 The expectation that if the risk conditions change (e.g., a resurgence of cases in the vicinity), in-person services may no longer be feasible. \u2022 Confidentiality in the case of infection (with potential duty to notify local authorities depending on jurisdiction). \u2022 Discussion of the potential threats to diagnostic conclusions in the context of the possibility that viral risk mitigation procedures such as masks might affect standard test administration. \u2022 A discussion of the risks and benefits of TeleNP, hybrid TeleNP, or no assessment as an alternative to in-person assessment.Consent for Combined ModelsClinicians will need to discuss the aspects of consent for both in-person and TeleNP.Documentation/Explanation of Nonstandard Procedures in Reports and During FeedbackAny departure from the nonmitigated in-person NP assessment procedure will need to be clearly documented in easy to understand language within the body of the NP report.", [["body", "ANATOMY", 1701, 1705], ["infection", "DISEASE", 954, 963], ["patients", "ORGANISM", 99, 107], ["patients", "ORGANISM", 210, 218], ["patients", "ORGANISM", 344, 352], ["patients", "ORGANISM", 439, 447], ["TeleNP", "SIMPLE_CHEMICAL", 1278, 1284], ["body", "ORGANISM_SUBDIVISION", 1701, 1705], ["patients", "SPECIES", 99, 107], ["patients", "SPECIES", 210, 218], ["patients", "SPECIES", 344, 352], ["patients", "SPECIES", 439, 447], ["the virus", "PROBLEM", 146, 155], ["any screening measures", "TEST", 466, 488], ["temperature checks", "TEST", 500, 518], ["the procedures", "TREATMENT", 657, 671], ["changes in procedure", "TREATMENT", 753, 773], ["the risk conditions change", "PROBLEM", 801, 827], ["infection", "PROBLEM", 954, 963], ["viral risk mitigation procedures", "TREATMENT", 1144, 1176], ["standard test administration", "TREATMENT", 1204, 1232], ["assessment", "TEST", 1307, 1317], ["person assessment", "TEST", 1342, 1359], ["procedure", "TREATMENT", 1614, 1623], ["increased", "OBSERVATION_MODIFIER", 116, 125], ["clear", "OBSERVATION", 188, 193], ["clear", "OBSERVATION", 359, 364], ["infection", "OBSERVATION", 954, 963]]], ["The IOPC Recommendations/Guidance for Teleneuropsychology (TeleNP) in Response to the COVID-19 Pandemic (Bilder et al., 2020) suggests the following (or similar) statement be included in NP assessment reports where TeleNP is utilized: Due to circumstances that prevent in-person clinical visits, this assessment was conducted using telehealth methods (including remote audiovisual presentation of test instructions and test stimuli, and remote observation of performance via audiovisual technologies).", [["Pandemic", "DISEASE", 95, 103], ["NP assessment", "TEST", 187, 200], ["this assessment", "TEST", 296, 311], ["telehealth methods", "TREATMENT", 332, 350], ["test stimuli", "TEST", 419, 431]]], ["The standard administration of these procedures involves in-person, face-to-face methods.", [["these procedures", "TREATMENT", 31, 47]]], ["The impact of applying non-standard administration methods has been evaluated only in part by scientific research.", [["non-standard administration methods", "TREATMENT", 23, 58]]], ["While every effort was made to simulate standard assessment practices, the diagnostic conclusions and recommendations for treatment provided in this report are being advanced with these reservations.Documentation/Explanation of Nonstandard Procedures in Reports and During FeedbackSimilarly, the impact on diagnostic conclusions and recommendations of departing from standard nonmitigated in-person NP assessment will need to be restated at the beginning of feedback sessions.", [["treatment", "TREATMENT", 122, 131], ["NP assessment", "TEST", 399, 412]]], ["It is important not to overstate clinicians' ability to \"take into account\" nonstandard test administration.", [["nonstandard test administration", "TREATMENT", 76, 107]]]], "acb4131dd4bf780a0f2ddf856e06bc2c86152d1e": [["Frederick G. Hayden, MD, FACPA cute viral respiratory infections (VRIs) encompass a range of illnesses that together constitute the most frequent infections of humans.", [["viral respiratory infections", "DISEASE", 36, 64], ["VRIs", "DISEASE", 66, 70], ["infections", "DISEASE", 146, 156], ["humans", "ORGANISM", 160, 166], ["humans", "SPECIES", 160, 166], ["humans", "SPECIES", 160, 166], ["FACPA cute viral respiratory infections", "PROBLEM", 25, 64], ["illnesses", "PROBLEM", 93, 102], ["respiratory", "ANATOMY", 42, 53], ["infections", "OBSERVATION", 54, 64], ["most frequent", "OBSERVATION_MODIFIER", 132, 145], ["infections", "OBSERVATION", 146, 156]]], ["The most prevalent syndrome is that characterized by signs and symptoms of the common cold, or acute viral rhinosinusitis.", [["viral rhinosinusitis", "DISEASE", 101, 121], ["The most prevalent syndrome", "PROBLEM", 0, 27], ["signs and symptoms", "PROBLEM", 53, 71], ["the common cold", "PROBLEM", 75, 90], ["acute viral rhinosinusitis", "PROBLEM", 95, 121], ["most prevalent", "OBSERVATION_MODIFIER", 4, 18], ["syndrome", "OBSERVATION", 19, 27], ["common cold", "ANATOMY", 79, 90], ["acute", "OBSERVATION_MODIFIER", 95, 100], ["viral rhinosinusitis", "OBSERVATION", 101, 121]]], ["These illnesses are typically acute, self-limiting events associated primarily with upper respiratory symptoms, but they also cause symptoms that are indicative of lower respiratory involvement, particularly in the very young, the elderly, and those with preexisting airways disease.", [["respiratory", "ANATOMY", 90, 101], ["respiratory", "ANATOMY", 170, 181], ["airways", "ANATOMY", 267, 274], ["upper respiratory symptoms", "DISEASE", 84, 110], ["airways disease", "DISEASE", 267, 282], ["airways", "MULTI-TISSUE_STRUCTURE", 267, 274], ["These illnesses", "PROBLEM", 0, 15], ["self-limiting events", "PROBLEM", 37, 57], ["upper respiratory symptoms", "PROBLEM", 84, 110], ["symptoms", "PROBLEM", 132, 140], ["lower respiratory involvement", "PROBLEM", 164, 193], ["preexisting airways disease", "PROBLEM", 255, 282], ["acute", "OBSERVATION_MODIFIER", 30, 35], ["self-limiting", "OBSERVATION_MODIFIER", 37, 50], ["upper", "ANATOMY_MODIFIER", 84, 89], ["respiratory", "ANATOMY", 90, 101], ["symptoms", "OBSERVATION", 102, 110], ["indicative of", "UNCERTAINTY", 150, 163], ["lower", "ANATOMY_MODIFIER", 164, 169], ["respiratory", "ANATOMY", 170, 181], ["involvement", "OBSERVATION", 182, 193], ["airways", "ANATOMY", 267, 274], ["disease", "OBSERVATION", 275, 282]]], ["[1] [2] [3] Rhinoviruses are the most common pathogen causing VRIs and account for approximately 50% of colds on an annual basis.", [["VRIs", "DISEASE", 62, 66], ["colds", "DISEASE", 104, 109], ["[1] [2] [3] Rhinoviruses", "SIMPLE_CHEMICAL", 0, 24], ["VRIs", "CANCER", 62, 66], ["Rhinoviruses", "PROBLEM", 12, 24], ["colds", "PROBLEM", 104, 109], ["most common", "OBSERVATION_MODIFIER", 33, 44]]], ["Not surprisingly, the recent development of antiviral compounds with activity targeted against rhinoviruses has intensified interest in these infections.", [["rhinoviruses", "DISEASE", 95, 107], ["infections", "DISEASE", 142, 152], ["rhinoviruses", "ORGANISM", 95, 107], ["antiviral compounds", "PROBLEM", 44, 63], ["rhinoviruses", "PROBLEM", 95, 107], ["these infections", "PROBLEM", 136, 152], ["antiviral compounds", "OBSERVATION", 44, 63], ["infections", "OBSERVATION", 142, 152]]], ["This supplement contains a series of articles based on presentations by internationally regarded experts who met on April 3 and 4, 2001 in Philadelphia, Pennsylvania, to discuss current knowledge and recent advances regarding the epidemiology, clinical impact, pathogenesis, and management of rhinoviral VRIs.Frederick G. Hayden, MD, FACPChildren get an average of 3 to 8 colds annually.", [["VRIs", "DISEASE", 304, 308], ["colds", "DISEASE", 372, 377], ["pathogenesis", "PROBLEM", 261, 273], ["rhinoviral VRIs", "TREATMENT", 293, 308]]], ["4 Preschool children get an average of 5 to 7 per year, but 10% to 15% may get up to 12 per year.", [["children", "ORGANISM", 12, 20], ["children", "SPECIES", 12, 20]]], ["5 The incidence decreases with age to an average of about 2 to 4 colds per year by adulthood.", [["colds", "DISEASE", 65, 70], ["decreases", "OBSERVATION_MODIFIER", 16, 25]]], ["5, 6 Data from a survey conducted in 1996 by the National Center for Health Statistics reported that 62 million cases of colds required some form of treatment.", [["colds", "DISEASE", 121, 126], ["colds", "PROBLEM", 121, 126], ["treatment", "TREATMENT", 149, 158]]], ["7 This survey also showed that colds were associated with 148 million days of restricted activity, approximately 20 million days of missed work, 22 million days of missed school, and 45 million days during which individuals were bedridden.", [["colds", "DISEASE", 31, 36], ["colds", "PROBLEM", 31, 36], ["colds", "OBSERVATION", 31, 36]]], ["7 Gonzales et al 8 Another important factor contributing to the cost of VRIs is the use of antibiotics.", [["VRIs", "DISEASE", 72, 76], ["antibiotics", "TREATMENT", 91, 102]]], ["Common colds and related VRI syndromes are among the most frequent reasons for inappropriate antibiotic use in the United States, which increases the costs of illness unnecessarily and contributes to the increasing prevalence of antibiotic-resistant bacteria.", [["colds", "DISEASE", 7, 12], ["illness", "DISEASE", 159, 166], ["Common colds", "PROBLEM", 0, 12], ["related VRI syndromes", "PROBLEM", 17, 38], ["inappropriate antibiotic use", "TREATMENT", 79, 107], ["illness", "PROBLEM", 159, 166], ["antibiotic", "TREATMENT", 229, 239], ["resistant bacteria", "PROBLEM", 240, 258], ["colds", "OBSERVATION", 7, 12], ["VRI syndromes", "OBSERVATION", 25, 38], ["resistant bacteria", "OBSERVATION", 240, 258]]], ["10 The Centers for Disease Control and Prevention estimates that about 50% of the approximately 100 million courses of antibiotics prescribed by office-based physicians each year are unnecessary.", [["Disease Control", "TREATMENT", 19, 34], ["antibiotics", "TREATMENT", 119, 130], ["Disease", "OBSERVATION", 19, 26]]], ["11 In 1994, it was estimated that more than 12 million antibiotic prescriptions were written annually for upper respiratory infections, at a cost of $37.5 million.", [["respiratory", "ANATOMY", 112, 123], ["respiratory infections", "DISEASE", 112, 134], ["12 million antibiotic prescriptions", "TREATMENT", 44, 79], ["upper respiratory infections", "PROBLEM", 106, 134], ["upper", "ANATOMY_MODIFIER", 106, 111], ["respiratory", "ANATOMY", 112, 123], ["infections", "OBSERVATION", 124, 134]]], ["12 In this regard, some of the common attributes of rhinovirus infection, discolored nasal discharge and postnasal drainage, are significantly associated with antibiotic prescribing.", [["nasal", "ANATOMY", 85, 90], ["rhinovirus infection", "DISEASE", 52, 72], ["rhinovirus", "ORGANISM", 52, 62], ["nasal", "ORGANISM_SUBDIVISION", 85, 90], ["rhinovirus infection", "PROBLEM", 52, 72], ["discolored nasal discharge", "PROBLEM", 74, 100], ["postnasal drainage", "PROBLEM", 105, 123], ["antibiotic prescribing", "TREATMENT", 159, 181], ["rhinovirus infection", "OBSERVATION", 52, 72], ["discolored", "OBSERVATION_MODIFIER", 74, 84], ["nasal", "ANATOMY", 85, 90], ["discharge", "OBSERVATION", 91, 100], ["postnasal drainage", "OBSERVATION", 105, 123]]], ["13 Furthermore, even though physicians are aware of the lack of benefit of antibiotics for these infections, surveys have shown that physicians were much more likely to prescribe antibiotics when they believed that their patients expected to receive them.", [["infections", "DISEASE", 97, 107], ["patients", "ORGANISM", 221, 229], ["patients", "SPECIES", 221, 229], ["antibiotics", "TREATMENT", 75, 86], ["these infections", "PROBLEM", 91, 107], ["antibiotics", "TREATMENT", 179, 190]]], ["11 However, physicians also overestimate the desire of their patients for an antibiotic.", [["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["an antibiotic", "TREATMENT", 74, 87]]], ["14 Given the substantial personal and societal impact of VRIs, the development of a safe and effective antiviral compound specifically targeted to the most common pathogen involved would represent a major advance in the field of respiratory infections.", [["respiratory", "ANATOMY", 229, 240], ["VRIs", "DISEASE", 57, 61], ["respiratory infections", "DISEASE", 229, 251], ["VRIs", "TREATMENT", 57, 61], ["a safe and effective antiviral compound", "TREATMENT", 82, 121], ["respiratory infections", "PROBLEM", 229, 251], ["substantial", "OBSERVATION_MODIFIER", 13, 24], ["respiratory", "ANATOMY", 229, 240], ["infections", "OBSERVATION", 241, 251]]], ["The picornavirus family includes important respiratory pathogens.", [["respiratory", "ANATOMY", 43, 54], ["respiratory pathogens", "DISEASE", 43, 64], ["important respiratory pathogens", "PROBLEM", 33, 64], ["picornavirus", "OBSERVATION", 4, 16], ["respiratory pathogens", "OBSERVATION", 43, 64]]], ["The major groups causing VRIs are the rhinoviruses, which consist of more than 100 serotypes, and the enteroviruses, which comprise approximately 70 antigenic types.", [["VRIs", "DISEASE", 25, 29], ["enteroviruses", "DISEASE", 102, 115], ["VRIs", "GENE_OR_GENE_PRODUCT", 25, 29], ["rhinoviruses", "ORGANISM", 38, 50], ["VRIs", "PROBLEM", 25, 29], ["the rhinoviruses", "PROBLEM", 34, 50], ["the enteroviruses", "PROBLEM", 98, 115], ["rhinoviruses", "OBSERVATION", 38, 50], ["enteroviruses", "OBSERVATION", 102, 115], ["antigenic types", "OBSERVATION", 149, 164]]], ["Rhinoviruses are the cause of about 50% of colds, and enteroviruses cause 5% to 15% of VRIs.", [["Rhinoviruses", "DISEASE", 0, 12], ["colds", "DISEASE", 43, 48], ["enteroviruses", "DISEASE", 54, 67], ["VRIs", "DISEASE", 87, 91], ["Rhinoviruses", "GENE_OR_GENE_PRODUCT", 0, 12], ["enteroviruses", "ORGANISM", 54, 67], ["VRIs", "PATHOLOGICAL_FORMATION", 87, 91], ["Rhinoviruses", "PROBLEM", 0, 12], ["colds", "PROBLEM", 43, 48], ["enteroviruses", "PROBLEM", 54, 67], ["VRIs", "TEST", 87, 91]]], ["1 Rhinoviruses are not only the primary etiologic agent in common colds; they also cause complications involving the upper and lower respiratory tract.", [["lower respiratory tract", "ANATOMY", 127, 150], ["colds", "DISEASE", 66, 71], ["upper", "ORGANISM_SUBDIVISION", 117, 122], ["lower respiratory", "ORGANISM_SUBDIVISION", 127, 144], ["tract", "ORGANISM_SUBDIVISION", 145, 150], ["1 Rhinoviruses", "PROBLEM", 0, 14], ["complications involving the upper and lower respiratory tract", "PROBLEM", 89, 150], ["Rhinoviruses", "OBSERVATION", 2, 14], ["complications", "OBSERVATION", 89, 102], ["upper", "ANATOMY_MODIFIER", 117, 122], ["lower", "ANATOMY_MODIFIER", 127, 132], ["respiratory tract", "ANATOMY", 133, 150]]], ["These include otitis media, particularly in children; sinusitis; and exacerbations of asthma and other forms of airways disease, such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis.", [["airways", "ANATOMY", 112, 119], ["pulmonary", "ANATOMY", 157, 166], ["cystic", "ANATOMY", 186, 192], ["otitis media", "DISEASE", 14, 26], ["sinusitis", "DISEASE", 54, 63], ["asthma", "DISEASE", 86, 92], ["airways disease", "DISEASE", 112, 127], ["chronic obstructive pulmonary disease", "DISEASE", 137, 174], ["COPD", "DISEASE", 176, 180], ["cystic fibrosis", "DISEASE", 186, 201], ["children", "ORGANISM", 44, 52], ["airways", "MULTI-TISSUE_STRUCTURE", 112, 119], ["pulmonary", "ORGAN", 157, 166], ["children", "SPECIES", 44, 52], ["otitis media", "PROBLEM", 14, 26], ["sinusitis", "PROBLEM", 54, 63], ["exacerbations", "PROBLEM", 69, 82], ["asthma", "PROBLEM", 86, 92], ["airways disease", "PROBLEM", 112, 127], ["chronic obstructive pulmonary disease (COPD)", "PROBLEM", 137, 181], ["cystic fibrosis", "PROBLEM", 186, 201], ["otitis", "OBSERVATION", 14, 20], ["sinusitis", "OBSERVATION", 54, 63], ["asthma", "OBSERVATION", 86, 92], ["airways", "ANATOMY", 112, 119], ["disease", "OBSERVATION", 120, 127], ["chronic", "OBSERVATION_MODIFIER", 137, 144], ["obstructive", "OBSERVATION_MODIFIER", 145, 156], ["pulmonary", "ANATOMY", 157, 166], ["disease", "OBSERVATION", 167, 174], ["COPD", "OBSERVATION", 176, 180], ["cystic", "OBSERVATION_MODIFIER", 186, 192], ["fibrosis", "OBSERVATION", 193, 201]]], ["1, [16] [17] [18] In addition, rhinoviruses can cause serious lower respiratory disease in certain populations, including infants and young children, 13, 15, 19 elderly persons, 20 and immunocompromised patients.", [["respiratory", "ANATOMY", 68, 79], ["rhinoviruses", "DISEASE", 31, 43], ["lower respiratory disease", "DISEASE", 62, 87], ["[16] [17] [18]", "SIMPLE_CHEMICAL", 3, 17], ["rhinoviruses", "ORGANISM", 31, 43], ["infants", "ORGANISM", 122, 129], ["children", "ORGANISM", 140, 148], ["persons", "ORGANISM", 169, 176], ["patients", "ORGANISM", 203, 211], ["infants", "SPECIES", 122, 129], ["children", "SPECIES", 140, 148], ["persons", "SPECIES", 169, 176], ["patients", "SPECIES", 203, 211], ["rhinoviruses", "PROBLEM", 31, 43], ["serious lower respiratory disease", "PROBLEM", 54, 87], ["serious", "OBSERVATION_MODIFIER", 54, 61], ["lower", "ANATOMY_MODIFIER", 62, 67], ["respiratory", "ANATOMY", 68, 79], ["disease", "OBSERVATION", 80, 87]]], ["21 Unfortunately, many clinical microbiology laboratories do not use optimal techniques to detect rhinovirus infections, so they remain underappreciated pathogens.", [["rhinovirus infections", "DISEASE", 98, 119], ["rhinovirus", "ORGANISM", 98, 108], ["rhinovirus infections", "PROBLEM", 98, 119], ["underappreciated pathogens", "PROBLEM", 136, 162], ["rhinovirus", "OBSERVATION", 98, 108]]], ["These techniques, such as culture, are not available in a clinically useful timeframe.", [["These techniques", "TEST", 0, 16], ["culture", "TEST", 26, 33]]], ["Also, recently developed polymerase chain reaction (PCR) techniques, which are the most sensitive for rhinovirus identification, are available only at research facilities.Frederick G. Hayden, MD, FACPIn this supplement, Dr. Arnold S. Monto begins with a review of epidemiologic studies that have assessed the age-related rates of respiratory illness, the pathogens involved, and their seasonality, as well as the modes of transmission of rhinovirus infections.", [["respiratory", "ANATOMY", 330, 341], ["respiratory illness", "DISEASE", 330, 349], ["rhinovirus infections", "DISEASE", 438, 459], ["rhinovirus", "ORGANISM", 102, 112], ["rhinovirus", "ORGANISM", 438, 448], ["polymerase chain reaction", "PROBLEM", 25, 50], ["PCR) techniques", "TEST", 52, 67], ["rhinovirus identification", "TEST", 102, 127], ["epidemiologic studies", "TEST", 264, 285], ["respiratory illness", "PROBLEM", 330, 349], ["the pathogens", "PROBLEM", 351, 364], ["rhinovirus infections", "PROBLEM", 438, 459], ["chain reaction", "OBSERVATION", 36, 50], ["respiratory illness", "OBSERVATION", 330, 349], ["rhinovirus", "OBSERVATION", 438, 448]]], ["These studies have confirmed rhinoviruses as the cause of a majority of common colds, particularly when advanced techniques have been applied, such as viral RNA detection by reverse-transcription PCR testing.", [["colds", "DISEASE", 79, 84], ["rhinoviruses", "ORGANISM", 29, 41], ["viral RNA", "RNA", 151, 160], ["These studies", "TEST", 0, 13], ["rhinoviruses", "PROBLEM", 29, 41], ["common colds", "PROBLEM", 72, 84], ["viral RNA detection", "TEST", 151, 170], ["reverse-transcription PCR testing", "TEST", 174, 207], ["rhinoviruses", "OBSERVATION", 29, 41]]], ["They also have reported the year-round occurrence of rhinovirus illness, with peaks in the fall and spring in temperate climates, and have highlighted the importance of children in introducing infections into the household.", [["rhinovirus illness", "DISEASE", 53, 71], ["infections", "DISEASE", 193, 203], ["rhinovirus", "ORGANISM", 53, 63], ["children", "ORGANISM", 169, 177], ["children", "SPECIES", 169, 177], ["rhinovirus illness", "PROBLEM", 53, 71], ["rhinovirus", "OBSERVATION", 53, 63]]], ["This information will be important in targeting specific antiviral therapy for VRIs resulting from picornaviruses and other viral respiratory pathogens.Frederick G. Hayden, MD, FACPIn the second article, Dr. Jack M. Gwaltney, Jr. discusses emerging information about the pathogenesis of infections with rhinoviruses.", [["VRIs", "DISEASE", 79, 83], ["viral respiratory pathogens", "DISEASE", 124, 151], ["infections", "DISEASE", 287, 297], ["rhinoviruses", "DISEASE", 303, 315], ["VRIs", "CANCER", 79, 83], ["rhinoviruses", "ORGANISM", 303, 315], ["specific antiviral therapy", "TREATMENT", 48, 74], ["VRIs", "TREATMENT", 79, 83], ["picornaviruses", "PROBLEM", 99, 113], ["other viral respiratory pathogens", "PROBLEM", 118, 151], ["infections", "PROBLEM", 287, 297], ["rhinoviruses", "PROBLEM", 303, 315], ["viral", "OBSERVATION_MODIFIER", 124, 129], ["respiratory pathogens", "OBSERVATION", 130, 151], ["infections", "OBSERVATION", 287, 297], ["rhinoviruses", "OBSERVATION", 303, 315]]], ["Rhinovirus infection is efficient, and the infectious dose is quite small in the immunologically susceptible host.", [["Rhinovirus infection", "DISEASE", 0, 20], ["Rhinovirus", "SPECIES", 0, 10], ["Rhinovirus infection", "PROBLEM", 0, 20], ["infection", "OBSERVATION", 11, 20], ["efficient", "OBSERVATION_MODIFIER", 24, 33], ["infectious", "OBSERVATION_MODIFIER", 43, 53], ["small", "OBSERVATION_MODIFIER", 68, 73]]], ["Furthermore, symptoms develop rapidly, within 16 hours of infection under experimental conditions, and are related to virally induced host responses, including the release of inflammatory mediators and neurogenic reflexes.", [["infection", "DISEASE", 58, 67], ["inflammatory mediators", "PROTEIN", 175, 197], ["symptoms", "PROBLEM", 13, 21], ["infection under experimental conditions", "PROBLEM", 58, 97], ["inflammatory mediators", "PROBLEM", 175, 197], ["neurogenic reflexes", "PROBLEM", 202, 221], ["infection", "OBSERVATION", 58, 67], ["inflammatory", "OBSERVATION_MODIFIER", 175, 187], ["neurogenic reflexes", "OBSERVATION", 202, 221]]], ["Knowledge of the pathogenesis is important in the timing of any therapeutic approach.", [["the pathogenesis", "PROBLEM", 13, 29], ["any therapeutic approach", "TREATMENT", 60, 84]]], ["These findings highlight the importance of antiviral therapy to address the primary cause of illness and of early intervention, within the first day of symptom onset, in order to reduce viral replication promptly.Frederick G. Hayden, MD, FACPThe third article, by Dr. James E. Gern, is an overview of the pathogenesis and clinical implications of rhinovirus VRIs in asthma.", [["illness", "DISEASE", 93, 100], ["rhinovirus VRIs", "DISEASE", 347, 362], ["asthma", "DISEASE", 366, 372], ["rhinovirus", "ORGANISM", 347, 357], ["antiviral therapy", "TREATMENT", 43, 60], ["illness", "PROBLEM", 93, 100], ["early intervention", "TREATMENT", 108, 126], ["symptom onset", "PROBLEM", 152, 165], ["viral replication", "TREATMENT", 186, 203], ["the pathogenesis", "PROBLEM", 301, 317], ["rhinovirus VRIs", "PROBLEM", 347, 362], ["asthma", "PROBLEM", 366, 372], ["viral replication", "OBSERVATION", 186, 203], ["rhinovirus", "OBSERVATION", 347, 357], ["asthma", "OBSERVATION", 366, 372]]], ["Viral infections, especially those caused by rhinovirus, are the most common cause of asthma exacerbations.", [["Viral infections", "DISEASE", 0, 16], ["asthma", "DISEASE", 86, 92], ["rhinovirus", "ORGANISM", 45, 55], ["Viral infections", "PROBLEM", 0, 16], ["rhinovirus", "PROBLEM", 45, 55], ["asthma exacerbations", "PROBLEM", 86, 106], ["infections", "OBSERVATION", 6, 16], ["rhinovirus", "OBSERVATION", 45, 55], ["most common", "OBSERVATION_MODIFIER", 65, 76], ["asthma", "OBSERVATION", 86, 92]]], ["Dr. Gern reviews several studies demonstrating the contribution of the host immune response to rhinovirus illness and the association between rhinovirus infection and exacerbations in individuals with established asthma.", [["rhinovirus illness", "DISEASE", 95, 113], ["rhinovirus infection", "DISEASE", 142, 162], ["asthma", "DISEASE", 213, 219], ["rhinovirus", "ORGANISM", 95, 105], ["rhinovirus", "ORGANISM", 142, 152], ["several studies", "TEST", 17, 32], ["rhinovirus illness", "PROBLEM", 95, 113], ["rhinovirus infection", "PROBLEM", 142, 162], ["exacerbations", "PROBLEM", 167, 180], ["established asthma", "PROBLEM", 201, 219], ["host immune", "OBSERVATION", 71, 82], ["rhinovirus", "OBSERVATION", 95, 105], ["rhinovirus", "OBSERVATION_MODIFIER", 142, 152], ["infection", "OBSERVATION", 153, 162], ["asthma", "OBSERVATION", 213, 219]]], ["In the experimental setting, increased colds severity is associated with increased airway reactivity as measured by objective tests.", [["airway", "ANATOMY", 83, 89], ["colds", "DISEASE", 39, 44], ["airway", "MULTI-TISSUE_STRUCTURE", 83, 89], ["increased colds severity", "PROBLEM", 29, 53], ["increased airway reactivity", "PROBLEM", 73, 100], ["objective tests", "TEST", 116, 131], ["increased", "OBSERVATION_MODIFIER", 29, 38], ["colds", "OBSERVATION", 39, 44], ["increased", "OBSERVATION_MODIFIER", 73, 82], ["airway reactivity", "OBSERVATION", 83, 100]]], ["The mechanisms by which a mucosal viral infection elicits systemic immune responses and contributes to exacerbations are areas of active investigation.", [["mucosal", "ANATOMY", 26, 33], ["viral infection", "DISEASE", 34, 49], ["mucosal viral", "ORGANISM", 26, 39], ["a mucosal viral infection", "PROBLEM", 24, 49], ["systemic immune responses", "PROBLEM", 58, 83], ["exacerbations", "PROBLEM", 103, 116], ["mucosal", "ANATOMY", 26, 33], ["viral", "OBSERVATION_MODIFIER", 34, 39], ["infection", "OBSERVATION", 40, 49], ["active", "OBSERVATION_MODIFIER", 130, 136]]], ["This complex interaction is incompletely understood at present; important questions must be answered regarding the frequency and extent of viral replication in the lower respiratory tract, and the host inflammatory responses to infection need to be more completely characterized.Frederick G. Hayden, MD, FACPPatients with COPD and the elderly are also at risk for the development of serious lower respiratory tract illness caused by rhinoviruses.", [["lower respiratory tract", "ANATOMY", 164, 187], ["lower respiratory tract", "ANATOMY", 391, 414], ["infection", "DISEASE", 228, 237], ["COPD", "DISEASE", 322, 326], ["lower respiratory tract illness", "DISEASE", 391, 422], ["rhinoviruses", "DISEASE", 433, 445], ["lower", "ORGANISM_SUBDIVISION", 164, 169], ["respiratory tract", "ORGANISM_SUBDIVISION", 170, 187], ["lower", "ORGANISM_SUBDIVISION", 391, 396], ["respiratory tract", "ORGANISM_SUBDIVISION", 397, 414], ["rhinoviruses", "ORGANISM", 433, 445], ["viral replication in the lower respiratory tract", "PROBLEM", 139, 187], ["the host inflammatory responses", "PROBLEM", 193, 224], ["infection", "PROBLEM", 228, 237], ["COPD", "PROBLEM", 322, 326], ["serious lower respiratory tract illness", "PROBLEM", 383, 422], ["rhinoviruses", "PROBLEM", 433, 445], ["viral replication", "OBSERVATION", 139, 156], ["lower", "ANATOMY_MODIFIER", 164, 169], ["respiratory tract", "ANATOMY", 170, 187], ["inflammatory", "OBSERVATION_MODIFIER", 202, 214], ["infection", "OBSERVATION", 228, 237], ["more completely characterized", "OBSERVATION_MODIFIER", 249, 278], ["COPD", "OBSERVATION", 322, 326], ["serious", "OBSERVATION_MODIFIER", 383, 390], ["lower", "ANATOMY_MODIFIER", 391, 396], ["respiratory tract", "ANATOMY", 397, 414], ["rhinoviruses", "OBSERVATION", 433, 445]]], ["Dr. Stephen B. Greenberg reviews this topic in the fourth article and discusses the findings of a prospective observational study in older ambulatory adults with or without COPD who were monitored over several years.", [["COPD", "DISEASE", 173, 177], ["adults", "ORGANISM", 150, 156], ["a prospective observational study", "TEST", 96, 129], ["COPD", "PROBLEM", 173, 177]]], ["The impact of rhinovirus infection in these populations was substantial.", [["rhinovirus infection", "DISEASE", 14, 34], ["rhinovirus", "ORGANISM", 14, 24], ["rhinovirus infection", "PROBLEM", 14, 34], ["rhinovirus", "OBSERVATION_MODIFIER", 14, 24], ["infection", "OBSERVATION", 25, 34], ["populations", "OBSERVATION_MODIFIER", 44, 55], ["substantial", "OBSERVATION_MODIFIER", 60, 71]]], ["Dr. Greenberg's study found that picornaviruses, 75% of which were identified as rhinoviruses, were the most common pathogen found, followed by parainfluenza viruses and coronaviruses.", [["parainfluenza viruses and coronaviruses", "DISEASE", 144, 183], ["picornaviruses", "ORGANISM", 33, 47], ["rhinoviruses", "ORGANISM", 81, 93], ["parainfluenza viruses", "ORGANISM", 144, 165], ["coronaviruses", "ORGANISM", 170, 183], ["parainfluenza", "SPECIES", 144, 157], ["parainfluenza viruses", "SPECIES", 144, 165], ["Greenberg's study", "TEST", 4, 21], ["picornaviruses", "PROBLEM", 33, 47], ["rhinoviruses", "PROBLEM", 81, 93], ["parainfluenza viruses", "PROBLEM", 144, 165], ["coronaviruses", "PROBLEM", 170, 183], ["picornaviruses", "OBSERVATION", 33, 47], ["rhinoviruses", "OBSERVATION", 81, 93], ["parainfluenza viruses", "OBSERVATION", 144, 165]]], ["Influenza was less common because of the high immunization rate in the populations studied.", [["Influenza", "DISEASE", 0, 9], ["Influenza", "PROBLEM", 0, 9], ["the high immunization rate", "TREATMENT", 37, 63]]], ["VRIs in the patients with COPD were associated with 2-fold higher health-care utilization rates including hospitalizations.", [["VRIs", "DISEASE", 0, 4], ["COPD", "DISEASE", 26, 30], ["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["COPD", "PROBLEM", 26, 30], ["COPD", "OBSERVATION", 26, 30]]], ["Furthermore, as the population of the United States ages, the burden of disease will increase with respect to medical care resource utilization.", [["disease", "PROBLEM", 72, 79], ["disease", "OBSERVATION", 72, 79]]], ["One approach to decreasing the disease burden is development of a vaccine.", [["the disease burden", "PROBLEM", 27, 45], ["a vaccine", "TREATMENT", 64, 73], ["decreasing", "OBSERVATION_MODIFIER", 16, 26], ["disease", "OBSERVATION", 31, 38]]], ["Because more than 100 rhinovirus serotypes exist, however, this task is impractical.", [["rhinovirus", "ORGANISM", 22, 32], ["100 rhinovirus serotypes", "PROBLEM", 18, 42], ["rhinovirus", "OBSERVATION", 22, 32]]], ["Given the low likelihood of an effective vaccine for rhinovirus infections, effective antiviral medications might prove beneficial in reducing this burden.", [["rhinovirus infections", "DISEASE", 53, 74], ["rhinovirus", "ORGANISM", 53, 63], ["rhinovirus", "SPECIES", 53, 63], ["an effective vaccine", "TREATMENT", 28, 48], ["rhinovirus infections", "PROBLEM", 53, 74], ["effective antiviral medications", "TREATMENT", 76, 107], ["low likelihood", "OBSERVATION_MODIFIER", 10, 24]]], ["Intervention studies targeting these populations are needed.Frederick G. Hayden, MD, FACPIn the fifth article, Dr. Gwaltney discusses both historical perspectives and recent therapeutic trials in the treatment of rhinovirus VRIs.", [["rhinovirus VRIs", "DISEASE", 213, 228], ["rhinovirus", "ORGANISM", 213, 223], ["Intervention studies", "TEST", 0, 20], ["recent therapeutic trials", "TREATMENT", 167, 192], ["rhinovirus VRIs", "PROBLEM", 213, 228], ["rhinovirus", "OBSERVATION", 213, 223]]], ["He reminds us of the importance of rigorous tests of common cold treatments under appropriately controlled and blinded conditions because of the variable but relatively short natural history of illness, the paucity of objective measures, and the large potential placebo effect, which earlier investigators commented on more than 60 years ago.", [["illness", "DISEASE", 194, 201], ["rigorous tests", "TEST", 35, 49], ["common cold treatments", "TREATMENT", 53, 75], ["blinded conditions", "PROBLEM", 111, 129], ["illness", "PROBLEM", 194, 201], ["large", "OBSERVATION_MODIFIER", 246, 251]]], ["22 Because the pathogenesis of symptoms is related to the host immune response to the virus, combining early treatment with an antiviral agent and an antiinflammatory compound may be the most effective therapeutic approach for VRIs resulting from rhinovirus and other viral respiratory pathogens.", [["respiratory", "ANATOMY", 274, 285], ["VRIs", "DISEASE", 227, 231], ["viral respiratory pathogens", "DISEASE", 268, 295], ["rhinovirus", "ORGANISM", 247, 257], ["symptoms", "PROBLEM", 31, 39], ["the virus", "PROBLEM", 82, 91], ["combining early treatment", "TREATMENT", 93, 118], ["an antiviral agent", "TREATMENT", 124, 142], ["an antiinflammatory compound", "TREATMENT", 147, 175], ["VRIs", "PROBLEM", 227, 231], ["rhinovirus", "PROBLEM", 247, 257], ["other viral respiratory pathogens", "PROBLEM", 262, 295], ["rhinovirus", "OBSERVATION", 247, 257], ["viral", "OBSERVATION_MODIFIER", 268, 273], ["respiratory pathogens", "OBSERVATION", 274, 295]]], ["Although all of the candidate antirhinoviral agents are currently investigational, the studies to date have established the potential for prevention and early treatment of rhinovirus infections by selective antiviral agents.", [["rhinovirus infections", "DISEASE", 172, 193], ["rhinovirus", "ORGANISM", 172, 182], ["antirhinoviral agents", "TREATMENT", 30, 51], ["the studies", "TEST", 83, 94], ["rhinovirus infections", "PROBLEM", 172, 193], ["selective antiviral agents", "TREATMENT", 197, 223], ["rhinovirus", "OBSERVATION", 172, 182]]], ["23 The supplement concludes with a review by Dr. Joseph S. Bertino of the burden of disease of VRIs and its association with excess antibiotic use, particularly in young children, and with the growing problem of antibiotic resistance in pathogenic respiratory bacteria.", [["VRIs", "DISEASE", 95, 99], ["VRIs", "CANCER", 95, 99], ["children", "ORGANISM", 170, 178], ["children", "SPECIES", 170, 178], ["disease of VRIs", "PROBLEM", 84, 99], ["excess antibiotic use", "TREATMENT", 125, 146], ["antibiotic resistance", "PROBLEM", 212, 233], ["pathogenic respiratory bacteria", "PROBLEM", 237, 268], ["disease", "OBSERVATION", 84, 91], ["antibiotic resistance", "OBSERVATION", 212, 233], ["respiratory bacteria", "OBSERVATION", 248, 268]]], ["Dr. Bertino discusses recent surveys of patient and physician attitudes and practices that confirm the significant impact of VRIs.", [["patient", "ORGANISM", 40, 47], ["patient", "SPECIES", 40, 47], ["the significant impact of VRIs", "PROBLEM", 99, 129], ["significant", "OBSERVATION_MODIFIER", 103, 114]]], ["This article also summarizes the controlled studies that indicate that antibiotic therapy generally has shown no clinical benefits or reductions in complications in those with colds or purulent rhinitis.", [["colds", "DISEASE", 176, 181], ["rhinitis", "DISEASE", 194, 202], ["the controlled studies", "TEST", 29, 51], ["antibiotic therapy", "TREATMENT", 71, 89], ["complications", "PROBLEM", 148, 161], ["colds", "PROBLEM", 176, 181], ["purulent rhinitis", "PROBLEM", 185, 202], ["purulent", "OBSERVATION_MODIFIER", 185, 193], ["rhinitis", "OBSERVATION", 194, 202]]], ["He then outlines the steps that can be taken to facilitate the introduction of antivirals into clinical practice and reminds us of the limitations and possible side effects of the over-the-counter medications commonly used for VRIs.Frederick G. Hayden, MD, FACPIn summary, the articles in this supplement underscore the significant burden of VRIs resulting from rhinovirus for the individual sufferer, for health care practitioners, and for society as a whole.", [["VRIs", "DISEASE", 342, 346], ["VRIs", "CANCER", 342, 346], ["rhinovirus", "ORGANISM", 362, 372], ["antivirals", "TREATMENT", 79, 89], ["the over-the-counter medications", "TREATMENT", 176, 208], ["VRIs", "PROBLEM", 227, 231], ["VRIs", "PROBLEM", 342, 346], ["rhinovirus", "PROBLEM", 362, 372], ["significant", "OBSERVATION_MODIFIER", 320, 331], ["burden", "OBSERVATION", 332, 338], ["rhinovirus", "OBSERVATION", 362, 372]]], ["They illustrate that for certain patient populations, the clinical consequences of VRIs can be serious.", [["VRIs", "DISEASE", 83, 87], ["patient", "ORGANISM", 33, 40], ["patient", "SPECIES", 33, 40], ["certain patient populations", "PROBLEM", 25, 52], ["VRIs", "PROBLEM", 83, 87]]], ["The purpose of this supplement is to discuss the increasingly recognized importance of rhinovirus infections in persons with or without comorbidities and to review current understanding of rhinovirus infection pathophysiology in light of newly developed agents targeted to this pathogen.", [["rhinovirus infections", "DISEASE", 87, 108], ["rhinovirus infection", "DISEASE", 189, 209], ["rhinovirus", "ORGANISM", 87, 97], ["persons", "ORGANISM", 112, 119], ["rhinovirus", "ORGANISM", 189, 199], ["persons", "SPECIES", 112, 119], ["this supplement", "TREATMENT", 15, 30], ["rhinovirus infections", "PROBLEM", 87, 108], ["comorbidities", "PROBLEM", 136, 149], ["rhinovirus infection pathophysiology", "PROBLEM", 189, 225], ["this pathogen", "PROBLEM", 273, 286], ["rhinovirus", "OBSERVATION", 87, 97], ["rhinovirus", "OBSERVATION", 189, 199]]]], "PMC7394316": [["Data Sources ::: MethodsBetween 1 February and 15 April 2020, the HIV clinics of 60 Spanish hospitals identified all polymerase chain reaction (PCR)-confirmed COVID-19 diagnoses among HIV-positive patients receiving ART.", [["HIV-positive", "DISEASE", 184, 196], ["HIV", "ORGANISM", 184, 187], ["patients", "ORGANISM", 197, 205], ["HIV", "SPECIES", 184, 187], ["patients", "SPECIES", 197, 205], ["HIV", "SPECIES", 66, 69], ["HIV", "SPECIES", 184, 187], ["all polymerase chain reaction", "PROBLEM", 113, 142], ["PCR", "TEST", 144, 147], ["COVID", "TEST", 159, 164], ["ART", "TREATMENT", 216, 219]]], ["For each confirmed case, the clinics ascertained age, sex, and ART regimen at the time of the COVID-19 diagnosis.", [["ART regimen", "TREATMENT", 63, 74], ["the COVID", "TEST", 90, 99]]], ["Regimens were classified according to both the NRTI backbone (TDF/FTC, TAF/FTC, ABC/3TC, or other drugs) and the third drug (integrase inhibitor, protease inhibitor, or NNRTI).Data Sources ::: MethodsIn addition, HIV clinics provided the total number of HIV-positive patients receiving ART who were being followed in their units.", [["NRTI", "CHEMICAL", 47, 51], ["TDF", "CHEMICAL", 62, 65], ["3TC", "CHEMICAL", 84, 87], ["HIV-positive", "DISEASE", 254, 266], ["TDF", "CHEMICAL", 62, 65], ["FTC", "CHEMICAL", 66, 69], ["FTC", "CHEMICAL", 75, 78], ["3TC", "CHEMICAL", 84, 87], ["TDF", "SIMPLE_CHEMICAL", 62, 65], ["ABC", "SIMPLE_CHEMICAL", 80, 83], ["3TC", "SIMPLE_CHEMICAL", 84, 87], ["HIV", "ORGANISM", 213, 216], ["HIV", "ORGANISM", 254, 257], ["patients", "ORGANISM", 267, 275], ["patients", "SPECIES", 267, 275], ["HIV", "SPECIES", 213, 216], ["HIV", "SPECIES", 254, 257], ["Regimens", "TREATMENT", 0, 8], ["the NRTI backbone", "TREATMENT", 43, 60], ["TDF/FTC", "TREATMENT", 62, 69], ["TAF", "TREATMENT", 71, 74], ["FTC", "TREATMENT", 75, 78], ["3TC", "TREATMENT", 84, 87], ["other drugs", "TREATMENT", 92, 103], ["the third drug (integrase inhibitor", "TREATMENT", 109, 144], ["protease inhibitor", "TREATMENT", 146, 164], ["NNRTI", "TREATMENT", 169, 174]]], ["We obtained the age and sex distribution, as well as the distribution of ART regimens, of all HIV-positive persons from the 2019 National HIV Hospital Survey (13).", [["HIV", "ORGANISM", 94, 97], ["persons", "ORGANISM", 107, 114], ["HIV", "SPECIES", 94, 97], ["persons", "SPECIES", 107, 114], ["HIV", "SPECIES", 94, 97], ["HIV", "SPECIES", 138, 141], ["ART regimens", "TREATMENT", 73, 85]]], ["To examine the possibility of recent changes in ART prescription not captured by the 2019 National HIV Hospital Survey, we compared this information with that provided by hospital pharmacies.", [["HIV", "SPECIES", 99, 102], ["recent changes", "PROBLEM", 30, 44]]], ["The age and sex distribution of the population of Spain was obtained from the National Statistics Institute.Outcome Definitions ::: MethodsThe diagnosis of laboratory-confirmed COVID-19 required positive results from a PCR test following the Ministry of Health protocols (26).", [["Methods", "TREATMENT", 132, 139], ["COVID", "TEST", 177, 182], ["a PCR test", "TEST", 217, 227], ["Health protocols", "TREATMENT", 254, 270], ["distribution", "OBSERVATION_MODIFIER", 16, 28], ["population", "OBSERVATION_MODIFIER", 36, 46]]], ["Clinical severity was graded as diagnosis, hospital admission, intensive care unit (ICU) admission, and death.", [["death", "DISEASE", 104, 109]]], ["Length of hospitalization was calculated in days from the date of hospital admission to the date of discharge.Statistical Analysis ::: MethodsFor each patient, follow-up started on 1 February and ended on 15 April 2020.", [["patient", "ORGANISM", 151, 158], ["patient", "SPECIES", 151, 158]]], ["We therefore calculated the 75-day risk (cumulative incidence) and 95% CI for COVID-19 diagnosis, hospital admission, ICU admission, and death, overall and by age group, sex, and NRTI regimen.", [["death", "DISEASE", 137, 142], ["NRTI", "CHEMICAL", 179, 183], ["COVID", "TEST", 78, 83], ["NRTI regimen", "TREATMENT", 179, 191]]], ["We used multivariable Poisson regression models to estimate risks and 95% CIs for COVID-19 diagnoses and hospital admissions by NRTI regimen.Statistical Analysis ::: MethodsWe restricted the analyses to persons living in Madrid, the region with the highest number of COVID-19 diagnoses and largest between-hospital variability in ART regimens (and, therefore, where the choice of regimen is more likely to be determined by local hospital preferences).", [["NRTI", "CHEMICAL", 128, 132], ["persons", "ORGANISM", 203, 210], ["persons", "SPECIES", 203, 210], ["COVID", "TEST", 82, 87], ["NRTI regimen", "TREATMENT", 128, 140], ["COVID", "TEST", 267, 272], ["ART regimens", "TREATMENT", 330, 342], ["regimen", "TREATMENT", 380, 387]]], ["Finally, we compared age- and sex-standardized risks in HIV-positive patients receiving ART with those in the general population aged 20 to 79 years.Statistical Analysis ::: MethodsAnalyses were conducted with Stata, version 15.0 (StataCorp).Institutional Review Board Approval ::: MethodsThis study was approved by the institutional review board at University Hospital Ram\u00f3n y Cajal, Madrid, Spain.Role of the Funding Source ::: MethodsThe funding sources had no role in the design, conduct, or analysis of the study or in the decision to submit the manuscript for publication.ResultsBetween 1 February and 15 April, 236 PCR-confirmed diagnoses of COVID-19 were made among 77 590 HIV-positive persons receiving ART in Spain.", [["HIV-positive", "DISEASE", 56, 68], ["HIV-positive", "DISEASE", 681, 693], ["HIV", "ORGANISM", 56, 59], ["patients", "ORGANISM", 69, 77], ["HIV", "ORGANISM", 681, 684], ["persons", "ORGANISM", 694, 701], ["HIV", "SPECIES", 56, 59], ["patients", "SPECIES", 69, 77], ["HIV", "SPECIES", 681, 684], ["persons", "SPECIES", 694, 701], ["HIV", "SPECIES", 56, 59], ["HIV", "SPECIES", 681, 684], ["Statistical Analysis", "TEST", 149, 169], ["MethodsAnalyses", "TEST", 174, 189], ["Methods", "TREATMENT", 282, 289], ["This study", "TEST", 289, 299], ["Methods", "TREATMENT", 430, 437], ["the study", "TEST", 508, 517], ["PCR", "TEST", 622, 625], ["COVID", "TEST", 649, 654], ["HIV", "TEST", 681, 684]]]], "615f822ea45e03824b752aabd831e2f594608d4a": [["To the Editor: Coronaviruses (CoVs) are enveloped, positive-sense, single-stranded RNA viruses that can cause acute and chronic respiratory, enteric, and central nervous system disease in a variety of animal species (1) .", [["respiratory", "ANATOMY", 128, 139], ["central nervous system", "ANATOMY", 154, 176], ["chronic respiratory, enteric, and central nervous system disease", "DISEASE", 120, 184], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 15, 28], ["CoVs", "GENE_OR_GENE_PRODUCT", 30, 34], ["central nervous system", "ANATOMICAL_SYSTEM", 154, 176], ["Coronaviruses (CoVs", "PROBLEM", 15, 34], ["single-stranded RNA viruses", "PROBLEM", 67, 94], ["acute and chronic respiratory, enteric, and central nervous system disease", "PROBLEM", 110, 184], ["Coronaviruses", "OBSERVATION", 15, 28], ["acute", "OBSERVATION_MODIFIER", 110, 115], ["chronic", "OBSERVATION_MODIFIER", 120, 127], ["respiratory", "OBSERVATION", 128, 139], ["enteric", "ANATOMY", 141, 148], ["central", "ANATOMY_MODIFIER", 154, 161], ["nervous system", "ANATOMY", 162, 176], ["variety", "OBSERVATION_MODIFIER", 190, 197]]], ["Recently, a novel ferret enteric CoV (FRECV) was indentifi ed in domesticated ferrets (Mustela putorius) in which epizootic catarrhal enteritis had been diagnosed; the illness was characterized by foulsmelling green diarrhea with high mucus content, lethargy, anorexia, and vomiting (2) .", [["mucus", "ANATOMY", 235, 240], ["catarrhal enteritis", "DISEASE", 124, 143], ["illness", "DISEASE", 168, 175], ["diarrhea", "DISEASE", 216, 224], ["lethargy", "DISEASE", 250, 258], ["anorexia", "DISEASE", 260, 268], ["vomiting", "DISEASE", 274, 282], ["ferret enteric CoV", "ORGANISM", 18, 36], ["FRECV", "ORGANISM", 38, 43], ["ferrets", "ORGANISM", 78, 85], ["Mustela putorius", "ORGANISM", 87, 103], ["mucus", "ORGANISM_SUBSTANCE", 235, 240], ["ferret", "SPECIES", 18, 24], ["ferrets", "SPECIES", 78, 85], ["Mustela putorius", "SPECIES", 87, 103], ["ferret enteric CoV", "SPECIES", 18, 36], ["FRECV", "SPECIES", 38, 43], ["Mustela putorius", "SPECIES", 87, 103], ["epizootic catarrhal enteritis", "PROBLEM", 114, 143], ["foulsmelling green diarrhea", "PROBLEM", 197, 224], ["high mucus content", "PROBLEM", 230, 248], ["lethargy", "PROBLEM", 250, 258], ["anorexia", "PROBLEM", 260, 268], ["vomiting", "PROBLEM", 274, 282], ["epizootic", "OBSERVATION_MODIFIER", 114, 123], ["catarrhal enteritis", "OBSERVATION", 124, 143], ["high mucus content", "OBSERVATION", 230, 248], ["anorexia", "OBSERVATION", 260, 268]]], ["Another ferret CoV emerged in ferrets for which systemic pyogranulomatous infl ammation, resembling the clinical and pathologic features of feline infectious peritonitis (FIP), was diagnosed (3) (4) (5) .", [["feline infectious peritonitis", "DISEASE", 140, 169], ["FIP", "DISEASE", 171, 174], ["ferret CoV", "ORGANISM", 8, 18], ["ferrets", "ORGANISM", 30, 37], ["feline", "ORGANISM", 140, 146], ["ferret", "SPECIES", 8, 14], ["ferrets", "SPECIES", 30, 37], ["feline", "SPECIES", 140, 146], ["ferret CoV", "SPECIES", 8, 18], ["Another ferret CoV", "PROBLEM", 0, 18], ["systemic pyogranulomatous infl ammation", "PROBLEM", 48, 87], ["feline infectious peritonitis", "PROBLEM", 140, 169], ["ferret CoV", "OBSERVATION", 8, 18], ["feline", "OBSERVATION_MODIFIER", 140, 146], ["infectious", "OBSERVATION_MODIFIER", 147, 157], ["peritonitis", "OBSERVATION", 158, 169]]]]}